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2ABSTRACT
A critical review of the clinical literature surveying subjective reports of sedation 
following administration of antihistamines (AH's) showed that some substances were 
perceived as more sedative than others. When a review was undertaken of 
standardised, objective and subjective, psychometric assessments of sedation used in 
experimental studies the results were broadly equivocal but no particular 
psychometric appeared to encapsulate the sedative activity of certain AH's. A series of 
controlled experiments, primarily in non-atopic volunteers, investigated various 
aspects of the methods and measures used to assess sedation following AH 
administration. These included studies investigating the impact of dose response 
relationship, time course of drug activity, route of administration, single versus 
repeated administration, sleep induction, possible interaction with other substances, 
and allergen induced histamine release. It was hoped that it would be possible to 
identify a particular protocol which would prove to be the most efficacious and valid 
way of evaluating sedation following AH's. However, there were three factors which 
mitigated against such parsimony, namely: the lack of sensitivity and reliability of the 
psychometrics, the inter-drug/dose regimen differences in the magnitude of the 
sedation produced, and, perhaps most importantly, the interindividual variation in 
sensitivity to the sedative effects of HI receptor antagonists.
© Niekol Rombaut, 1995
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CHAPTER 1 INTRODUCTION AND RATIONALE
This thesis is concerned with the sedative effects of antihistamines (AH's) and with 
the methodologies and techniques needed to detect and quantify the extent of this 
sedation.
AH's are widely prescribed for the treatment of allergic disorders, especially seasonal 
and perennial rhinitis, and chronic urticaria (Advenier and Queille-Roussel, 1989; 
Flowers et ah, 1986; Tamasky and Van Arsdel, 1990; Wood, 1988). They are also 
used, to a much lesser extent, in the treatment of asthma, although in this indication 
they seem to be of limited value (Holgate, 1994). Many AH's are sold over the counter 
(OTC) either as sole entities or in combination preparations, primarily as treatment for 
non-allergic indications such as the common cold (West et al., 1975), motion sickness 
and vertigo (Norris, 1988; Wood, 1965). Antihistaminic properties are not limited to 
the class of the so-called AH's or HI-receptor antagonists. There are other drugs, such 
as calcium antagonists (e.g. cinnarizine), tricyclic antidepressants (e.g. amitriptyline), 
neuroleptics (e.g. chlorpromazine) which also have antihistaminic effects as part of 
their pharmacological profile, and it is interesting to note that such substances are 
also characterised by their sedative activity. This sedative activity undoubtedly plays a 
part in the adverse behavioural effects of the tricyclic antidepressants (Waldmeier, 
1983) and is amongst the principal causes of the Neuroleptic Induced Deficit 
Syndrome (Barnes and Edwards, 1993; Lader, 1993). This thesis, however, will not 
discuss other drug classes with non-selective AH antagonism further, but will 
concentrate on compounds with primary antihistaminic activity: the AH's.
As a result of the widespread prescribing and the OTC availability of AH's there is a 
large number of ambulant patients using such drugs. Because sleepiness and tiredness 
are incompatible with accident-free performance of the tasks of everyday living 
(Arbus, et al., 1991; Leger, 1994) it is important to examine closely the nature and 
extent of sedation produced by drugs of this class. It is particularly important to 
identify appropriate methods and measures to discriminate between different 
compounds so as to make an accurate differentiation between AH's which do not 
produce sedation from those which are inherently sedative.
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The psychopharmacological paradigm assumes that the effects a substance produces 
on the Central Nervous System (CNS) will be manifest in changes in overt behaviour 
(Michon, 1976). The task of the psychopharmacologist is therefore to develop valid 
and reliable tests by which these changes in behaviour can be accurately and 
pragmatically measured (Hindmarch, 1980).
With the AH's we are concerned with a lowering of CNS arousal which would be 
manifest as an impairment or reduction of cognitive, sensorimotor and memory 
performance. There are many ways to describe lowering of arousal, and the clinical 
literature is replete with words such as tiredness, drowsiness, somnolence, sleepiness, 
fatigue, etc. When used to describe the effects of a CNS active drug, these effects are 
generally grouped under the term "sedation". In the following section the meaning of 
this term will be examined further.
1.1 Sedation: definitions and perceptions
The word sedation came into English use in the late Middle Ages (circa 1543). It is 
derived from the Latin verb sedare, which means to calm. The Oxford Dictionary 
defines the term as "the action of allaying, assuaging or making calm" (Onions,
1964). Interestingly, the word sedation can be easily translated (and effortlessly 
recognised) in a large number of languages. Indeed the spelling of the words 
"sedation, Sedation, sedacion, sedatione, sedatie" is not only very similar but also has 
the same significance in French, German, Spanish, Italian and Dutch respectively.
The term sedation gradually became part of medical jargon. This is not entirely 
surprising. "Allaying" suggests the existence of some form of unease or "pain" which 
might require professional attention. Indeed, although Taber's Cyclopedic Medical 
Dictionary gives a virtually identical definition of sedation as the Oxford dictionary, 
namely "1. process of allaying nervous excitement 2. state of being calmed it makes 
the connection with (the functioning of) the Central Nervous System more explicit. 
(Thomas, 1975).
The history of pharmacotherapy has, until recent times, had a positive regard towards 
sedation. As long ago as Sheng Nung's treatise on pharmacology (2737 B.C.), it was 
recognised that opium was a powerful sedative and analgesic, a tradition that
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continues via the current use of opiates (heroin and morphine) (Hindmarch, 1972). 
Other significant sedatives were developed to augment the physician's 
armamentarium: chloral hydrate was introduced in 1832 as a sleep inducer and 
sedative (Goodman et ah, 1980); the barbiturates were developed around the turn of 
the century as powerful hypnotics and anaesthetics (Lyons and Petrucelli, 1987); 
meprobamate was introduced in the 1950's as a tranquilliser and a sedative; and the 
benzodiazepines were made available from 1960 primarily as sedatives (minor 
tranquillisers) hypnotics and anxiolytics (Oster et ah, 1990). Another part of the 
development of "sedatives" was directed by a specific need for substances which 
would have a calming effect on patients with florid (psychotic) symptoms, and a 
breakthrough in finding a medication with such properties was made in the early 50's 
(Delay et ah, 1952). The group of drugs that was discovered was the aliphatic 
phenothiazines of which chlorpromazine was the prototype. These early neuroleptics 
(major tranquillisers) are of interest for this thesis since they also have pronounced 
antihistamine properties.
It was towards the end of the 1970's that the sedation produced by psychoactive drugs 
was recognised as a negative (side) effect, because of the consequence of impairing 
the activities of daily life. In 1972 the World Health Organisation (WHO) issued a 
caution about the use of psychoactive drugs liable to induce sedation in ambulant 
patients. The fact that sedation was increasingly seen as a threat and hindrance, not 
only to patient's safety but also to patient's compliance with drug treatment regimens, 
was the impetus to develop non-sedative psychoactive drugs. It became particularly 
unacceptable that drugs which had no primary CNS effects (such as AH's) caused 
secondary sedation.
Therefore, despite the fact that the term "sedation" had no a priori negative 
connotations, it now seems that the general interpretation of the term sedation 
indicates an adverse effect and represents a source of impairment of normal daytime 
functioning, particularly in the context of ambulant patients driving cars or working in 
risk prone industrial or domestic situations (Ramaekers, et al., 1992b). The increase in 
general accident risk of patients taking sedative tranquillisers was found to be twice 
that of patients not using these drugs (Oster et al., 1990) and hip fractures were more 
common in patients using sedative hypnotics, antidepressants and antipsychotics (Ray 
et al., 1987). Several epidemiological studies have shown an increased risk of road 
traffic accidents (RTA's) following sedative psychoactive drugs ranging from 1.9 to
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4.9 times relative to the risk of non drug users (Honkanen et al., 1980; MacPherson et 
al., 1984; Skegg et al., 1979). The relative extent of sedation produced by different 
drugs is important (Volz and Stumm, 1995), not only for the safety of the patient in 
accident risk situations (O'Hanlon, 1988) but also because sedation is, in many 
situations, counter therapeutic in that it reduces patient compliance with drug 
treatment regimens (Hindmarch et al., 1990). Indeed a recent paper (Simons, 1994) 
has suggested that the extent to which AH's impair psychological performance on a 
range of psychometric tests to draw up an therapeutic index of newer HI antagonists. 
In Europe psychoactive drugs are found in 10% of RTA's and fatalities (De Gier, 
1993). The incidence of psychoactive drugs in RTA's and fatalities was assessed in the 
UK (Everest et al., 1989). An overall incidence of 7.4% of drugs likely to affect the 
CNS was found in all road users and in 6.7 % of those suffering fatal RTA's. AH's, 
either as single antihistaminic entities or as combination drugs with antihistaminic 
activity, were present in 1.76 % of the fatal accidents. Such figures place AH's 
amongst the most dangerous for RTA's. AH's were also found more frequently (12 %) 
in the bloods of accident involved car drivers when compared to non accident 
involved car drivers (9%) (Jick et al., 1981).
1.2 Antihistamines
Substances with antihistamine activity were first described in the mid 40's, after some 
30 years of pharmacological research which started with the discovery of histamine.
In 1910, Sir Henry Dale discovered that the injection of a biogenic amine, histamine, 
into mammals elicited a shock-like syndrome (Holgate, 1988). Twenty years later 
Watanabe (1931) noted differences in the histamine content of guinea-pig lung before 
and after shock, and subsequent investigations showed increased histamine content in 
blood and lymph of dogs (Dragstedt and Mead, 1936) and quantities of histamine in 
shocked guinea-pigs which were adequate to cause anaphylaxis (Cole, 1937).
In the same year Bovet and Straub (1937) published their findings on the ability of 
certain agents to inhibit histamine-induced smooth-muscle contraction and 
anaphylaxis. This was a major step towards establishing a new therapeutic class of 
drugs: the AH's. One of the first clinically useful antihistamines was pyrilamine 
maleate, described by Bovet in 1944 (Douglas, 1985).
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Histamine is an endogenous substance that binds to and activates histamine HI, 
histamine H2, and the more recently discovered, histamine H3 (Arrang et ah, 1983), 
receptors at various sites through the body. The principal pharmacological effects of 
histamine involve the cardiovascular system, extravascular smooth muscle, and 
exocrine glands. Stimulation of nerve endings by histamine may also cause pruritus. 
Characteristic effects of histamine on HI receptors include changes in vascular 
permeability causing erythema, runny nose, watery eyes, wheal and flare reactions, 
and other allergic symptoms. The term AH historically refers to drugs that act as 
histamine HI receptor antagonists rather than histamine H2 or H3 receptor 
antagonists. Because the mechanism of action of AH's is competitive blockade of 
histamine receptor sites rather than inhibition of histamine release, AH's are more 
effective in preventing than reversing the effect of histamine (Cirillo and Tempero, 
1976; Pearlman, 1976).
Historically AH's have been classified into 6 categories, based upon the substitution 
groups linked to the ethylamine structure which many of them they have in common. 
These chemical classes (ethanolamines, ethylenediamines, alkylamines, 
phenothiazines, piperazines and piperidines) form the great majority of the AH's. Each 
of these classes have a slightly different pharmacological and, consequently, side 
effect profile.
Sedation is the most common side-effect of HI receptor blocking agents (Douglas, 
1985; Martindale, 1993; White and Rumbold, 1988; Wyngaarden and Severs, 1951). 
The underlying mechanism by which CNS effects are caused by AH's is not precisely 
understood, even though the role of histamine as a neurotransmitter is firmly 
established (Goodman and Gilman, 1990; Simons and Simons, 1993). Generally, AH 
induced sedation is attributed to the blockade of central histaminergic receptors 
(Kmjevic and Phyllis, 1963; Schwartz et al., 1993). The histaminergic system seems to 
be involved in regulating vigilance and wakefulness, and blockade of histamine 
production has been found to produce sedation. For example, Stevens (1982) 
demonstrated that the administration of alpha fluormethyl histidine caused severe 
sedation in normal healthy volunteers. The histaminergic pathways are widespread 
and project diffusely in the cerebral cortex. Most AH's are highly liposoluble and are 
reputed to cross the so-called blood-brain barrier with relative ease. Their ability to 
block central HI receptors has been postulated to be the primary cause of the sedaton, 
observed with the older, first generation AH's. Since the beginning of the seventies, a
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number of non-sedative, second generation AH's have been developed which are 
relatively lipophobic and penetrate but poorly into the CNS due to their larger 
molecular size and/or electrostatic charge. As predictive of and/or indicative for the 
absence of sedation the affinity for central as opposed to peripheral histamine H l- 
receptors has been considered by several authors (Le Fur et ah, 1981; Leysen et ah, 
1991; MacQuade et ah, 1990; Rose et ah, 1982; Uzan et ah, 1979). While sedation is 
produced by many dose regimen of AH's it is not clear, however, as to the relative 
contribution of each of these factors in producing CNS effects. An alternative 
explanation for the sedation induced by AH's of the first generation is the inhibition 
of the metabolism of histamine by N-methyltransferase (Netter and Bodenschatz, 
1967). Through this mechanism increased amounts of histamine would be available 
to block central cholinergic, alpha-adrenergic or serotonin receptors, producing effects 
which might be synergistic or additive to the HI effects.
AH's are universally considered as effective therapy for a variety of allergic disorders, 
and as such frequently and extensively used. For example, a household survey held in 
the USA in 1984, suggested that more than 30 million Americans take antihistamines 
each year with total sales of single-entity antihistamines amounting to $ 211 million 
(Kaliner, 1992). The prevalence rate of allergic disorders has increased over the past 
10-20 years. A British study in general practice in the London area demonstrated a 
dramatic increase in the total number of diagnoses of various types of allergies 
(seasonal and allergic rhinitis, conjunctivitis, asthma, urticaria, dermatitis, eczema, 
and food allergy). From 1974 to 1979, the allergy prevalence rate grew from a total of
28.1 % to 37.3 % (Eaton, 1982). A similar trend was reported in another general 
practice study with regard to allergic rhinitis where prevalence rose from 11 to 20 per 
1000 persons (Fleming and Crombie, 1987).
It is clear therefore that AH's are taken by a group of patients who, apart from their 
allergic symptoms, are basically healthy. They are generally young individuals with 
an active professional life. It has been reported that, because of allergic rhinitis alone, 
approximately 3.5 million workdays are lost yearly in the USA, corresponding to an 
estimated annual cost of $ 154 million in lost wages (Ricketti, 1985).
When considering the socio-economic implications of a certain disease, however, it is 
important to distinguish between the primary effects of the illness and the secondary 
effects caused by its treatment. One of the therapeutic areas in which this issue was
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first addressed (Kamofsky and Burchenal, 1947), and implemented in a more 
systematic way was oncology (Spitzer et al., 1981), although psychologists interested 
in evaluating the effects of psychotherapy had used a similar approach earlier (Blau, 
1977). The use of "Quality Of Life" (QOL) scales which initially was aimed at 
evaluating the general well-being of patients suffering from life threatening diseases, 
became increasingly popular and was soon extended to the assessment of the actual 
impact of drugs used in "otherwise healthy", and therefore socially and professionally 
active patients, such as insomniacs (Rombaut et ah, 1990c). In the allergy field, both 
asthma specific and rhinoconjunctivitis specific QOL scales have been developed and 
validated (Hyland et al., 1991; Juniper and Guyatt,1991), but little is known about 
their overall value in assessing the effects of antihistamines. However, in order to 
assess QOL it is necessary to cover a wide range of factors "which interfere with the 
ability to function and derive satisfaction from doing so" (Walker and Rosser, 1988) 
and therefore QOL scales are generally broad, non-specific tools which are certainly 
not focused enough to assess sedation per se.
It is evident that any form of sedation experienced by an active individual interferes in 
a negative way with his/her daily lifestyle and activities. With regard to antihistamine- 
induced sedation, this is no less so. Sedation is especially dangerous when patients do 
not recognise it as such. However if the sedation is not subjectively experienced, an 
increase in risk of domestic, industrial, and road traffic situations cannot be 
discounted and an association between the use of certain antihistamines and road 
traffic accidents has been reported by several researchers (Cimbura et al., 1982; Tinkle 
et al., 1968; Garriot et al., 1977; Starmer, 1985). The association between sedative 
drug effects and accidents has led some authors (Hindmarch et al., 1990) to talk of a 
behavioural toxicity index as a measure of the extent to which a particular drug 
possesses counter therapeutic activity. Behavioural toxicity is regarded as the extent to 
which CNS effects (sedation) not only interfere with the accurate performance of the 
tasks of everyday living but also reduce compliance with therapeutic drug regimens. 
Such indices, including the relative activity of antidepressants and hypnotics 
(Hindmarch et al., 1990) have caused some regulatory authorities (Denmark, 
Netherlands) to indicate such toxicity on drug packaging and the European Union's 
Committee for Proprietary Medicinal Products to formulate a 3 tier warning system 
on the ability of drugs to impair car driving or the operation of machinery (CPMP, 
1991) and since January 1994 all package inserts have to include a statement of drug 
effects on the ability to drive or use machinery (EEC, 1992).
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1.3 Measuring antihistamine-induced sedation
The intention of this thesis is to review different methods and measures for detecting 
and assessing the sedation produced by AH's. The most obvious way to gather 
information about drug-induced sedation is to ask the patient. This can be done either 
at regular time intervals during treatment, as the patients visit their physician, or daily, 
by means of diary cards. In both situations this "questioning" can be structured to 
varying degrees, from open, non-directive interviewing to specific, elicited 
interrogation using set lists of potential effects. Whatever method is chosen, it is 
evident that the answer cannot be verified by and/or combined with the opinion of the 
treating physician, as the reported experience is entirely subjective, both with regard 
to its possible presence and severity.
The fact that sedation following the administration of certain AH's exists, is amply 
demonstrated by the number of compounds which are currently marketed as sleeping 
draughts for both adults (Promethazine, Doxylamine) and children (Pimethixene, 
Trimeprazine). On the other hand, seasonal allergies and the like, by reducing the 
patient's overall feeling of well being, may induce a subjective feeling of tiredness and 
drowsiness. In order to establish the degree of sedation due to the drug per se from 
that originating from other causes, a judicious use of tests and assessments is 
necessary.
As a first step in identifying the extent to which sedation is produced by 
antihistamines, Chapter 2 presents a review of the clinical literature.
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CHAPTER 2 SUBJECTIVE REPORTS OF SEDATION: CLINICAL
STUDIES OF ANTIHISTAMINES
2.1 Introduction and outline
The present review summarises data on the incidence of sedation, as reported in a 
limited, carefully chosen number of clinical trials, which have been selected for a 
number of common features (in order to minimise the effect of external factors). The 
results of this survey are described and discussed, with special attention to the 
potential advantages and actual limitations of this "clinical approach". As such they 
are meant to provide the clinical background for the experimental approach which 
forms the greater part of the subject matter of this thesis. The contents of this chapter 
therefore should not in any way be interpreted as an attempt to ascertain the actual 
sedative potential of the antihistamines described. The sole aim of the present 
literature review was to gather data from an impartially selected, representative 
sample of published trials to serve as a basis for further studies employing more 
objective assessments.
Sedation as a drug-induced side-effect occurs in the clinical situation. The 
investigation of the incidence of side-effects produced by a given treatment therefore 
logically draws on the patient as a primary source of information. Patient reports 
however are highly subjective, especially when these concern personal experiences of 
changes in energy level, mood, etc., and the methods used in clinical trials for 
obtaining this type of information are generally either ill defined or non existent.
Since the introduction of terfenadine, the first antihistamine claiming to be non­
sedative, extensive reviews on the incidence of sedation observed in clinical trials 
have been published for the drug and its successors. These reviews aimed to 
demonstrate that, over a wide range of trials and indications, the compound under 
investigation failed to produce more sedation than placebo, and that therefore the label 
"non-sedative" should be considered appropriate. As a rule these summaries focused 
on studies specifically set-up to support the development and (pre-)marketing 
activities of a specific drug, and as a rule only contained data on other antihistamines 
in so far these were included in the comparative studies with the drug under 
investigation (Campoli-Richards et al., 1990; Clissold et al., 1989; Rombaut and
28
Vanden Bussche, 1985; Sorkin and Heel, 1985). The results of these reviews must 
therefore be regarded as slightly biased. A different, more neutral approach lies in 
surveying the literature by means of a computer search, which aims at including as 
many accessible data as possible, on a predetermined number of antihistamines 
(Rombaut and Hindmarch, 1991).
It is evident that the compilation of data obtained through a variety of studies with 
different patient populations treated according to various designs, can only produce 
results which are suggestive of a general trend. The present review therefore sought to 
purify the selection of studies to be included in this analysis in order to obtain a more 
homogeneous and less corrupted database.
2.2 Selection of studies
A literature search was conducted for clinical studies with antihistamines published 
between 1966 and 1990. This search was mainly, but not exclusively, based upon 
citations obtained via the Medline and Excerpta Medica data bases; other sources 
were references found in selected articles and promotional materials. To be included 
in this review the following criteria had to be met:
1. the studies had to be conducted with the aim of investigating the clinical efficacy of 
one or more antihistamines; both therapeutic and prophylactic studies were considered 
acceptable.
2. the studies had to be conducted under strict double-blind conditions, including both 
parallel group (PG) and cross-over (CO) comparisons; studies with a single-blind 
design were excluded.
A total of 163 publications were scrutinised. Only placebo-controlled trials in which 
the number of patients with sedation was clearly stated for each treatment group, were 
included, while usage of rescue medication or combination preparations, and studies 
with children were considered reasons for exclusion. This resulted in a final 
acceptance of 48 studies (Table 1). A list of the originally selected papers with reasons 
for non-inclusion can be found in Table 2.
For each of the selected studies the actual number of reports of sedation per treatment 
group was listed. The term sedation was chosen as a collective term to represent all
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statements referring to a general lowering of CNS activity, which, in these selected 
publications, was described as: sedation (e.g. Belaich et al., 1990; Irander et al.,
1990), somnolence (e.g. Bruno et al., 1981; Bisen et al., 1988), drowsiness (e.g. 
Blamoutier, 1978; Bruno et al., 1989), fatigue (e.g. Dockhom et al., 1987; Girard et 
al., 1985), tiredness (e.g. Gastpar et al., 1988; Grant et al., 1988), asthenia (e.g. 
Frolund et al., 1990), lethargy (e.g. Boggs et al., 1989), CNS depression (e.g. Brandon 
and Weiner, 1982), sleepiness (e.g. Dugue et al., 1982; Mellillo et al, 1982) and 
dizziness (e.g. Schaaf et al., 1979).
Table 1: A list of AH’s studied in clinical situations using placebo-controlled
parallel (PG) or cross over (CO) group designs.
Compound PG/CO No. of 
studies
Reference
Acrivastine CO 7 Gibson et al., 1984; Juhlin et al., 1987; Kobza-Black et al., 
1988; Leyh et al., 1989; Neittaanmaki et al., 1988; Salo et 
al., 1989; Van Joost et al., 1989;
Astemizole PG 6 Bruno et al., 1981; Eisen et al., 1988; Girard et al., 1985; 
Knight, 1985; Nair et al., 1985; Tanay and Neuman, 1989;
Cetirizine CO 3 Go et al., 1989; Juhlin and Arendt, 1988; Schmeisser et al., 
1989;
Ebastine PG 1 Ankier and Waddington, 1989;
Hydroxyzine PG 1 Schaaf et al., 1979;
Levocabastine PG 1 Azevedo et al., 1991;
Loratadine PG 10 Belaich et al., 1990; Bruttman and Pedrali, 1987; Bruttman 
et al., 1989; Del Carpio et al., 1989; Dockhom et al., 1987; 
Frolund et al., 1990; Horak et al.,1988; Irander et al., 1990; 
Oei, 1988; Skassa-Brociek et al., 1988;
Terfenadine PG 15 Backhouse et al., 1982; Boggs et al.,1989; Brandon and 
Weiner, 1982*; Brostoff and Lockhart, 1982; Buckley et 
al.,1988; Buckley et al.,1985; Dugue et al., 1982; Gaffey et 
al., 1988; Gastpar et al., 1988; Grant et al., 1988; Kemp et 
al., 1985; Melillo et al., 1982; Wuthrich and Dietrich, 1982;
CO 4 Cerio and Lessof 1984; Ferguson et al.,1985; Krause and 
Shuster, 1984;
Salisbury et al., 1987;
* 3 separate studies reported in same publication.
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Table 2: A list of studies of AH’s excluded from analysis.
Compound
Acrivastine
Astemizole
Cetirizine
Clemastine
Reason for exclusion No. of
studies
no placebo 3
no placebo
rescue medication
no placebo
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rescue medication 8
incomplete information 4
no placebo
Diphenhydramine no placebo 1
HC20-511 no placebo 1
Reference
Bruno et al., 1989; Gervais et al., 
1989; Meran et al., 1990;
Ambrozio and Mori, 1988; Baurle, 
1985; Bemd, 1989; Boland, 1988; 
Boniver et al., 1986; Cainelli et al., 
1986; de Souza et al., 1985; Fish, 
1988; Grillage et al., 1986; Juniper et 
al., 1988; Juniper et al., 1989; Kiehn, 
1986; Krause and Shuster, 1983; 
Lobaton et al., 1990; Lofkvist et al., 
1984; Malet et al., 1989; Moscato and 
Fasani, 1988; Paul and Bodeker,
1989; Repp, 1985; Rijntjes et al., 
1989; Rombaut et al., 1986; 
Salomonsson et al., 1988; Sussman 
and Jancalewitz, 1988; Troise et al., 
1989; Wilson and Moss, 1987; Wood, 
1986a; Wood, 1986b; Zellweger and 
Zullig, 1987;
Bernstein and Bernstein, 1986; 
Honsinger and Thomsen, 1990; 
Howarth and Holgate, 1984; Howarth 
et al., 1984; Kailassam and Matthews, 
1987; Malmberg et al., 1983; Perez- 
Martin, et al., 1985; Wilson and 
Hillas, 1982;
Brobyn et al., 1982; Fox et al., 1986; 
Holgate and Howarth, 1983; Wihl et 
al., 1984;
Alomar et al., 1990; Arendt and 
Bemheim, 1989; Backhouse et al., 
1990a; Boniver and Arendt, 1989; 
Bruttman et al., 1989a; Charpin et al., 
1990; Dijckman et al., 1990; Emonot 
et al., 1990; Watson, 1989;
Bruttman et al., 1990; Kint et al., 
1989; Panayotopoulos and 
Panayotopoulou, 1990;
Sheriff and Wallace, 1976; Todd, 
1975;
Moscati and Moore, 1990; 
Kuokkanen, 1977;
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Table 2: A list of studies of AH’s excluded from analysis (cont’d).
Compound Reason for exclusion No. of 
studies
Reference
Hydroxyzine incomplete information 1 Wong and Hendeles, 1981;
Ketotifen no placebo 3 Hlouskova, 1980; Kamide, 1989; 
Yoshida, 1989;
Levocabastine no placebo 6 Bende and Pipkom, 1987; Bjorksten 
and Kjellman, 1989; Ciprandi et al., 
1990; Moller and Blychert, 1990; 
Odelram et al., 1989;
incomplete information 1 Pipkom et al., 1985;
Loratadine no placebo 6 Banov, 1989; Bertrand et al., 1990; 
Boner et al., 1989; Longo, 1990; 
Schultze-Weminghaus et al., 1989; 
Zaun and Peter, 1990;
combination 3 Stroms et al., 1989; Berkowitz, 1989; 
Grossman et al., 1989;
incomplete information 2 Dirksen, 1989; Bruttman and Pedrali, 
1985;
Mequitazine no placebo 1 Blamoutier, 1978;
incomplete information 1 Laugier and Orusco, 1978;
Oxatomide no placebo 1 Beck, 1985;
Terfenadine no placebo 24 Backhouse et al., 1986; Backhouse 
and Rosenberg, 1987; Beswick et al., 
1985; Biederman-Hefher, 1990; 
Dickson and Cmickshank, 1984; 
Gutkowski et al., 1985; Henauer et 
al., 1987; Hugonot, 1986; Hugonot, 
1988; Johansen and Bjerrum, 1987; 
Lau et al., 1990; Leophonte et al., 
1984; Lindsay-Miller and Chambers, 
1987; Murphy-O'Connor et al., 1984; 
Neumann, 1984; Nuutinen, 1989; 
Ormerod et al., 1986; Pastorello et al., 
1987; Paul and Bodeker, 1986; Paul, 
1989; Robinson et al., 1989; Saito et 
al., 1988; Stem et al., 1990;
rescue medication 1 Kagan et al., 1980;
incomplete information 6 Barlow, et al., 1982; Brandon and 
Weiner, 1982; Brewster, 1982; 
Hjorth, 1988; Fredriksson et al., 
1986; Wahlgren et al., 1990;
combination 1 Backhouse et al., 1990b;
children 3 Guill et al., 1986; Lockhart and 
Maneksha, 1983; Molkhou and 
Beaumont, 1985;
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However, a cursory review of the clinical studies showed that the large majority of 
authors had provided only a total number of reports of "sedation", without any 
particular indication of the number of patients reporting this side-effect. Since some 
authors used multiple descriptors for what in this review is defined as sedation it was 
difficult to know whether e.g. a report of 3 side-effects was due to one patient 
reporting tiredness and sedation and asthenia, or whether 3 patients were reporting one 
side-effect (one patient reporting tiredness, one reporting sedation and one reporting 
asthenia). As it proved impossible, from the published materials, to resolve this issue, 
a direct pragmatic approach had to be adapted assuming that each report of sedation 
reflected a particular patient.
No distinction was made between the methods used to discover potential sedation. 
However, it was noted whether or not this was specified in the publication, and if  so, 
whether reporting of sedation was either elicited or spontaneous (see Tables 3 and 4). 
Since the majority of the publications failed to give the relevant information, sedation 
was recorded irrespective of when it occurred.
2.3 Results
Thirty-four of the 48 selected studies were conducted using parallel groups; in the 
remaining 14 studies treatments were allocated in cross-over designs. The clinical 
indications tested in the parallel-group comparisons were: seasonal rhinitis (23 
studies), seasonal conjunctivitis (1 study), perennial rhinitis (6 studies), common cold 
(1 study) and chronic urticaria (3 studies). All but one of the cross-over studies were 
carried out in dermatological disorders (chronic urticaria: 11, cold urticaria 1, 
dermographia: 1, and perennial rhinitis: 1 study). Duration of treatment ranged 
between 3 days (e.g. Krause and Shuster, 1984) and 6 weeks (e.g. Tanay and 
Neumann, 1989).
Five antihistamines were included in 3 or more placebo-controlled parallel-group 
studies. These were: astemizole, clemastine, chlorpheniramine, loratadine, and 
terfenadine. Other antihistamines featured only once (ebastine, levocabastine, 
mequitazine) or twice (hydroxyzine) in the double-blind parallel-group studies; they 
are only listed for the sake of completeness, but will not be further discussed, because 
of the small numbers of patients involved (Table 3).
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Terfenadine featured in 21 studies with a total of 1394 patients receiving the drug at 
the prescribed dose of 60 mg b.i.d. (18 studies) or between 20 mg and 200 mg t.i.d. (3 
studies). In 11 of these terfenadine studies, chlorpheniramine was selected as a 
standard comparator and used in a total of 795 patients at doses of 2 mg t.i.d. (2 
studies), 4 mg t.i.d. (5 studies), 4 mg q.i.d. (2 studies), 8 mg b.i.d. (1 study) and 8 mg 
t.i.d. (1 study). Loratadine was compared with placebo in a total of 10 studies, of 
which 5 included terfenadine as a positive control for efficacy. In 9 of these studies 10 
mg of loratadine was administered once daily (mane); in one study a dose of 40 mg 
was given mane. The total number of patients receiving loratadine was 599. 
Astemizole was used in 7 placebo-controlled parallel-group trials of which one 
included terfenadine as an active comparator. In all 7 studies astemizole was given at 
the prescribed dose of 10 mg mane, to a total of 159 patients. Clemastine, 1 mg b.i.d. 
was added as an active comparator in 5 studies: 3 of these investigated the effects of 
terfenadine and 2 of loratadine. Clemastine was given to a total of 241 patients.
To achieve a comparison between AH's the total number of reports of sedation was 
expressed as a percentage of patients receiving each AH. Given the caveats expressed 
above these indices of sedation showed that the so-called non-sedative antihistamines 
(astemizole: 6.3%; loratadine: 7.1 %; terfenadine; 8.4 %) were indistinguishable from 
placebo (7.5 %), and in sharp contrast with with the classical antihistamines 
(chlorpheniramine: 23.5 %; clemastine: 36.1%), as regards the incidence of sedation.
These results were further subjected to a meta analysis, according to the Mantel- 
Haentzel and Peto method, in which within study placebo differences were compared 
for each of the active treatment groups. Results, analysed using 95% confidence 
intervals, showed that both chlorpheniramine and clemastine, but not astemizole, 
terfenadine or terfenadine were significantly (PO.OOl; Chi-square test) different with 
regard to placebo (Fig. 1). This difference was also reflected in the higher odds ratio 
for sedation with both substances (chlorpheniramine 3.67, clemastine 3.44) when 
compared with those from the other compounds (astemizole 0.94, loratadine 0.91 and 
terfenadine 1.27).
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Fig. 1: Parallel Group (PG) studies: percentage of sedation expressed as
differences from placebo with 95% confidence intervals (Mantel- 
Haentzel and Peto method).
(AST = astemizole, CHLOR = chlorpheniramine. CLEM = 
clemastine. LOR = loratadine, TER = terfenadine)
*: P< 0.001 w.r.t placebo (Chi square test)
%
25
2 0 -
1 5 -
10  -
5 -
AST CHLOR CLEM LOR 
Treatment Groups
TER
The remainder of the placebo-controlled studies followed a cross-over design. A total 
of 320 patients received placebo and antihistamines in a randomised order.
Terfenadine was administered in 7 studies to a total of 186 patients at the 
recommended dose of 60 mg b.i.d., acrivastine was given to a total of 160 patients at 
doses of 4 and/or 8 mg t.i.d.. Other antihistamines (cetirizine: 86 patients in 3 studies, 
clemastine: 38 patients in 2 studies; hydroxyzine: 28 patients; and cyproheptadine: 18 
patients) were less frequently included and used as a second, active comparator, 
except for cetirizine which was the only active compound used in a placebo-controlled 
study (Table 4).
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In this group of studies, the incidence of sedation with placebo reached 9.3%, while 
with the antihistamines of the new generation the incidence was 8.1 (terfenadine),
11.6 (ceterizine) and 18.1 % (acrivastine).
None of the placebo drug differences in percentage of sedation reached significance 
(Fig. 2), although cetirizine showed a higher odds ratio (2.53) than terfenadine (1.17) 
and acrivastine (1.38). The overall incidence of sedation obtained with the older 
compounds was 25 % (hydroxyzine), 42.1 % (clemastine), and 66.7 % 
(cyproheptadine), but as these percentages were calculated from small active 
treatment samples (hydroxyzine: NOPS: 28; clemastine: NOPS: 38; cyproheptadine: 
NOPS: 18) the results are not statistically comparable with those following active 
treatment in larger samples (terfenadine, NOPS: 186; acrivastine, NOPS: 160; 
cetirizine, NOPS: 86).
Fig. 2: Cross-over (CO) studies: percentage of sedation expressed as
differences from placebo with 95% confidence intervals (Mantel- 
Haentzel and Peto method).
(CET = cetirizine, TER = terfenadine, ACR = acrivastine)
20
1 5 -
1 0 -
5 -
CET TER
Treatment Groups
ACR
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2.4 Discussion and conclusions
In this chapter, the overall incidence of sedation in patients receiving placebo varied 
from 7.5 % in parallel group comparisons, to 9.1 % in cross-over trials. The incidence 
of sedation reported with the well-known newer AH's was comparable to that of 
placebo in both PG comparisons and CO trials, when considering calculations based 
upon data extracted from more than 2 studies, namely: terfenadine (PG: 8.4 %; CO:
8.1 %), astemizole (PG: 6.3 %), cetirizine (CO: 11.6%) and loratadine (PG: 7.1 %). 
Acrivastine, although not considered to be a classical antihistamine, was found to be 
notably more sedative than placebo (CO: 18.1 %), but less so than the older 
antihistamines (chlorpheniramine, PG: 23.5 %; clemastine, PG: 36%; hydroxyzine, 
PG: 68.7%). Meta analytic procedures confirmed that both chlorpheniramine and 
clemastine were more liable to produce sedation than any of the other compounds (see 
above: confidence intervals and odds ratio), whilst cetirizine, with an odds ratio of 
2.53, appeared to be less free from sedation than the other so-called non-sedative 
AH's.
Despite the absence of precise methods and measures, the results of the present review 
confirms that, in terms of sedation, patients are able to distinguish between placebo 
and the older, sedative HI antagonists (chlorpheniramine, clemastine, hydroxyzine). 
On the other hand, with the new generation of antihistamines (terfenadine, astemizole, 
cetirizine, loratadine) the patients' experiences of sedative effects are few and not 
dissimilar to placebo.
Two explanations may be found as to why patients' discrimination was so successful. 
The first is related to the principal criterion for inclusion of studies in this review was 
that they had to be double-blind placebo-controlled. However, as with all clinical 
studies, the actual degree to which patients are blinded to active or placebo treatment 
is questionable. This is especially true for treatments which produce a relatively fast 
and easily recognisable effect. Antihistamines generally work within a few days and it 
is not inconceivable that patients quickly realised whenever they had placebo. 
Depending upon the briefing from their treating physician as to whether they were 
participating in a trial with a new non-sedative antihistamine or not, their capability in 
recognising sedation might have been enhanced. It seems therefore that with clinical, 
as with experimental studies, the inclusion of a so-called positive control (i.e. an 
active compound which is known to display the effects under investigation) for
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sedation might be of value. Incidentally, in this review 23 of the 34 PG studies and 8 
of the 14 CO studies were set up this way; as this represents approximately three 
quarters of the total number of studies (31 of 48) which are discussed here, it might be 
concluded that, in this case, such criticism is not entirely appropriate.
A second factor which may influence the patient's detection of sedation is related to 
the symptomatology of allergic disorders. It is well-recognised that allergic rhinitis, in 
addition to the typical nasal symptoms, may also produce a degree of drowsiness 
(often described as a heavy, fuzzy head,.. etc.). Relief of rhinitis symptoms therefore 
may well (apart from a clinical placebo reaction), ameliorate perceived sedation. As a 
non-active treatment is without clinical effect, it will not reduce the "sedation" which 
is intrinsic to the clinical manifestation of the allergy. Thus placebo treatments could 
well be associated with some sedation and a differentiation from active compounds 
(particularly the less sedative ones) will be difficult to maintain. It is clear that such 
pseudo-placebo effects do not play a part in the treatment of allergies of 
dermatological nature. In this review data on 15 studies were compiled investigating 
the effects in chronic urticaria, cold urticaria and dermographia. Terfenadine was the 
only compound which was well-represented in both types of indication, i.e. mainly 
rhinitis in PG (18 rhinitis, 2 chronic urticaria) and only dermatological indications in 
CO (6 chronic urticaria, cold urticaria and dermographia) studies. Nevertheless the 
drug was found to produce an almost identical incidence of sedation in both PG 
(8.4%) and CO (8.1%) studies. With placebo, the incidence observed in the urticaria 
trials was even slightly higher than in PG studies with mainly allergic rhinitis results 
(9.1 % versus 7.5 %). These findings seem to suggest that the symptomatology of the 
allergy plays a minor part in determining the extent of the sedation reported.
This review of clinical trials confirmed the fact that patients' experience sedation with 
certain AH s. Although the methods used to measure sedation in these clinical studies 
were not standardised and rather vague (patient reports), the results seemed to indicate 
this method was adequate enough to demonstrate differences in the sedative profile of 
AH's. The next chapter will evaluate to what extent experimental studies using 
validated test batteries are able to further distinguish between the sedative activities of 
different AH's, and will investigate which measures are most sensitive in detecting 
this sedation.
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CHAPTER 3 PSYCHOMETRIC ASSESSMENT OF DAYTIME
SEDATION IN EXPERIMENTAL STUDIES WITH 
ANTIHISTAMINES
3.1 Introduction and outline
This chapter examines to what extent validated psychometrics have been used 
successfully, not only to detect and assess the sedative potential of AH's in studies 
with non-atopic volunteers, but also to discriminate in a reliable manner between 
different AH's. It is widely accepted that the value of volunteer studies is directly 
related to the sensitivity of the test measures employed. It furthermore seems 
reasonable that test batteries which have previously proven to be sensitive in detecting 
CNS effects of psychotropic agents in general are more likely to be both reliable and 
valid in determining the CNS activity of drugs having HI receptor antagonist activity. 
It is the intent of this thesis to determine to what extent such premises are valid.
Clinical trials with AH's show that even with the so-called classical (i.e. sedative) 
AH's, only a certain percentage of the patients report CNS effects. Despite the fact 
that the number of patients experiencing these effects varies considerably between 
AH's, it is clear that even with the most sedating compounds there is a substantial 
number of patients who do not complain of any sedative effects (Rombaut and 
Hindmarch, 1991). It has been shown in Chapter 2 that amongst the AH's studied in at 
least 3 clinical trials meeting the selection criteria, clemastine was found to be the 
most sedative compound. Nevertheless, more than half of patients who had been 
taking the drug did not complain of any sedation at any time during the studies 
reported.
Clearly, the observations made in these clinical studies are solely based upon 
assessments of spontaneous or elicited patient complaints. In some instances 
subjective reports and objective assessments of CNS effects are in agreement, 
although it is also the case that sometimes subjective and objective assessments are 
not in concordance (Clarke and Nicholson, 1978; Grundstrom et al., 1977; Hindmarch 
and Gudgeon, 1980). It is important to make a distinction between a drug's tendency 
to induce subjective drowsiness and its potential to influence CNS function and 
psychological aspects of performance. This distinction however, does not address the
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fact that some subjects are more prone to experience sedation (albeit subjective 
drowsiness and/or objective impairment) than others. As this variability in sensitivity 
to the psychoactive properties of AH's might potentially hamper the predictive quality 
of volunteer studies, the selection of experimental subjects becomes of primary 
importance. Ideally, volunteers should be screened and only those who have shown 
demonstrable sensitivity to a standard sedative AH included in the trial (Hindmarch 
and Easton, 1986; Hindmarch and Bhatti, 1987). This approach, however, might not 
always be feasible as it is not only time consuming but also adds to the general 
workload of the trial in terms of additional testing, analyses etc. Instead of introducing 
a "volunteer bias", it is preferable to include a positive internal control or verum*, 
whose effects should be demonstrable on a standard test battery in any volunteer 
sample (Nicholson and Stone, 1986; Nicholson et al., 1989; O'Hanlon et al., 1988).
This present review focuses on studies using both placebo and verum controls, as the 
inclusion of both conditions is of paramount importance for the interpretation of the 
results. Its primary goal is to identify (in studies using this paradigm) those 
psychometrics which are particularly sensitive to the CNS effects of HI receptor 
blockers. A secondary objective is to examine whether the results obtained are 
consistent with the results of patient studies of sedation. The results oinon verum 
studies and experiments of interaction of antihistamines and other CNS substances 
will be evaluated by comparison with the findings from placebo and verum controlled 
studies.
For this review all obtainable data from experimental studies with AH's were 
collected, using computer assisted searches of bibliographic databases (Medline, 
Excerpta Medica) to identify publications. There was no "pre-selection" of studies: the 
only criterion was: psychometrics. All antihistamines were included. No distinction 
was made between patient or volunteer studies (although the vast majority of studies 
was conducted in volunteers). There was no particular date limit set regarding earlier 
publications and data was included up to the end of 1992. As well as publications, 
data has also been included from published abstracts, proceedings and conference 
presentations.
* a positive control or -verum is a comparator treament which has been previously shown to reliably 
produce a significant (w.r.t placebo) change or effect on the test(s) or test battery to be used.
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3.2 Results
A total of 109 studies (contained in 79 different source documents) were analysed. 
Thirty-seven of these were both placebo and verum controlled (Table 6), 43 were 
placebo controlled without verum (Table 8) and 9 studies were uncontrolled. Drug- 
AH interaction (with alcohol and benzodiazepines) was the sole object of 2 studies 
and an important aspect of a further 18 studies (Table 10).
The placebo and verum controlled studies produced data on a total of 19 
antihistamines, while the placebo controlled studies investigated a total of 27 
compounds. Sixteen HI blockers were tested in drug interaction studies. In all, data 
on 33 different antihistamines were found with results featuring up to 5 different dose 
levels of particular compounds. Both acute (A: 1 day) and repeated (R: more than 1 
day) dosing regimes were used.
The majority of the studies used a double-blind cross-over design, and although some 
double-blind parallel group comparisons were made, single-blind cross-over or 
parallel group comparison methods were rarely chosen . The number of volunteers 
included in each study was directly related to the design: cross-over studies involved 
as few as 4 subjects (range: 4 to 36; median: 12) while parallel group comparisons 
were conducted with up to 300 patients (range: 8 to 300; median: 45). As anticipated, 
a great variety of tests were used. They have been categorised, grouping tests 
measuring similar CNS events and actions together (Table 5).
While not completely foolproof it provides for a parsimonious way of comparing the 
different measures for their sensitivity to CNS effects in general and sedation in 
particular. For each drug and test dose, results have been listed as "impairment" or "no 
impairment" for each test (using the letter codes as presented in Table 5). If a 
statistically significant difference (P<0.05 or better) between test substance and 
placebo was found on a particular test indicating a disturbed CNS activity then the 
results were listed as "impairment".
The theoretical framework for this categorisation was based on the assumption that 
any (drug) effect can be observed in changes of overt behaviour (Michon, 1973). To 
distinguish between the different components of behaviour which are addressed by 
each measure, an information processing model (Gaillard, 1980; Saunders, 1983),
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Table 5: Categories and codes for psychoperformance measures
Psychomotor performance
A: Actual car driving: weaving and gap acceptance, car steering
B: Simulated car driving: Bettendorfgerat, tracking
Sensorimotor coordination and speed
C: Sensorimotor coordination: adaptive tracking, pursuit rotor, Mashbum coordination task,
Wiener Koordinationsgerat.
D: Reaction Time: reaction time, auditory reaction time, Wiener Determinationsgerat
CNS arousal, information processing
E: Mental arithmetic: serial substractions, numerical reasoning, Duker test
F: Visual search: D2 cancellation, digit symbol substitution, letter cancellation, card sorting,
disc dotting, Bourdon-Wiersma test, Fieldmarkierungstest 
G: Critical Flicker Fusion
H: Colour matching test: Stroop test
I: Logical reasoning: Free association, verbal fluency.
Memory
J: Memory: working memory, visual memory, Sternberg test
Sensory skills
K: Spatial perception: alternation test, visual field index
L: Attention and vigilance: auditory vigilance, visual attention task, continuous performance
task
M: Sensory discrimination: tachistoscope, dynamic visual acuity, auditory discrimination
Motor ability
N: Fine motor ability: Grove pegboard, glass bead picking test, Crawford small parts
dexterity test, tapping rate and accuracy.
O: Body sway: standing steadiness, stabilometer
Electro-physiological
P: EEC: continuous EEG, multiple sleep latency test
Subjective ratings
Q: Rating scales: visual analogue ratings, Leeds Sleep Evaluation Questionnaire, 3 point rating,
estimation o f performance, intoxication, sedation, mood and activation
commonly used in experimental psychopharmacology, was adopted along the lines 
suggested by Hindmarch (1980). The information processing model in 
psychopharmacology uses changes in performance brought about by drugs as a 
cardinal index of the effects of the substance administered. Changes in information 
processing can manifest as changes in speed and accuracy. Although both outcome 
measures are used, speed of reaction is far more common. The classic work of Hick 
(1952) and Hyman (1953) demonstrated that reaction time as a measure of the speed
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of information processing is perhaps the most basic index of psychochological 
behaviour, and is undoubtedly the reason for the emphasis on speed of behaviour in 
the tasks reviewed in Table 5. The information processing model allows the 
identification of three processing stages which mediate between a stimulus and a 
response: viz. a sensory information processing stage, a central stage where 
information is consolidated and coordinated, with output systems in the third stage of 
motor responses. Tests which assess both sensory and motor response stages would be 
regarded as sensorimotor measures and those that include also central (cognitive) 
features would assess psychomotor or skilled behaviour (Fig. 3). The listing in Fig.3 
shows which aspects of psychological performance it was possible to assess using a 
particular test system. It is evident that AH's have been tested, in general, by a wide 
range of psychometrics concerning most aspects of human information processing.
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3.2.1 Placebo and verum controlled studies (Table 6)
The studies where the verum or internal control showed the expected sedative activity 
can be regarded as benchmarks for identifying sensitive test batteries and for reliably 
discriminating between AH's. In general most internal controls behaved as expected.
The most frequently used verum was triprolidine (Alford et al., 1989; Betts et al., 
1984; Betts et al., 1988; Bradley and Nicholson, 1987; Cohen et al., 1985; Nicholson, 
1979; Nicholson et al., 1982; Nicholson and Stone, 1983; Nicholson and Stone, 1986; 
Nicholson et al., 1989; O'Hanlon et al., 1988; Peck et al.,1975; Swire et al.,1988; 
Volkerts et al., 1992). Triprolidine produced effects on most test measures at doses 
between 1.25 mg to 10 mg, but not all tests were sensitive to sedation at the lower 
range of doses used.
Apart from triprolidine, diphenhydramine (50 to 100 mg), hydroxyzine (25 mg) and 
ketotifen (1 mg) were also used as verum, and chlorpheniramine (4 and 16 mg) and 
clemastine (1 mg) were used in some instances, and in others as compounds under 
investigation. However, the majority of tests used failed to discriminate sedation with 
the latter compounds to any consistently reliable criterion.
Table 7a summarises the results obtained with triprolidine. Unvarying effects were 
found in tests which measured the effects of triprolidine on sensorimotor coordination 
(C) where sedation was detected consistently in 9 out of 9 instances. Car steering 
tests (A) which measure a similar sensorimotor function, reflected this sensitivity in 
the five instances in which they were used. Attention tasks (L) were used in three 
comparisons and detected sedation in each of these. The Critical Flicker Fusion Test 
(CFF), an overall measure of information processing capacity and alertness (G) 
demonstrated sedation, indicated as a significant lowering of the threshold, in 5 of the 
6 studies where it was used. The detection rate of sedative effects of triprolidine was 
somewhat lower in other tasks, e.g. reaction time (D: 5 from 8), sensory 
discrimination (M: 5 from 8), EEG measures (P: 4 from 7) and subjective measures of 
sedation ( Q:11 from 18). The remaining tests (B, E, F, J, and K) were either unable to
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detect impairment more frequently than not (Visual search: F, 6 times out of 12; 
Memory: J, 3 times out of 8) or were only used once and without result (Simulated car 
driving: B; Mental arithmetic: E).
Table 7a: Verum controlled studies with triprolidine.
Frequency of detection of impairment, frequency of usage, and 
successful detection of impairment expressed as a percentage of the 
number of times each test category was used.
Code Type of test No. of times Total no. of Successful Detection
impairment detected times used of Impairment (%)
Psychomotor performance
A: Actual car driving: 5 5 100
B: Simulated car driving: 0 1 0
Sensorimotor coordination and speed
C: Sensorimotor coordination: 9 9 100
D: Reaction Time: 5 8 62.5
CNS arousal, information processing
E: Mental arithmetic: 0 1 0
F: Visual search: 6 12 50
G: Critical Flicker Fusion 5 6 83.3
H: Colour matching test: 0 0 0
I: Logical reasoning: 0 0 0
Memory
J: Memory: 3 8 37.5
Sensory skills
K: Spatial perception: 0 0 0
L: Attention and vigilance: 3 3 100
M: Sensory discrimination: 5 8 62.5
Motor ability
N: Fine motor ability: 0 0 0
0 : Body sway: 0 0 0
Electro-physiological
P: EEG: 4 7 57.2
Subjective ratings
Q: Rating scales: 11 18 61.1
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With positive controls other than triprolidine, the tests detected sedation less frequently 
and less reliably (Table 7b). This was partly due to the fact that the measures which had 
been found to be consistently sensitive to the effects of triprolidine were either not (actual 
car driving: A) or less frequently used (sensorimotor coordination, C: 5 instances as
Table 7b: Verum controlled studies with chlorpheniramine, clemastine,
diphenhydramine, hydroxyzine and ketotifen.
Frequency of detection of impairment, frequency of usage, and 
successful detection of impairment expressed as a percentage of the 
number of times each test category was used.
Code Type of test No. of times Total no. of Discrimination rate
impairment detected times used of impairment (%)
Psychomotor performance
A: Actual car driving: 0 0 0
B: Simulated car driving: 2 4 50
Sensorimotor coordination and speed
C: Sensorimotor coordination: 1 5 20
D: Reaction Time: 2 10 20
CNS arousal, information processing
E: Mental arithmetic: 0 0 0
F: Visual search: 5 11 45.4
G: Critical Flicker Fusion 3 6 50
H: Colour matching test: 0 0 0
I: Logical reasoning: 0 0 0
Memory
J: Memory: 1 5 20
Sensory skills
K: Spatial perception: 0 0 0
L: Attention and vigilance: 4 6 66.6
M: Sensory discrimination: 1 3 33.3
Motor ability
N: Fine motor ability: 1 3 33.3
0 : Body sway: 0 1 0
Electro-physiological
P: EEG: 5 9 55.5
Subjective ratings
Q: Rating scales: 15 24 62.5
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compared to 9). The latter test however showed impairment in one treatment 
condition only (diphenhydramine 50 mg). Also the Critical Flicker Fusion test (G) 
detected impairment less frequently (3 out of 6 times) with the other vera than with 
triprolidine. Attention tasks (L) showed a similar detection rate (4 out of 6 times) as 
for triprolidine, as did EEG measures (P: 5 times out of 9) and subjective ratings (Q: 
15 out of 24). Reaction time tests (D), in contrast with the triprolidine data, only 
demonstrated impairment in two of the 10 instances in which they were used, while 
sensory discrimination measures (M) showed detrimental effects in only 1 out of the 3 
instances in which they were used.
Of the remaining tests, the detection of the effects of non-triprolidine vera was low in 
visual search (F: 5 out of 11), non conclusive in simulated car driving (B: 2 out of 4) 
and absent in fine motor ability (N: 1 out of 3), memory (J: 1 out of 5) and body sway 
(O) which was used once, without result.
When combining the results obtained with all the positive internal controls (Table 7c), 
it is appears that actual car driving (A) is the most sensitive measure with a detection 
rate of 100 %, followed by attention tasks (L) 77.8 %, sensorimotor coordination (C)
71.4 %, Critical Flicker Fusion (G) 66.6 % and subjective ratings (Q) 61.9 %. Less 
sensitive are EEG (?) 56.3 % and sensory discrimination (M) 54.5 %, while the 
remaining tests more frequently failed to demonstrate CNS effects with verum 
treatments than they succeeded in detecting them.
It is evident from this group of studies which are considered as being the most 
adequately controlled, that there is no consistent objective or subjective evidence that 
acrivastine (4 to 16 mg), astemizole (10 to 40 mg), azatadine (4 to 8 mg), cetirizine (5 
to 20 mg), levocabastine (topical, 0.5 mg/ml to 2 mg/ml), loratadine (10 to 20 mg), 
tazyfilline (5mg), temelastine (100 mg) and terfenadine (60 to 240 mg) have any 
significant effects on a range of tests of CNS activity.
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Table 7c: Verum controlled studies with triprolidine, chlorpheniramine,
clemastine, diphenhydramine, hydroxyzine and ketotifen. 
Frequency of detection of impairment, frequency of usage, and 
successful detection of impairment expressed as a percentage of the 
number of times each test category was used.
Code Type of test No. of times Total no. of Discrimination rate
impairment detected times used of impairment (%)
Psychomotor performance
A: Actual car driving: 5 5 100
B: Simulated car driving: 2 5 40
Sensorimotor coordination and speed
C: Sensorimotor coordination: 10 14 71.4
D: Reaction Time: 7 18 38.9
CNS arousal, information processing
E: Mental arithmetic: 0 1 0
F: Visual search: 11 23 47.8
G: Critical Flicker Fusion 8 12 66.6
H: Colour matching test: 0 0 0
I: Logical reasoning 0 0 0
Memory
J: Memory: 4 13 30.8
Sensory skills
K: Spatial perception: 0 0 0
L: Attention and vigilance: 7 9 77.8
M: Sensory discrimination: 6 11 54.5
Motor ability
N: Fine motor ability: 1 3 33.3
0: Body sway: 0 1 0
Electro-physiological
P: EEG: 9 16 56.3
Subjective ratings
Q: Rating scales: 26 42 61.9
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3.2.2 Placebo controlled studies without verum (Table 8)
Several of the substances which were used as a verum in the previous set of studies 
(triprolidine, chlorpheniramine, clemastine, diphenhydramine and ketotifen) featured
as test drug in this group of placebo controlled studies. With both chlorpheniramine
and triprolidine impairment was seen in each of the tests which were used, while with
the remaining three compounds detrimental effects were less consistent.
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Table 9: Non-verum controlled studies with triprolidine, chlorpheniramine,
clemastine, diphenhydramine, hydroxyzine and ketotifen. 
Frequency of detection of impairment, frequency of usage, and 
successful detection of impairment expressed as a percentage of the 
number of times each test category was used.
Code Type of test No. of times Total no. of Discrimination rate
impairment detected times used of impairment (%)
Psychomotor performance
A: Actual car driving: 0 1 0
B: Simulated car driving: 1 8 12.5
Sensorimotor coordination and speed
C: Sensorimotor coordination: 2 17 5.8
D: Reaction Time: 3 15 20
CNS arousal, information processing
E: Mental arithmetic: 0 8 0
F: Visual search: 1 4 25
G: Critical Flicker Fusion 0 2 0
H: Colour matching test: 0 1 0
I: Logical reasoning 0 1 0
Memory
J: Memory: 1 2 50
Sensory skills 
K: Spatial perception:
L: Attention and vigilance: 1 3 33.3
M: Sensory discrimination: 1 4 25
Motor ability
N: Fine motor ability: 2 8 25
0: Body sway: 0 1 0
Electro-physiological
P: EEG: 3 4 75
Subjective ratings
Q: Rating scales: 5 16 31.2
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EEG measures (P), with a detection rate for sedation of 75 %, were used in 4 
instances (Table 9). The detection rate for sedation of the other tests used in these 
studies was generally low and failed to reach the 50% level. Even the tests which were 
used most frequently (sensorimotor coordination, C: 17 times and rating scales, Q: 16 
times) and which showed reasonable detection rates (71.4 and 61.9 %) in the verum 
controlled trials, failed to be consistently sensitive (5.8 and 33.3 % respectively) to 
sedation.
On the other hand, in a few instances impairment was found with compounds which 
had failed to produce significant effects in the verum controlled studies. For example:
- Seven studies taken together (Betts et al. 1989; Dorns et al., 1988; Pechadre et al., 
1988; Pechadre et al., 1991; Ramaekers et al., 1992; Rihoux and Dupont, 1987;
Rihoux et al., 1990) provided data on 25 discrete measures following acute 
administration of cetirizine lOmg. In one study (Ramaekers et al., 1992) significant 
impairment was demonstrated on 4 different test measures (actual car driving, 
sensorimotor coordination, memory, EEG), although the 6 other studies which 
investigated the same dose, failed to detect any CNS effects in a total of 21 measures . 
However, one of the latter studies included acute doses of 20 mg as well and reported 
impairment on 2 of 4 measures.
- With loratadine there was one study (Rihoux et al., 1990) which showed a 
significant impairment on the only (subjective) measure following an acute dose of 
20mg.
- In a series of 6 studies (Betts et al., 1989; Bhatti and Hindmarch, 1989; Clarke and 
Nicholson, 1978; Pechadre et al., 1988; Reinberg et al., 1978; Rihoux and Dupont, 
1987) combining a total of 15 tests following an acute dose of 60 mg of terfenadine 
significant CNS effects could be detected in EEG measures only (Reinberg et al.,
1978). One study investigated the effects of acute administrations of 240 mg of 
terfenadine, and found significant impairment only on a simulated car driving task 
(Bhatti and Hindmarch, 1989).
- Following mequitazine 5 mg no detrimental effects could be detected in 2 studies 
(Barres and Dall'ava, 1977; Hindmarch and Easton, 1986), in contrast to the verum 
controlled study where significant detrimental effects were noticed on a sensorimotor 
coordination test (Nicholson and Stone, 1983).
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3.2.3. Interaction Studies (Table 10)
Only two of the former internal controls (chlorpheniramine and diphenhydramine) 
were included in interaction studies. Their potential for interaction proved to be rather 
low, apart from diphenhydramine which at the highest dose tested (100 mg: A) 
produced impairment in 6 out of the 16 tests used.
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Although the frequency with which most tests were used in the interaction studies was 
clearly lower than in the verum controlled studies, the low sensitivity of the tests for 
detecting alcohol or diazepam interaction is undeniable (Table 11). As with the
Table 11: Interaction studies with chlorpheniramine and diphenhydramine.
Frequency of detection of impairment, frequency of usage, and 
successful detection of impairment expressed as a percentage of the 
number of times each test category was used.
Code Type of test No. of times Total no. of Discrimination rate
impairment detected times used of impairment (%)
Psychomotor performance
A: Actual car driving: 0 0 0
B: Simulated car driving: 0 2 0
Sensorimotor coordination and speed
C: Sensorimotor coordination: 2 7 28.6
D: Reaction Time: 3 8 37.5
CNS arousal, information processing
E: Mental arithmetic: 1 3 33.3
F: Visual search: 1 4 25
G: Critical Flicker Fusion 0 3 0
H: Colour matching test: 0 1 0
I: Logical reasoning: 0 1 0
Memory
J: Memory: 0 1 0
Sensory skills
K: Spatial perception: 0 0 0
L: Attention and vigilance: 0 1 0
M: Sensory discrimination: 0 5 25
M otor ability
N: Fine motor ability: 1 2 50
0 : Body sway: 0 1 0
Electro-physiological
P: EEG: 0 0 0
Subjective ratings
Q: Rating scales: 1 6 28.6
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placebo controlled studies the discrimination rate of sensorimotor coordination (C) 2 
out of 7) and rating scales (Q) (1 out of 6) was low (28.6 % for both tests) and in 
contrast with what was observed in the verum controlled studies (71.4 and 61.9 % 
respectively).
Overall, the results from the interaction studies showed little evidence that would 
contradict the findings obtained in the more controlled experiments in Table 6. 
However, results suggesting a potentiation of the effects of alcohol were found 
following acute doses of alcohol and acrivastine (8mg) on tests of reaction time and 
body sway (Cohen et al., 1985) and terfenadine 240 mg on simulated car driving 
(Bhatti and Hindmarch, 1989).
3.3 Discussion and conclusions
Perhaps the most important finding from the studies reviewed is the lack of objective 
evidence for the sedative activity of certain antihistamines, generally considered to be 
sedative. The only substance that regularly shows a sedative action is triprolidine (at 
doses up to 10 mg), although the effect is not totally consistent since from the studies 
in Tables 1 and 2 it is evident that 62 tests register impairment whereas 30 tests are 
unable to show any detrimental effect. It is accepted that with the slow release 
formulation of the substance the expected sedation might not occur within the time 
frame of some acute dose studies. The problem of showing a consistent and persistent 
impairment of CNS functions with triprolidine even at doses of 10 mg encapsulates 
the problems of psychopharmacological profiling of antihistamines. The reasons for 
the relative low (67%) detection rate for impairment needs explanation, as such a poor 
discrimination is barely acceptable for a verum condition. There would seem to be 
possible contributory factors to help explain the lack of a universal verum effect. 
Firstly, the test times used in studies were not consistent, which, coupled with 
different pharmacodynamics brought about by the various galenic formulations 
available, created a variation of effects. Secondly, the various psychometrics seem to 
have a different sensitivity to the sedative effects of triprolidine, although a 
consideration of the results in Tables 6 and 8 shows that there are no consistently 
insensitive tests. On the other hand, it seems that adaptive tracking and related tests of 
sensorimotor coordination, e.g. car steering, (C and A) and attention tasks (L) all with 
a sensitivity of 100% are particularly good in detecting triprolidine induced sedation, 
as is critical flicker fusion (G) with a detection rate of 83.3%. Reaction time tests and
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subjective questionnaires (Q) discriminated sedation in respectively 66.6 % and 63.7 
% of the times, and also sensory discrimination (M) seemed to detect impairment 
more frequently than not (62.5 %), while EEG measures (P: 57.2 %) and visual 
searches (F: 53.8 %) seemed to discover detrimental effects in only slightly more than 
half of the instances (Table 12).
Table 12: Verum and non-verum controlled studies with triprolidine.
Frequency of detection of impairment, frequency of usage, and 
successful detection of impairment expressed as a percentage of the 
number of times each test category was used.
Code Type of test No. of times Total no. of Discrimination rate
impairment detected times used of impairment (%)
Psychomotor performance
A: Actual car driving: 5 5 100
B: Simulated car driving: 0 1 0
Sensorimotor coordination and speed
C: Sensorimotor coordination: 9 9 100
D: Reaction Time: 6 9 66.6
CNS arousal, information processing
E: Mental arithmetic: 0 1 0
F: Visual search: 7 13 53.8
G: Critical Flicker Fusion 5 6 83.3
H: Colour matching test: 0 0 0
I: Logical reasoning: 0 0 0
Memory
J: Memory: 4 9 44.4
Sensory skills
K: Spatial perception: 0 0 0
L: Attention and vigilance: 4 4 100
M: Sensory discrimination: 5 8 62.5
Motor ability
N: Fine motor ability: 1 1 100
0 : Body sway: 0 0 0
Electro-physiological
P: EEG: 4 7 57.2
Subjective ratings
Q: Rating scales: 12 19 63.7
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It is somewhat surprising that there seems to be no greater impairment of a range of 
tests produced by 10 mg triprolidine as compared to 5 mg, and perhaps the dose 
threshold for the sedative CNS effects of triprolidine, in non-spansule formulation is 
quite low. However, it appears that 10 mg triprolidine is a reasonably certain verum 
treatment when given in immediate, as opposed to sustained, release formulation. 
None of the other sedative substances, sometimes used as vera (e.g. chlorpheniramine 
and diphenhydramine) show as much consistency in the effects produced and/or 
detected by the psychometrics used in these studies.
If the later antihistamines did not behave as consistent vera in the verum controlled 
studies, it is not surprising that these substances also failed to produce consistent 
effects in the non verum controlled and interaction studies.
This partly explains the low overall success rate of the tests to detect impairment with 
these substances. As can be seen from the analysis of the test results obtained in the 3 
sets of studies {verum and non verum controlled and interaction studies) with 
triprolidine and the lesser consistent vera (chlorpheniramine, clemastine, 
diphenhydramine, hydroxyzine and ketotifen) the discrimination rates of sedation of 
the majority of the tests do not even reach 50% (Table 13).
There are only 3 tests categories which have a detection rate of more than 50%. It is 
interesting to note, however, that 2 of them (actual car driving, A: 83.3% and EEG, P: 
60%) represent a number of different types of measures each (see Table 5). These 
measures were grouped because of a common approach, which mainly consisted of 
the use a specific piece of equipment (i.e. a car and a polygraph respectively), rather 
than because of the technique used with this equipment. Especially with regard to 
actual car driving, a further division into the different types of measures (deviation, 
gap acceptance, weaving etc.) would result in a set of subcategories of tests which 
have been used only in a few instances each, and therefore can not reasonably be put 
forward as tests with proven discriminative value. Similarly, EEG measures (?) 
covered a variety of techniques where electroencephalographic recordings were made 
over a range of time periods from 20 minute (during which time subjects were invited 
to sleep; Roth et al., 1987) to continuous 24 hour recordings (during which time 
subjects continued their normal daytime activities; Alford et al., 1989). This test
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Table 13: Verum, non-verum controlled and interaction studies with
triprolidine, chlorpheniramine, clemastine, diphenhydramine, 
hydroxyzine and ketotifen.
Frequency of detection of impairment, frequency of usage, and 
successful detection of impairment expressed as a percentage of the 
number of times each test category was used.
Code Type of test No. of times Total no. o f Discrimination rate
impairment detected times used of impairment (%)
Psychomotor performance
A: Actual car driving: 5 6 83.3
B: Simulated car driving: 3 15 20
Sensorimotor coordination and speed
C: Sensorimotor coordination: 14 41 34.1
D: Reaction Time: 13 39 33.3
CNS arousal, information processing
E: Mental arithmetic: 1 12 8.3
F: Visual search: 13 31 41.9
G: Critical Flicker Fusion 8 17 47
H: Colour matching test: 0 2 0
I: Logical reasoning 0 2 0
Memory
J: Memory: 5 16 31.2
Sensory skills
K: Spatial perception: 0 0 0
L: Attention and vigilance: 8 13 61.5
M: Sensory discrimination: 7 20 35
Motor ability
N: Fine motor ability: 4 13 30.8
0: Body sway: 0 3 0
Electro-physiological
P: EEG: 12 20 60
Subjective ratings
Q: Rating scales: 32 66 48.5
category was only mildly successful in detecting sedative effects. It is possible 
however, that the discriminative potential of this undoubtedly objective test category 
might have been diluted by combining results obtained using different techniques.
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Attention and vigilance tasks (L), on the other hand, despite using different modalities 
and pieces of equipment (e.g. visual versus auditory tasks) are all measuring the same 
type of basic process. This category can therefore be regarded as reasonably 
homogeneous. Nevertheless these tests were able to discriminate in slightly less than 
two thirds (61.5 %) of the instances in which they were used (13).
It is evident that the detection of sedation is directly dependent on the actual presence 
of sedative effects of the drug. If the sedative effects of AH's are dose related, it is not 
surprising that test measures are unable to detect sedation below their lowest threshold 
for stimulus detection. In the previous analyses no distinction was made between the 
different doses of the selected AH's, as a further breakdown into different dosage 
groups would have resulted in too few tests being available for comparisons between 
drugs to be made and some tests being used too infrequently to draw any conclusions 
at all. It is clear from tables 6, 8 and 10, however, that with the vera some evidence of 
sedation could be seen over the full range of doses used. Similarly, as indicated in the 
introduction of this review, there is a substantial inter individual variability with 
regard to AH induced sedation, and it is possible that a number of subjects do not 
experience any sedative effects at all. In that case the failure to detect sedation is 
obviously not due to the psychometrics, and the tests or test battery cannot be blamed 
for lack of sensitivity of not registering any sedation.
The analysis of the psychoperfomance results obtained in the above described studies 
failed to identify any particular measure which by itself could be relied on as a valid 
indicator of the sedation brought about by a range of sedative antihistamines. On the 
other hand those measures that seemed to demonstrate sedation successfully were not 
used widely enough to make possible any generalisation about their reliability. Even 
the use of psychometric test batteries failed to show clear-cut results in terms of the 
sedative effects of established sedative AH's. Most verums behaved as such on 
number of tests, but these did not always represent the majority of the measures used. 
The lack of sedation of the AH's of the new generation was broadly confirmed.
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CHAPTER 4 GENERAL CONSIDERATIONS REGARDING
METHODS AND MEASURES OF SEDATION IN 
EXPERIMENTS WITH ANTIHISTAMINES
It is clear that routine clinical studies, through their very nature, are capable only of 
providing relatively vague clues about the sedative potential of AH's, and that they are 
unable to uncover the intrinsic CNS properties of these compounds. Even when the 
investigation of therapeutic efficacy is not the sole (or primary) aim, attempts to gauge 
sedation are usually restricted to a descriptive analysis of subjective reports collected 
in heterogeneous populations of patients. Although such methods are not without 
pragmatic clinical value, they can only give a general indication of the overall 
incidence of CNS effects (or sedation) in a given population, and it is obvious that a 
number of basic questions cannot even be touched upon. For instance, the clinical 
environment in which efficacy trials take place makes it difficult (in terms of the 
extent to which dependent variables can be controlled) to simultaneously research the 
effect of HI-receptor antagonists on other, more objective aspects of CNS 
functioning. This is primarily because objective tests require computer hardware or 
other non portable equipment.
From the previous chapter it was clear that even in the controlled environment of the 
laboratory, the sedative effects of AH's on different aspects of CNS functioning can 
only be inferred on a probability as opposed to certain basis. While the sensitivity of 
the test batteries used undoubtedly play an important role, the possible interference of 
a combination of drug specific variables cannot be ruled out. If an experimentally 
reliable and valid assessment of sedation is to be made following administration of 
AH's, several variables must be attended to and controlled. The principal ones which 
need attention in psychopharmacological studies are:
1. inter-subj ect variability
2. dose response relationship
3. different routes of drug administration
4. single versus repeated dosing (at steady state), including aspects of 
pharmacokinetics
5. the time course (pharmacodynamics) of drug action and
6. the possible interaction with other substances
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This thesis investigates the part played by each of these variables using a series of 
controlled experiments in a population of normal healthy (non-atopic) volunteers. 
However, while it is evident that volunteer studies provide a superior setting for 
sy stematic observation, it has to be kept in mind that many of the questions which are 
the subject matter of this thesis are interrelated. The majority of the individual 
experiments described hereafter will therefore inevitably address more than one of 
these issues simultaneously. Table 14 shows which possible sources of variability are 
dealt with in each of the 7 separate experiments which follow.
Table 14: Influences on test measures investigated in each experiment.
x: primary purpose of the experiment 
(x): other sources of variability considered
Experiment No.
Source 1 2 3 4 5 6 7
dose response 
relationship
x (x) (x) (x ) (X) (x)
route of 
administration
X
acute vs repeated 
administration
X (x)
time course 
of action
(x) X (x) (x) (x) (X)
effects on 
sleep
X X
potential interaction 
with other substances
(x) X
All experiments described in this thesis were commissioned by the manufacturers of 
the AH's under investigation, and all protocols had to be approved by them in order to 
receive blinded medication. It was therefore not possible to decide freely about the 
design of the studies and very difficult to follow an a priori defined research plan. The 
compromises which had to be made were generally related to the choice of the 
comparator and/or the size of the experiment.
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Clearly, the chief objective of the manufacturers for performing a volunteer study with 
their compound was to demonstrate that it lacked sedative effects. This thesis, 
however, was not primarily concerned with the (lack of) sedation of the AH's tested, 
but aimed at investigating the sensitivity of test measures used for detecting AH 
induced CNS effects. The next chapters will describe how the latter aim was pursued. 
It is hoped that they will illustrate that, even within the confinements of opportunistic 
research, valuable conclusions can be formulated.
The first 3 experiments are discussed in Chapter 5 which is concerned with verum 
controlled treatment regimens of AH's and a range of psychometric tests.
Experiments 1 and 2 assessed the possible sedative of different doses of 
R 72 075, in comparison with placebo and a positive control (oral levocabastine), 
with special attention to inter-subject variabilities. In Experiment 1 acute effects 
(after single administration) were studied and compared between subjects, while 
Experiment 2 examined both acute and subchronic effects (after repeated 
administration, at a pharmacokinetic steady state) of a higher range of doses and a 
first attempt was made to study the time course of the CNS effects, by testing at two 
different times following drug administration. Although not specifically intended to 
provide information about route of administration, the results obtained with oral 
levocabastine in Experiments 1 and 2 are of interest for the discussion of a later 
experiment, in which a topical formulation of the drug was used. Experiment 3 
investigated the possible sedative effects of another HI blocking agent, ebastine in a 
placebo-controlled experiment with triprolidine as a verum. The overall goals of this 
experiment were twofold: firstly to evaluate the sensitivity of the psychometrics in 
assessing the effects of dose ranging treatment regimens and secondly in detecting 
differences between the effects of single and repeated doses. Of primary interest for 
this thesis, however, was the assessment of the time course of pharmacodynamic 
activity which was determined for up to 8 hours following acute drug treatment and 
for 5 days with repeated drug regimens.
The next experiment is described in Chapter 6. The main aim of Experiment 4 was to 
evaluate the effects of an AH when different routes of drug administration were used. 
After having demonstrated in Experiments 1 and 2 that oral levocabastine behaves as 
a reliable verum. Experiment 4 measured the effects of the single administration of 
two different concentrations of topical levocabastine (eye drops and nasal spray), for 5
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hours after administration. Triprolidine, as in Experiment 3, was used as positive 
control and the sensitivity of the tests in assessing the time course of the pharmaco 
dynamic activity of this verum for up to 5 hours was considered as being of primary 
interest within the context of this thesis.
Chapter 7 used measures of sedation and/or arousal during the sleep/wake cycle to 
investigate the effects of AH's, alone or in combination. In order to assess the effects 
of a known sedative HI receptor antagonist, hydroxyzine, a new measure, Continuous 
EEG (C-EEG) was added to the usual test battery in Experiment 5. C-EEG provides 
the possibility of continuously assessing sedation and other changes in CNS activity 
during the 24 hours immediately following medication. This allowed for a comparison 
between continuous EEG measures and the more intermittent testing employed with 
psychometric test batteries. Experiment 6 was set-up to investigate the measures of 
sedation in studies where there was concomitant use of decongestants with 
antihistamines. Since decongestants are known to affect sleep, the C-EEG was again 
used, this time mainly to detect any sleep disruption following medication.
In Chapter 8 a battery of psychometrics was used to assess the differences in 
measured sedation between AH's. Experiment 7 investigated both the dose response 
relationship and dose equivalence of the five AH dose treatment regimens by using 
inhibitory effects on the histamine wheal and flare reaction. A secondary objective of 
this experiment was to use psychometrics to measure the effects of the co­
administration of alcohol. Finally as a subgroup of volunteers was evaluated on C- 
EEG, and the time course of the CNS effects was examined.
Before describing each of these experiments in detail, their common features will be 
discussed. These concern the test measures, the statistical methods and any relevant 
general methodological issues.
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4.1 Experimental procedures
All 7 experiments were conducted using the same basic procedures. Therefore, instead 
of repeating the methods section in full for each separate experiment, a detailed 
description is given in this section. Consequently, this description serves as a primary 
reference for the detailed discussion of each of the experiments in the next Chapters.
4.1.1 Subject selection
All experiments were conducted in normal healthy non-atopic volunteers. They all 
were Caucasian. The key selection criteria for all 7 studies were identical.
Inclusion criteria:
1. Between 18 and 55 years of age.
2. Within 20% of normal body weight.
3. Healthy (as confirmed by medical examination), except for experiment 10 
(subjects had to have a history of hay fever, and positive skin tests and/or 
RAST for pollen).
4. All female volunteers to be using contraceptive measures.
Exclusion criteria :
1. Use of any systemic medication including both prescribed and OTC 
preparations but excluding the contraceptive pill.
2. History of alcohol or drug abuse.
3. History or cardiovascular, renal, hepatic or gastrointestinal disorder.
4. History of psychiatric illness.
5. Pregnancy.
6. Lactation.
7. Inability to give written informed consent.
4.1.2 Pre-study
All experimental protocols were approved by the independent Ethics Committees 
responsible for the Research Centre at which they were performed. Experiments 1 
and 2 were conducted at the pharmacology department of Janssen Pharmaceutica, 
Beerse, Belgium, while all the other experiments (Experiments 3 to 7) were
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performed at the Human Psychopharmacology Research Unit, The University of 
Leeds, UK. Each experiment was carried out in accordance with the Declaration of 
Helsinki (Tokyo, Rome and Venice amendments). All subjects gave written informed 
consent before starting the study and their general practitioners were informed, and 
gave approval for participation.
At pre-study screening the following routine evaluations were made:
Demography: 
Personal habits: 
Medical history
Age, weight, height, race.
Smoking, alcohol, caffeine intake.
Allergic disease, drug allergy, cardiovascular, hepatic, renal, 
pulmonary, psychiatric or neurological disorders, any relevant 
history.
Physical examination: General appearance, condition of skin, condition of mucosae,
eyes, ears, nose, mouth and throat, thyroid, lymph nodes and 
extremities.
Supine heart rate, supine blood pressure, standing heart rate, 
standing blood pressure, clinical examination.
Clinical examination.
Clinical examination.
Clinical examination, cranial nerves, peripheral nerves, fundi, 
nystagmus, lateral sway, reflexes, finger tremor.
Details of all drugs taken (including drugs of abuse and OTC 
preparations) both past and current were recorded.
Only subjects who, in the opinion of the clinical investigator, were in good physical 
and psychological health were admitted to the various studies.
Cardiovascular:
Respiratory: 
Gastrointestinal: 
Nervous system:
Drug history:
In order to minimise learning effects, all subjects underwent, before entry to the study, 
a thorough training and familiarisation on each of the psychometric test procedures 
until their task performance was stabilised and had reached a plateau.
Although the studies were conducted in two different research centres, they were all 
performed using the same equipment, methods and procedures.
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4.1.3 During study
Subjects were randomly allocated to treatment according to a predetermined code.All 
subjects acted as their own control and received treatments according to a schedule 
based upon a set of self conjugate Latin squares. As a rule, study medication was 
administered at the Research Centre, under supervision of a Study Nurse. However, 
all treatments in Experiments 1 and 2, and all except the first in Experiment 7, the 
third and fourth in Experiment 3 and the evening intakes in Experiments 6 and 7, 
occurred at home and could therefore not be directly supervised. Subjects were 
forbidden to take other medications during the study. In all experiments subjects were 
required to abstain from alcohol and caffeine containing beverages (tea, coffee, cola, 
chocolate) for 12 hours prior to and during each study day. At the Study Centre 
caffeine-free drinks were provided on request. Smoking was not allowed during the 
study days. Food intake was standardised in the experiments which required subjects 
to take meals at the Study Centre.
Subjects were not allowed to drive or operate heavy machinery on days that 
medication had been taken. They were transported to and from the Study Centre on 
all test days. There were no restrictions with regard to any other activities except that 
subjects were not allowed to swim or take showers when wired up for EEG evaluation 
(Medilog) in Experiments 5 to 7 .
Adverse events were recorded from spontaneous comments volunteered by the 
subjects and from comments made in response to the open question "How are you 
feeling at the moment". Any reported events were graded by the clinical investigator 
with respect to severity and causal relationship, if any, to the test treatment.
4.1.4 Post-study
Compliance was checked in all experiments and the tablet returns recorded in the Case 
Report Form. At the end of the treatment period, subjects underwent the same medical 
examinations as at the pre-study screen (i.e. physical, cardiovascular, respiratory, 
gastrointestinal, nervous system).
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4.2 Test measures
A limited number of test measures have been used in the 7 experiments which form 
the experimental part of this thesis. Some tests have been included in all 7 
experiments, other measures have been added to the test battery in selected 
experiments only. To avoid repetition, the present section will deal with the selection 
and description of each of these test measures, and serve as a reference and 
description for each use of the tests in subsequent studies.
4.2.1 Introduction
Psychoperformance, i.e. the overt behavioural expression of CNS functioning, 
involves numerous subfunctions, which precludes it being treated as a unit. At its 
simplest level the transmission of information is related to certain CNS events which, 
at present, have no proven basis in neurochemical substrates. Every response to an 
external stimulus must involve some identification and "reaction" to the 
transformation contained in the stimulus via a series of CNS events. (Birren et al.,
1979). It is an extension of this information processing approach that has led to the 
development of tests for these various CNS events that go to make up the information 
chain between stimulus (signal) and response (behaviour). Hindmarch (1980) argued 
that information processing was divided into three essential components viz. sensory, 
central integration, and motor coordination (see previous Chapter, Fig 3). Therefore a 
thorough investigation of the effects of psychoactive compounds presupposes that 
each of these components is carefully examined. It is clear that this can only be 
achieved by means of a battery of selected tests. Ideally this battery should comprise a 
test for each of the following aspects: sensory input (e.g. vigilance task, letter 
cancellation), central processing, integration and memory (e.g. mental arithmetic,
CFF, digit span), motor activity (peg board), psychomotor performance (card sorting, 
choice reaction time) and sensorimotor coordination (pursuit rotor, tracking test).
Sedation significantly affects psychoperformance, and a variety of tests have proven 
to be sensitive to the sedative effects of a number of known sedative substances, such 
as benzodiazepines, antidepressants etc. However, when it comes to AH's the situation 
seems to be more complex. The previous Chapter revealed that the detection of 
sedative effects is much less straightforward and there are no specific tests which
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seem to be particularly pertinent for measuring AH induced sedation. It was therefore 
decided, with regard to all 7 experiments, to focus on those tests which, over the 
years, had proven to be sensitive to drug induced sedation in general: CFF and choice 
reaction time tests. Both tests were found to be amongst the most sensitive to the 
effects of anaesthetics (Hindmarch and Bhatti, 1987), benzodiazepines (Church and 
Johnson, 1979; Crome and Newman, 1978) and antidepressants (Hindmarch, 1988; 
Seppala, 1977).
In addition to these core tests, which were used in all experiments, other measures 
were added to the battery. Of these, the tracking test was considered the most 
important, as this type of sensorimotor coordination was shown to be one of the most 
successful measures in detecting triprolidine induced sedation (see Chapter 3, Table 
12), showing a discrimination rate of 100 %. CFF and CRT also proved to be able to 
detect triprolidine induced sedative effects reasonably well: they were successful in
83.3 and 66.6 % of the cases respectively.
4.2.2 Selection of measures: theoretical framework
In each of the experiments, which in the following Chapters will be described in 
detail, a battery of tests was used, comprising measures which had previously been 
shown to be reliable and sensitive in detecting central effects of psychoactive 
medications (see also next section; references for each test are given below). The main 
measures were:
Critical Flicker Fusion (CFF)
Choice Reaction Time (CRT)
Simulated Car Tracking Test (SCTT)
Sternberg Memory Scanning Task (SMST)
Line Analogue Rating Scale (LARS) or Visual Analogue Scale (VAS)
Leeds Sleep Evaluation Questionnaire (LSEQ)
The first four tests are objective measures of information processing, which are 
concerned either with central processing activities {CFF\ integration; SMST: 
memory), a combination of sensory and motor processes (sensorimotor coordination: 
SCTT) or a combination of sensory and motor processes with a CNS processing 
component (psychomotor performance: CR7)(Fig. 4). Each of the assessments of the
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components of information processing used in this thesis have proved successful in 
detecting CNS effects of psychoactive drugs (Hindmarch, 1980; Volz and Stumm, 
1995). Specifically, AH's were shown to possess sedative effects in more than 80% of 
the times that specific tests were used from a literature search (see previous Chapter, 
Table 1; Rombaut and Hindmarch, 1994). Ideally, as indicated in the introduction, a 
battery of tests should be used to maximise the detection of drug induced change.
Such battery should include measures of sensory processing, motor activity as well as 
central abilities. However, many of the tests of sensory processing (detection, 
perception and recognition) have not proved very reliable in psychopharmacology, 
except for attention and vigilance tasks. These latter measures are by nature very time 
consuming and not appropriate for inclusion in a test battery which is performed at 
regular (short) time intervals. It was therefore decided not to include them in the 
battery used thruoghout this thesis. Measures of motor activity were also excluded, as 
they tend to be contaminated by the great inter-individual differences in performance 
which exist prior to the administration of a drug. It is evident from Fig. 4 that, 
although no specific psychometric is used for either sensory or motor activity, the 
basic information processing mechanisms are assessed. This battery ensures that 
deficits in psychoperformance will be detected.
In addition to these main objective measures of information processing, two main 
subjective evaluations consisting (of sets of) visual analogues were added to examine 
the subject's personal assessment of daytime (LARS or VAS) or nighttime (LSEQ)
CNS effects.
4.2.3 Selection of measures: experimental set-up
CFF, CRT and LARS or VAS were selected as the core tests of this main battery. They 
were included in all 7 experiments. SCTT and SMST were added from Experiment 3 
onwards, as was LSEQ, except for Experiment 4.
In addition to this main battery, other measures were included in some of the 
experiments in order to explore their potential value in detecting drug induced central 
effects. These were Word Recognition Task (WRT), to explore other aspects of 
psychological and memory function (recall) (Experiments 4 and 7); Fitness Rating 
Scale (FRS) as an additional global measure of subjective sedation and well-being
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(Experiments 1 and 2); and Continuous Electrophysiological Measurement (C-EEG) 
as a psychophysiological measure of brain activity, to ensure that all significant 
changes in wakefullness were captured over a 24-hour period (Experiments 5, 6 and 
7). All objective and subjective measures, except C-EEG, were administered 
intermittently, at predetermined time intervals, before and after drug administration. 
Table 15 summarises the tests which were used in each experiment.
Table 15: Experimental measures used in each of the 10 experiments
Experiment No.
Measures 1 2 3 4 5 6 7
CFF X X X X X X X
CRT X X X X X X X
SCTT X X X X X
SMST X X X X X
WRT X X
LARS X X X X X
VAS X X
FRS X X
LSEQ X X X X
C-EEG X X X
4.2.3 Description of measures 
CFF
CFF is a measure of CNS arousal which "must be regareded as the measure of choice 
for investigating the change in overall integrative activity of the CNS produced by 
psychoactive drugs" (Hindmarch, 1980). In the first scientific meeting held on CFF, 
Bobon called this test "a valid and economical measure of sedation versus alertness"
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which "can also be reliable if certain variables are taken into account" (Bobon et ah, 
1982). Although the interest in CFF goes back to the 18th century (Landis, 1953), this 
measure first started to raise the attention of psychopharmacologists in the early 40's 
because of its relationship to CNS "fatigue" (Simonson and Enzer, 1941). More 
recently it has been used extensively (Curran, 1990) to assess the effects of 
psychoactive compounds on the CNS. Despite the variety of experimental equipments 
(monocular versus binocular viewing; foveal versus peripheral measurement) and 
psychophysical methods (method of limits; forced choice; method of adjustment) the 
literature shows a remarkable consistency in the observed effects of sedatives and 
stimulants (Hindmarch, 1982). CFF has also shown to related to other measures of 
CNS arousal and activity (Parrot, 1982).
The CFF test used in all 7 experiments was part of the Leeds Psychomotor tester 
(Hindmarch, 1975; Hindmarch and Parrott, 1978; Hindmarch and Subhan, 1983) and 
was applied as a means of measuring the ability to distinguish discrete sensory data, 
taken as an index of overall CNS activity. Subjects were required to discriminate 
flicker fusion in a set of four light emitting diodes held in foveal fixation at one metre. 
Individual thresholds were determined by the psychophysical methods of limits on 3 
ascending and 3 descending scales (Woodworth & Schlosberg, 1958).
CRT
Reaction time to a critical stimulus is a popular, and basic, measure of sensorimotor 
performance in psychopharmacology (Hindmarch et al., 1988). Simple reaction time 
tests are concerned with the latency of the response only, while choice reaction time 
tests introduce an extra attentional element to the stimulus response situation which is 
more dependent upon concentration. The CRT, as part of the Leeds Psychomotor 
Tester (Hindmarch, 1975; Hindmarch & Parrott, 1978; Hindmarch, 1988) was used as 
a measure of psychomotor performance. Subjects were required to extinguish one of 
six red lights illuminated at random, by touching the appropriate response button. The 
Leeds Psychomotor Tester enabled the recognition {RRT) and motor (MRT) 
components to be separated from the total reaction time {TRT). The response measure 
used was the mean reaction time for 20 stimulus presentations (after 5-10 rehearsals).
SCTT
Tracking tasks have proved reliable in detecting sedation produced by psychoactive 
drugs (Borland and Nicholson, 1974; Muller-Oerlinghausen, 1977). The SCTT
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(Hindmarch et al., 1983; Hindmarch & Bhatti, 1987), an interactive test of 
psychomotor function entailed tracking an arrow, where movement was controlled by 
a fixed program, using a joystick. The response measure (RMS) was the mean 
deviation from the track program over the 1 minute trial period, with a lower score 
indicating more accurate tracking. In addition, a 'peripheral awareness' task was 
included in which the subject had to respond to a stimulus presented in the periphery 
of vision, while simultaneously attending to the tracking task. The mean reaction time 
(RT) to 10 of these peripheral stimuli per trial was also used as a response measure.
SMST
High speed scanning ability and retrieval from short-term memory was assessed using 
a technique based on the reaction time method in memory research (Bhatti & 
Hindmarch, 1987; Hindmarch & Subhan, 1985; Sternberg, 1966; 1969; 1975). 
Subjects were required to judge whether a test digit was contained within a short 
memorised sequence of digits. Both the presentation of stimulus material and the 
measurement of response latency were computerised. The test has been shown to be 
reliable in detecting sedation in studies of various sedative agents (Sherwood and 
Kerr, 1993).
WRT
Retrieval of verbal information from memory was assessed by measuring recognition 
times for test words, some of which were from a list presented earlier in the tests. The 
subjects were required to memorise a list of 14 words presented at a rate of one per 
second. This was followed by the presentation of a test list of similar length, half the 
words were from the original list, half were new words. Subjects were instructed to 
respond as quickly and as accurately as possible by pressing the appropriate key on a 
two choice response box. Both the presentation of stimulus material and the 
measurement of response latency was computerised. This test had been specifically 
devised for the detection of benzodiazepine sedation (Hindmarch et al., 1988), and 
was added to some of the experiments in order to investigate its potential value in 
detecting AH induced sedation.
LARS and VAS
Visual analogue scales originated in the 1920's (Freyd, 1923; Hayes and Patterson, 
1921) and since the late 60's have been useful in demonstrating sedation in studies of 
psychoactive drugs (Aitken, 1969; Bond and Lader, 1974).
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LARS : Subjective ratings of drug effects were obtained from a set of 10 cm line 
analogue rating scales (Hindmarch & Gudgeon, 1980). The mean score of ratings of 
"tiredness" "drowsiness", and "alertness" (included among several distractor scales) 
was taken as a measure of perceived sedation.
VAS : The VAS consisted of a 100 mm line with the extremes "fully awake" and 
"completely asleep", (Huskinsson, 1974; Nicholson et al., 1985). This scale had the 
same origin as the LARS, but was, in contrast to the LARS, limited to one the 
assessment of one effect only (sleepiness).
FRS
This scale consisted of a 4-point rating scale (0: not fit at all, to 3: as fit as possible) 
according to which subjects indicated their perceived level of "fitness" (note: this 
scale was used only in the experiments 1 and 2, which were conducted in a Dutch 
speaking population, for whom the word "fit" unquestionably indicated a state of 
mental and physical alertness).
LSEQ
The LSEQ (Hindmarch 1975; Hindmarch, 1980; Parrott and Hindmarch, 1978) 
consisting of a set of 10 cm visual analogue lines, was used to record subjects' 
impressions of the Ease of Getting to Sleep {GTS), the Quality Of Sleep {QOS), the 
ease of Awakening From Sleep {AES) and the integrity of Behaviour Following 
Waking {BFW). It has been shown to be particularly sensitive to drugs that produce 
sedation and has been used to assess sleep promoting properties of various hypnotics 
(Hindmarch, 1984; Parrott and Hindmarch, 1980).
C-EEG
Electrophysiological measures were taken with the help of an electrophysiologist 
affiliated to the Human Psychopharmacology Research Unit, University of Leeds, 
using four channel Oxford 'Medilog' ambulatory recorders providing a non-invasive 
technique for continuous electrophysiological measurement. Three channels of 
electrophysiological (EEG) activity were recorded (FP%-A%; G^-A^ ; O2 -A^ ), of 
which the occipital channel provided specific information for the determination of 
sleep/wake status (Carskadon, 1979). The fourth channel recorded time/event 
information.Three additional channels provided eye movement (EOG: 2 channels) and 
muscle activity (EMG: 1 channel). The utility of portable recorders for assessing sleep 
has been demonstrated by Se witch and Kupfer (1985).
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Each record was analysed visually by replaying the tape through the Oxford PMD12 
replay monitor, with a 16 second epoch window. When required, individual epochs 
are examined in detail.
For the analysis of daytime sedation a note was made of the time and duration of a 
number of waking categories. The main categories were: Wake (JVA = continuous 
Alpha), Drowsiness (DR = continuous Alpha and Theta) and Sleep Stage 1 (STJ = 
continuous Theta). Additionally the time and duration of three more active waking 
categories were calculated: Quiet Waking Plus( QWP = EEG: active/alert, EOG: > 2 
eye movements per epoch, EMG: increased body movements); Quiet Waking (QW = 
EEG: alert, EOG: > 2 eye movements per epoch; EMG: average or no body 
movements); Wake with Intermittent Alpha (fVIA = EEG: definite burst of 
AlphaEOG: > 2 eye movements per epoch; EMG: average or no body movements) 
The time/event channel recorded the times that medication is administered, 
questionnaires completed, performance test batteries undertaken etc.
For the analysis of sleep, sleep status was evaluated using Rechtschaffen and Kales 
EEG criteria (Rechtschaffen & Kales, 1968), for each 16 second epoch. The sleep 
period was evaluated for sleep disruption measured as the frequency and duration of 
movements (EMG), reflecting intra-sleep Restlessness. Waking periods were assessed 
to determine changes in Sleep Onset Latency to Stage 1 (SOLI = time to reach Stage 
1 sleep), and Stage 2 (SOL2 = time to reach Stage 1 sleep). Frequency and Duration 
of Waking (FW = number of waking periods; DuW = total duration of waking 
periods) within sleep, reflecting sleep fragmentation, and early morning awakening or 
Duration of Final Waking (DuFW ^duration of final waking period).
4.2.4 Standardisation, validity, reliability and pharmaco-sensitivity of the main test 
battery
In his review of performance tests used in human psychopharmacological studies, 
Parrot (1991) states that "Reliability, validity and standardisation are well-established 
principles in most areas of psychometrics, but are rarely mentioned in performance 
assessment within human psychopharmacology", suggesting that lack of 
documentation implies absence of data. The latter, however, does not apply to the 
tests which were selected for the experiments which are the subject of this thesis. 
Apart from a wealth of unpublished data which were gathered since the inception of
the Leeds Psychomotor* tester in the 1970's, a substantial number of publications on 
the validity, reliability and pharmaco-sensitivity of the main test battery has been 
produced.
This is particularly so for CFF. The test has evident "face validity" in that drugs 
known to produce sedation produce a reduction in CFF treshold, and those causing 
clinical arousal produce an elevation of CFF (Smith and Misiak, 1976; Hindmarch, 
1982). CFF also showed "concurrent validity" when it was correlated with other 
scores of objective psychomotor function (Kometsky and Orzak; 1964; Pillard and 
Fisher, 1967; Harvard, 1970; Malpas et al., 1970; Walters and Lader, 1971;
Nicholson, 1979). Furthermor, CFF has been found to correlate significantly with 
EEG measures of arousal (Gortelmeyer and Wieman,1982; Grunberger et al., 1982) 
and with changes in self-reported levels of alertness using visual analogue scales 
(Grundstrom, 1977,1978; Grandjean et al, 1977; Hindmarch et al., 1979; Holmberg, 
1982; Parrot, 1982). The test-retest reliability of the CFF has been examined by a 
number of authors and was found to be in the range of 0.85 to 0.98 (e.g. Me Nemar, 
1951; Simonson and Brozek, 1952; Agurell et al., 1976; Hindmarch, 1980; Holmberg, 
1981; Levander, 1982; Parrot, 1982; Hindmarch, 1986; Koelega, 1989). Detailed 
reviews on the pharmacosensitivity of CFF have been published (Turner, 1986; Smith 
and Misiak, 1976; Hindmarch, 1981, 1982, Grunberger et al., 1982) and it has been 
demonstrated that CFF is able to distinguish between different doses of the same drug 
in addition to being able to distinguish between different drugs, e.g. different 
benzodiazepines (Smith and Misiak, 1976; Hindmarch, 1981,1982). The literature on 
the validity, reliability and pharmacosensitivity of CRT, SCTT and SMST is less 
extensive. The publications which demonstrated that these tests were valid, reliable 
and pharmacosensitive are listed in Table 16. Specifically for all four tests (CFF,
CRT, SCTT and SMST) used in the experiments of this thesis, a longitudinal study of 
51 normal subjects tested at intervals over a 3.5 year period showed no significant 
regression effects (Kilminster, 1991).
* The Leeds Psychomotor tester is a standardised combination o f the CFF and CRT test.
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Table 16: List of publications demonstrating the validity, reliability and
pharmacosensitivity of the 4 main objective tests used in this 
thesis.
Test Validity
CFF  Kometsky and Orzak, 1964 
Pillard and Fisher, 1967 
Harvard, 1970 
Malpas et al., 1970 
Walters and Lader, 1971 
Smith and Misiak, 1976 
Grandjean et al, 1977 
Grundstrom et al, 1977 
Grundstrom et al, 1978 
Hindmarch et al., 1979 
Nicholson, 1979 
Gortelmeyer and Wieman,1982 
Grunberger et al., 1982 
Hindmarch, 1982 
Holmberg, 1982 
Levander, 1982 
Parrot, 1982 
Hindmarch, 1986 
Hindmarch, 1988
CRT  Hindmarch and Kerr, 1992
SCTT  Kennedy et al., 1981 
Hindmarch, 1988 
Schufried, 1990
SM ST  Anders et al., 1972
Harris and Fleer, 1974 
Smith and Langolf, 1981 
Sherwood and Griffin, 1990
Reliabilty
Me Nemar, 1951 
Simonson and Brozek, 1952 
Agurell et al., 1976 
Hindmarch, 1980 
Holmberg, 1981 
Levander, 1982 
Parrot, 1982 
Hindmarch, 1986 
Koelega, 1989 
Kilminster, 1991
Hindmarch et al, 1980 
Hindmarch, 1986 
Kilminster, 1991
Kennedy et al., 1981 
Schufried, 1990 
Kilminster, 1991
Carter et al., 1980 
Kilminster, 1991
Pharmacosensitiviy
Smith and Misiak, 
1976
Holmberg, 1980 
Hindmarch, 1981 
Hindmarch, 1982 
Grunberger et al. 1982 
Turner, 1986
Hinmarh, 1980 
Hindmarch, 1986 
Kleindienst- 
Vanderbeke and 
Irmisch, 1988
Hindmarch, 1980
Subhan and 
Hindmarch, 1984 
Sherwood et al., 1992
4.2.5 Non CNS measures
It would have been of interest to take blood samples for pharmacokinetic analysis of 
the AH's under investigation in order to investigate the relationship between 
detectable sedation and plasma levels. However as it was necessary for performing the
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test battery that the subjects be able to move their hands (and arms) freely, it was felt 
that blood sampling would interfere too much with their normal motor behaviour and 
potentially invalidate the test results.
In Experiment 7 the histamine wheal and flare test was used to distinguish between 
the potency of the AH's tested. In order to prevent this test from intefering with the 
test battery, it was performed only once, after administration of the last test battery. 
Treatments had been administered 1.5 hours before. Peripheral antihistaminic activity 
was evaluated by calculating the areas of wheal and flare skin reactions, as calculated 
by planimetry, produced 10 minutes after intradermal injections of " g of histamine
4.3 Statistical procedures
The following page summarises the statistical methods which were used in the 
different experiments. In the main, they consist of standard procedures (e.g. analysis 
of variance), which were applied in a number of experiments. It seemed therefore 
preferable to describe these statistical procedures here instead of repeating the 
contents of the statistical section for each of the 7 experiments.
4.3.1 Latin square design
All experiments were conducted according to a similar basic design, i.e. a double­
blind placebo-controlled cross-over with subjects randomly allocated to treatment 
schedules derived from Latin squares. The Latin square design ensures that treatments 
are balanced between subjects and experimental periods, and was used to protect 
against order effects.
In order to reduce intersubject variability, all experiments used subjects as their own 
control with each receiving all treatments.
into the flexor side of the forearm..
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4.3.2 Sample size
CFF, one of the core tests of the battery, was considered as the main variable to be 
used in terms of sample size calculations. Over 25 years of experience with this test 
has shown that significant drug-induced CNS effects can be demonstrated in 
experiments including as few as 7 or 8 subjects (e.g. Hindmarch et al. 1977; 
Hindmarch, 1987). Power calculations based upon published data indicate that it is 
reasonable to expect a difference between placebo and a positive control of between
1.2 and 1.5 Hz. Given a standard deviation of the difference between placebo and 
positive control of 1.4 to 1.8 a sample size of 10 gives a 80% power to detect this 
difference at the 5% level of significance. In deciding about the sample size for each 
experiment the above mentioned considerations were taken into account, and in 
accordance with the Latin square design, extra subjects were added so that an equal 
number of subjects would be receiving the same treatment on different test days 
(Table 17).
Table 17: Number of subjects and number of treatments in each experiment
Experiment No.
1 2 3 4 5 6 7
N subjects 10 10 10 12 12 12 12
N treatments 5 5 5 4 3 3 6
4.3.3 Statistical tests
Analysis procedures were determined a priori at the design stage of each experiment 
and only planned comparisons were made.
All measures used in the 7 experiments were analysed using parametric tests, except 
for the FRS, a 4-point rating scale, which was taken in Experiments 1 and 2 only. 
With regard to the analysis of the 10 cm line visual analogue scales ( LARS, VAS and 
LSEQ) it can be argued that either parametric or non-parametric tests should be
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applied. There are two schools of thought which each have valuable arguments in 
their favor but as Maxwell (1978) demonstrates, it makes little difference, in terms of 
the results, which method is used. He comments that clear (relevant) differences 
proved to be significant by parametric test, while slight (non-relevant) differences 
were sometimes significant only with ordinal ones. He also states that the T-test was 
very robust and that arcsine transformations make little difference to the 
"significance" of the results. As the LESQ (Hindmarch 1975; Parrott and Hindmarch, 
1978; Parrott and Hindmarch, 1980; Hindmarch, 1984) and LARS (Hindmarch & 
Gudgeon, 1980) had been specifically developed and validated using parametric 
procedures it was decided to continue with this practice. For the analysis of the visual 
analogue scores in the experiments described in this thesis, data were routinely 
checked for normality and had to be found to be acceptable before parametric tests 
were performed.
The results of Experiments 1 and 2 were analysed with regard to intra-(versus 
baseline) and inter-treatment (versus placebo) comparisons, using the Student-T test 
for the parametric (CFF, CRT, VAS) and the Wilcoxon Matched-Pairs Signed-Ranks 
test for the non-parametric data (FRS). In addition to the above comparisons, a 
statistical analysis, taking into account the duration of treatment, was performed in 
Experiment 2, using Analysis of Variance procedures (ANOVA). In this analysis, 
contrasts were used to compare the effect of the active treatments with placebo, and 
Tukey's test was used for multiple post-hoc comparisons between treatments.
In Experiments 3 to 7, pre-treatment baseline and post-treatment values, as well as 
differences from baseline scores were analysed. The assumption of normality of the 
data was examined by probability plots (Gnandesikan, 1977) and found to be 
acceptable. All data manipulations and analyses were performed with a combination 
of in-house software and SYSTAT. Analysis of variance procedures (ANOVA) for 
factorial designs with fully repeated measures were used to assess overall significance 
(P<0.05 or better) between treatments. Where significant effects were obtained with 
ANOVA, differences between treatment means were contrasted using post-hoc two- 
tailed 95 % confidence intervals (Bulpitt, 1987; Kirk, 1968; Gardner and Altman, 
1986 ). An advantage of confidence intervals is that they provide more information 
than conventional (point estimate) hypothesis tests. Confidence intervals express a 
range of sample values which are the best estimate of the range of the true population; 
so that inferences can be made between the sample used and the population from
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which it was drawn. Further, by expressing a range for the (sample) population at a 
given level of confidence (e.g. 95%) it assists comparisons between treatments and 
associated means; i.e. if the confidence intervals do not overlap than a significant 
difference may be inferred. Similarly, the level of effect may be seen from the range 
of confidence intervals rather than precise but less informative P-values. The results 
of the (two-sided) hypothesis test was then inferred at the associated level of statistical 
significance, i.e. P<0.05 for a 95% confidence interval (Berry, 1986; Bulpitt, 1987; 
Gardner and Altmann, 1986).
Experiments 5 to 7 also included electrophysiological measures (C-EEG). Data from 
these studies are frequently skewed (Oswald, 1980) and transformations were 
performed, in order to improve normality, prior to parametric analysis. C-EEG data 
that were not normally distibuted were transformed (Winer, 1962, 1971; Snedecor and 
Cochran, 1967; Kirk, 1968; Dunlap and Duffy, 1974) and ANOVA's were used to 
identify significant effects. Differences between significant treatment means were 
examined using post-hoc confidence intervals.
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CHAPTER 5 USE OF VERUM CONTROLLED TREATMENT 
REGIMENS TO ASSESS POTENTIAL SEDATIVE 
EFFECTS OF ANTIHISTAMINES
5.1 Experiment 1: The central effects of three doses of R 72075 (single 
administration).
5.1.1 Introduction and rationale
The primary aim of this study was to investigate any potential dose related CNS 
effects of R 72 075, an AH which was in an early stage of development (Phase I). 
However, as this experiment was the first of a series of studies which were planned to 
answer a number of psychopharmacological questions about the CNS effects of AH's 
in general, it also served as an exploratory attempt to gain experience with the main 
tests {CFF and CRT) in the battery. These two tests would be used subsequently in all 
other experiments. In addition it was hoped that some preliminary information would 
be obtained about the perceived problem of inter-subject variability with regard to AH 
induced sedation. Finally, since the verum or positive internal control, levocabastine, 
was available in both an oral and a topical formulation, the study allowed for the 
collection of some basic data after oral administration, which, in a later experiments 
(4 ) could be compared with those obtained after topical administration.
R 72 075 is a potent and fast-acting HI-antagonist, developed by Janssen 
Pharamceutica (Leysen et al.„ 1986; Van Wauwe and Goossens, 1986). First 
experiences in healthy, non-atopic volunteers using a single dose of 10 mg R 72 075, 
showed a rapid and potent inhibition of the histamine induced wheal and flare reaction 
(Vanden Bussche et al, 1986). The present study continued the development of the 
drug and investigated the possible central effects of a range of single doses of R 72 
075 and examined whether a dose response relationship could be established. 
Levocabastine, another AH developed by the same manufacturer had shown, in earlier 
studies, to possess sedative properties (Janssen and Laduron, 1984). From these 
studies it was inferred that an oral dose of 3 mg would be consistently sedative. 
Therefore levocabastine 3mg was chosen as a positive control.
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The final design of this study was the result of discussions between two parties (the 
manufacturer and the author). Each party had its own specific objectives and 
hypotheses to be tested . These are summarised below.
For the manufacturer:
Objective: To investigate whether R 72 075 up to 20 mg is free of sedation.
Hypothesis: No sedation can be demonstrated at 2 hours after intake of either 5, 10
or 20 mg R 72 075.
For the author:
Objective: To investigate the comparable sensitivity of CFF, CRT and VAS in
detecing possible dose related sedative effects of 5, 10 and 20 mg of R 
72 075.
Hypothesis: Significant sedation, if demonstrable with CFF, CRT and VAS, after
administration of R 72 075 is dose related.
5.1.2 Material and methods
Ten healthy, non-atopic volunteers, 7 males and 3 females, ranging in age from 29 to 
48 years (median: 36) were selected for this trial. The study was conducted using a 
double-blind, placebo controlled cross-over design, with oral levocabastine used as a 
verum. All volunteers received each treatment once, in a random order. A washout 
period of 1 week separated each administration (Table 18a).
Table 18a: Experimental design (example of possible sequence for one
subject)
Time Study Condition
interval period
Week -1 pre-trial screen
Week 1 day 1 
washout
treatment B
Week 2 day 1 
washout
treatment E
Week 3 day 1 
washout
treatment D
Week 4 day 1 
washout
treatment C
Week 5 day 1 treatment A
Week 6 post-trial screen
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The test medication consisted of a single dose of either 5, 10 or 20 mg of R 72 075,
3 mg of levocabastine, or placebo, mane, given as a solution. All test bottles were 
numbered and looked completely identical. Assessments on the tests detailed below 
were made 2 hours after intake (D1H2), and comprised both objective and subjective 
measurements of sedation. Objective evaluations consisted of CFF thresholds and the 
CRT test, both tests being part of the Leeds Psychomotor Tester. Subjective 
evaluations included VAS and FRS. In addition, volunteers were asked whether in 
their opinion, the substance they had received was sedating or not (Y/N) (Table 18b).
Table 18b: Schedule of events
N day Day 1
N administration I
Time
(day/hours)
D1H0 D1H2
Medication X
Measures
CFF X
CRT X
VAS X
FRS X
Y/N X
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5.2.3 Results 
CFF
CFF thresholds obtained after the intake of 5, 10 and 20 mg R 72 075 were similar to 
those obtained after placebo. After the oral dose of 3 mg of levocabastine, however, 
thresholds were lower than after placebo, but the difference failed to reach statistical 
significance (Fig 5). This appeared to be due to the individual subjects variability in 
thresholds which, following levocabastine proved to be larger than after placebo or 
any of the three doses of R 72 075 (Table 19 and Appendix I, Table 1).
Fig. 5: CFF: Mean values and SEM for each treatment condition
(P = placebo, L 3mg = levocabastine 3mg, R 5mg = R 72 075 5 mg,
R lOmg = R 72 075 lOmg, R 20mg = R 72 075 20mg; Hz = Hertz)
Hz
31 -|
30  -
29 -
28  -
0
P L3m g R 5mg R 10mg R 20mg
Treatment Condition
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Table 19: CFF: Individual scores (Hertz), mean values and SEM for each
treatment condition.
Initiais P L3m g R 5m g R 10 mg R 2 0  mg
RK 32.14 32.86 30.61 31.92 33.06
JT 31.20 29.70 28.88 30.71 30.01
MP 22.37 23.00 26.05 25.85 26.48
GS 32.86 32.62 34.17 32.41 33.05
GVDB 30.74 29.19 28.88 28.28 29.41
BM 31.64 30.34 29.94 29.67 30.18
JP 27.49 20.41 25.53 27.13 29.13
LC 29.41 29.51 31.69 31.69 30.19
LB 31.69 29.05 29.94 30.55 31.97
TR 29.41 29.99 28.84 30.13 29.72
Mean 29.89 28.67 29.43 29.83 30.32
SEM .97 1.25 .81 .68 .62
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CRT
All three doses of R 72 075, failed to affect performance on the CRT test: no 
significant differences could be detected as compared to placebo for RRT, MRT or 
TRT. With levocabastine, on the other hand, all component reaction times were 
significantly longer than those found following placebo (Fig. 6 and Appendix I, Table 
2).
Fig. 6: CRT (TRT): Mean values and SEM for each treatment condition
* P<0.05, w.r.tplacebo, Student-t Test.
(P = placebo, L 3mg = levocabastine 3mg, R 5mg = R 72 075 5 mg,
R lOmg = R 72 075 lOmg, R 20mg = R 72 075 20mg; msec = 
millisecond)
msec
6 5 0
6 0 0 -
5 5 0 -
L 3mg R 5mg RIOmg R 20mg
Treatment Condition
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VAS ratings after R 72 075 were virtually identical to the ratings after placebo for all 
doses tested, while after levocabastine a significant shift towards the extreme 
"completely asleep" was noted (Fig. 7). As with CFF thresholds, the variability of 
scores after levocabastine was larger than under the other treatment conditions; three 
volunteers did not change their VAS scores from placebo ratings when the verum 
and/or the 3 doses of R 72 075 were given (Table 20 and Appendix I, table 3).
Fig. 7: VAS: Mean values and SEM for each treatment condition
* P<0.05, w.r.t.placebo, Student-t Test.
(P = placebo, L 3mg = levocabastine 3mg, R 5mg = R 72 075 5 mg, 
R lOmg = R 72 075 lOmg, R 20mg = R 72 075 20mg; mm = 
millimeter)
L3m g R 5mg R 10mg R 20mg 
Treatment Condition
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Table 20: VAS: Individual scores (mm), mean values and SEM, per
treatment condition (*: P<0.05 w.r.t. placebo, Student-t Test).
Initials P L 3  mg R 5 mg R 10 mg R 20 mg
RK 15 17 18 17 30
JT 4 40 3 5 3
MP 6 54 11 5 5
GS 1 31 9 5 2
GVDB 8 90 6 9 5
BM 9 18 20 20 12
JP 19 67 9 16 10
LC 5 2 1 2 1
LB 22 55 20 21 25
TR 5 88 13 3 6
Mean 9.4 46.2* 11.0 10.3 9.9
SEM 2.2 9.5 2.1 2.3 3.1
FRS
Similarly, no statistical differences could be found between the alertness scores (FRS) 
after placebo and the different doses of R 72 075, while after levocabastine volunteers 
felt significantly less "fit".
Sedation (Y/N)
When asked whether the test medications were sedating, all answers were negative at 
all occasions, except after levocabastine when 8 out of 10 subjects reported the drug 
was sedative. This difference was statistically significant (PO.05 w.r.t. placebo, 
McNemar test).
5.2.4 Discussion and conclusions
Although no sedative effects could be detected 2 hours after acute administration of 
up to 20 mg R 72 075, no final conclusions could be drawn about the possibe absence 
of any sedative properties, which might be inherent to the compound (Rombaut and 
Vanden Bussche, 1989a). Even when assuming that the 2 hour interval, which 
coincided with average peak plasma levels (Heykants and Janssens, 1994), was the 
most appropriate time to detect sedation, the question remained whether or not higher 
doses would produce any decrease in alertness which would be detectable with the test
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battery. Therefore a second experiment was designed in which higher dose regimens 
were tested using the same group of psychometric measures (Experiment 2).
Since no sedation was observed with any of the doses of R 72 075 it was impossible 
to draw any concludions about possible dose related sedative activities. However, 
sedation was observed after levocabastine 3 mg with all three main measures {CFF, 
CRT and VAS), but only the latter two tests showed results which were statistically 
significantly different w.r.t. placebo (PO.05, Student t Test). It is unusual not to be 
able to demonstrate a significant impairment on CFF after administration of a sedative 
agent. Therefore it can be assumed that the large intersubject variability to the effects 
of levocabastine precluded the test from distinguishing between this AH and placebo 
in a significant way.
Levocabastine was chosen as a verum because of its presumed pronounced sedative 
effects when given orally (Janssen and Laduron, 1984). Indeed 7 out of the 10 
volunteers showed a substantial change in alertness on the VAS after intake of 
levocabastine. The remaining 3 volunteers however, seemed, according to the same 
scale, not to experience any noticeable sedation. CFF results showed a similar inter­
subject variability, although the spread of CFF threshold scores after levocabastine 
was less spectacular than with VAS, and not limited to the above mentioned 3 
volunteers. Similar variations in sensitivity to antihistamine-induced sedation have 
been described before (Clarke and Nicholson, 1978). It has been proposed to include a 
pre-study screen for the selection of volunteers, which would allow only those, who 
showed significant sedation after the administration of a verum, to enter the study 
(Hindmarch and Bhatti, 1987; Hindmarch and Easton, 1986). Scanning subjects as 
Hindmarch and Easton did, adds considerable effort to the conducting of studies: 
some 21 volunteers had to be screened to produce 9 eligible subjects. In the study of 
Hindmarch and Bhatti, a population of 40 female volunteers were given a challenge 
dose of chlorpheniramine 4 mg and only the 18 subjects who experienced 
demonstrable sedation were used in the subsequent study. This technique may 
improve the consistency of response to the various test treatments, by increasing the 
homogeneity of the group, but, apart from being cumbersome and time consuming, it 
clearly reduces the predictive value of the experiment as a whole. By selecting 
antihistamine sensitive subjects, a bias is introduced which makes it difficult to 
extrapolate the results of individual studies to the general population. It was therefore 
decided, for the next experiments, not to proceed with these pre-selection procedures,
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but to continue using the customary pre-experimental screening for physical and 
psychological health.
5.2 Experiment 2: The central effects of three doses of R 72 075 (single and 
repeated administration).
5.2.1 Introduction and rationale
This second experiment followed-up the results of the first. It was intended to explore 
to what extent higher dose regimens of R 72 075 would prove to be free of sedation.
In addition to investigating a potential dose relationship, the impact of repeated 
administration of AH's on the psychometric scores was considered. On the assumption 
that psychodynamic effects would be reasonably correlated with plasma levels, test 
measures were planned to be performed after 3 days of daily administration, at which 
time steady state blood plasma levels were known to be reached (Van de Velde et ah, 
1987). The study also examined, at a preliminary level, the time-course of any 
pharmacodynamic activity by applying the test battery at two different time intervals 
(2 and 4 hours) after drug administration. Finally, as with Experiment 1, the study 
made it possible to gather more information with regard to the effects of oral 
levocabastine, which might be of interest when studying the topical effects of the 
same compound in later experiments (4).
R 72 075, which produced a strong inhibition of the histamine-induced wheal and 
flare reactions, both after single and multiple dose administration (Vanden Bussche et 
al., 1986; Vanden Bussche et al., 1987; Rombaut et al., 1989), was found to be free of 
sedation when given in single doses up to 20 mg (see Experiment 1, Rombaut and 
Vanden Bussche, 1989a). In order to mirror repeated dose usage in a clinical situation, 
this present experiment studied the possible sedative effects of a higher range of doses 
of R 72 075, both after acute and subchronic (at pharmacokinetic steady state) 
administration, and investigated whether a dose relationship could be established 
using the same test battery as in Experiment 1. As in the previous experiment, 
levocabastine was used as a positive control.
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The final design of this study was the result of discussions between two parties (the 
manufacturer and the author). Each party had its own specific objectives and 
hypotheses to be tested . The main objective are summarised below.
For the manufacturer:
Objective: To investigate whether R 72 075 up to 40 mg is free of sedation.
Hypothesis: No sedation can be demonstrated at 2 and 4 hours after one single or
three daily doses of either 20, 30 or 40 mg R 72 075.
For the author:
Objectives: 1. To investigate the comparable sensitivity of CFF, CRT and VAS in
detecting sedation as influenced by frequency of administration (single 
versus repeated)
2. To investigate the comparable sensitivity of CFF, CRT and VAS in 
detecting possible dose related sedative effects of 20, 30 and 40 mg of 
R 72 075.
3. To investigate the comparable sensitivity of CFF, CRT and VAS in 
detecting sedation as influenced by time of administration.
Hypotheses: 1. Significant sedation, if demonstrable with CFF, CRT and VAS, is
related to the frequency of administration.
2. Significant sedation, if demonstrable with CFF, CRT and VAS, is 
dose related.
3. Significant sedation, if demonstrable with CFF, CRT and VAS, is 
time related.
5.2.2 Material and methods
Ten healthy non-atopic volunteers, 5 males and 5 females, ranging in age from 29 to 
42 years (median: 35 years) were selected. The study was designed as a double-blind 
placebo controlled cross-over comparison, comprising 5 experimental treatments of 3 
days each. The treatments consisted of 3 different doses of R 72 075, one dose of 
levocabastine, and placebo. Between each treatment there was a washout period of 11 
days (Table 21).
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Table 21: Experimental design (example of possible sequence for one
subject)
Time Studv Condition
interval period
Week -1 pre-trial screen
Week 1 day 1-3 
washout
treatment C
Week 3 day 1-3 
washout
treatment B
Week 5 day 1-3 
washout
treatment D
Week 7 day 1-3 
washout
treatment E
Week 9 day 1- 3 treatment A
Week 19 post-trial screen
Volunteers were randomly allocated to receiving oral doses of either 20, 30, or 40 mg 
of R 72 075, 3 mg of levocabastine, or placebo. Each of the experimental treatments 
was administered mane, once daily, for 3 days. All treatments were identical in 
appearance and packing.
Assessments were performed on day 1, before the first intake (D1HO), 2 and 4 hours 
later (D1H2 and D1H4), and on day 3, before (D3HO) as well as 2 and 4 hours after 
the third (and last) intake (D3H2 and D3H4, respectively) comprising the same 
objective and subjective measurements of central activity as in Experiment 1 
(Rombaut and VandenBussche, 1989a) (Table 22).
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Table 22: Schedule of events
N day DAY 1 DAY 2 DAY 3
N administration I II III
Time D1H0 D1H2 D1H4 D3H0 D3H2 D3H4
(day/hours)
Medication X X X
Measures
CFF X X X X X X
CRT X X X X X X
VAS X X X X X X
FRS X X X X X X
Y/N X X X X X X
5.2.3 Results 
CFF
CFF thresholds obtained 2 and 4 hours after the first intake (D1H2 and D1H4) of 20,
30 and 40 mg R 72 075 were similar to those obtained at baseline. After intake of 
levocabastine however, thresholds at both time points decreased significantly, as 
compared to both baseline and placebo (Fig .8). On the third administration day the 
results were comparable to those obtained on day 1 : again no significant changes 
could be found 2 and 4 hours after intake (D3H2 and D3H4) of any dose of R 72 075, 
while with levocabastine the differences with baseline and with placebo remained 
statistically significant. Levocabastine also was found to produce a significant 
decrease in threshold immediately before the third dose (D3H0). At that time point, all 
three R 72 075 treatment groups had thresholds which were higher than at baseline, 
indicating a relative increase in alertness, but no statistical differences were found 
when compared to placebo (Fig. 9).
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Fig. 8: CFF: Mean values for each treatment condition, day 1
*: P< 0.05 w.r.t. placebo (Student-t test)
(P = placebo, L 3mg = levocabastine 3mg, R 20mg = R 72 075 20mg, 
R 30mg = R 72 075 30mg, R 40mg = R 72 075 40mg; Hz = Hertz)
Hz
29-1
2 6 -
0  ~ v  i i i i i
D1H0 D1H2 D1H4
Test Times
placebo  
L 3mg 
-*■ R 20mg 
R 30mg 
R 40mg
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Fig. 9: CFF: Mean values for each treatment condition, day 3
*: P< 0.05 w.r.t. placebo (Student-t test)
(P = placebo, L 3mg = levocabastine 3mg, R 20mg = R 72 075 20mg, 
R 30mg = R 72 075 30mg, R 40mg = R 72 075 40mg; Hz = Hertz)
Hz
29 -,
2 7 -
2 6 -
D3H0 D3H2 D3H4
Test Times
■®* placebo  
"*■ L 3mg 
R 20mg 
R 30mg 
R 40mg
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CRT
No significant increase in Recognition Reaction Time {RRT) was seen with the three 
doses of R 72 075, neither as compared to placebo nor as compared to baseline. On 
the contrary RRT values with 30 mg of R 72 075 were found to be significantly 
decreased at D1H4 and D3H4. With levocabastine both intra-group (at D1H2, D1H4 
and D3H2) and inter-group (D1H4) differences showed impairment and were 
statistically significant. With regard to Movement Reaction Time (MRT), no 
significant differences with any of the statistical tests used could be detected for any 
of the experimental treatments at any of the time intervals. Total Reaction Time {TRT) 
did not lengthen significantly with any of the R 72 075 doses; the only significant 
differences that were seen, were again those, which pointed towards increased 
alertness (i.e. shorter reaction times than at baseline, with 30 mg at D3H2, and with 40 
mg at D3H0 and D3H4). Levocabastine on the other hand produced a significant 
increase in TRT at D1H2 versus baseline, and at D1H2 and D3H0 versus placebo (Figs. 
10 and 11).
110
Fig. 10: CRT (TRT): Mean values for each treatment condition, day 1
*: P< 0.05 w.r.t. placebo (Student-t test)
(P = placebo, L 3mg = levocabastine 3mg, R 20mg = R 72 075 20mg, 
R 30mg = R 72 075 30mg, R 40mg = R 72 075 40mg; msec = 
millisecond)
5 7 0  n
msec *
560"
5 5 0  "
placebo  
L 3mg
540 _________a----------- R 20mg 
R 30mg
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Fig. 11: CRT (TRT): Mean values for each treatment condition, day 3
*: P< 0.05 w.r.t. placebo (Student-t test)
(P = placebo, L 3mg = levocabastine 3mg, R 20mg = R 72 075 20mg, 
R 30mg = R 72 075 30mg, R 40mg = R 72 075 40mg; msec = 
millisecond)
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K/IS
After R 72 075 no significant intra- or inter-group changes in subjective ratings of 
sedation could be found with any of the doses tested, at any of the time intervals, 
except for 40 mg at D1H2 (w.r.t. placebo). After levocabastine, however, volunteers 
felt more sedated as compared to both baseline (D1H2, D1H4 and D3H4) and placebo 
(D1H2, D1H4, D3H2 and D3H4) (Figs. 12 and 13).
Fig. 12: VAS: Mean values for each treatment condition, day 1
*: P< 0.05 w.r.t. placebo (Student-t test)
(P = placebo, L 3mg = levocabastine 3mg, R 20mg = R 72 075 20mg, 
R 30mg = R 72 075 30mg, R 40mg = R 72 075 40mg; mm = 
millimeter)
mm
35-| 
3 0 -  
2 5 -  
2 0 -  
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1 0 -  
5 —
01 HO D1H2 
Test Times
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■®" placebo  
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Fig. 13: VAS: Mean values for each treatment condition, day 3
*: P< 0.05 w.r.t. placebo (Student-t test)
(P = placebo, L 3mg = levocabastine 3mg, R 20mg = R 72 075 20mg, 
R 30mg = R 72 075 30mg, R 40mg = R 72 075 40mg; mm = 
millimeter)
mm
3 5 1
3 0 -
2 5 -
2 0 -
1 5 -
1 0 -
D3H0 D3H2 D3H4
Test Times
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No changes were seen with R 72 075, while with levocabastine volunteers were 
significantly less "fit" (P<0.05, Wicoxon Matched-Pairs Signed-Ranks test) after the 
first dose (D1H2 and D1H4), as compared to both baseline and placebo.
Sedation (Y/N)
With R 72 075, a positive answer was given only once (with 20 mg at D3H0), while 
with levocabastine positive answers were collected at all time intervals and given by 
up to 6 (from 10) volunteers per time point. This difference was statistically 
significant (PO.05, McNemar test) for all time intervals except the last (D3H4).
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5.2.4 Discussion and conclusions
This experiment is in line with the previous one in which no evidence of sedation was 
found with lower doses of R 72 075. The present study failed to detect any sedative 
effects after acute and subacute administration of oral daily doses up to 40 mg. 
Neither the objective measures {CFF and CRT), nor the subjective ratings {VAS and 
FRS) were able to show any impairment of psychomotor function, except for one 
isolated change on the VAS, 2 hours after the first intake of 40 mg. As the latter was 
observed only in one subjective test and at only one time interval, it may be 
considered as a chance finding. To explore fully the apparent lack of CNS effects of 
R 72 075, further experiments need to be conducted in which another series of higher 
doses are tested. However, since the therapeutically active dose of R 72 075 was 
thought to be at the lower end of the dose range which has been tested thus far, the 
question about total (i.e. inherent) absence of sedation, was a purely theoretical issue, 
without any real clinical relevance and it was therefore decided not to pursue it any 
further.
As in the previous experiment, the test battery proved to be adequately sensitive for 
AH induced sedation as shown by the consistent and statistically significant changes 
observed after levocabastine, indicating sedation and an overall decrease in CNS 
activity (Rombaut and Vanden Bussche, 1989b). The fact that impairment was 
observed both after acute and subchronic administration of levocabastine, suggests 
that no habituation to the verum induced CNS effects seems to occur over a 3 day 
treatment period. However, the fact that none of the tested doses of R 72 075 were 
found to produce sedation, either after single or after repeated administration, made it 
impossible to formulate any conclusive statements about a potential dose response 
relationship. The small changes w.r.t. baseline produced by 30 and 40 mg of R 72 075 
on the CRT atD lH 2 and D1H4 suggesting increased alertness may be explained by 
learning. However, two facts mitigate against this explanation: firstly there is no 
indication of time related improvement after placebo administration, and secondly all 
subjects were trained to a plateau performance before entering the study.
The results obtained with levocabastine in this experiment suggest that the sedative 
effects of this AH are not limited to the first day of administration, but are able to 
persist after repeated intake. Objective measures {CFF and CFF) seem to be capable 
of detecting a significant decrease in CNS functioning after both single and repeated
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administration. Subjective scores (VAS) of the effects of repeated use, although still 
registering significant tiredness, are seen to be less pronounced than after the first 
intake. This suggests that there is some subjective habituation to the acute sedative 
effects of AH's.
5.3. Experiment 3: The central effects of three doses of ebastine (single and 
repeated administration).
5.3.1 Introduction and rationale
As the manufacturer of R 72 075 had decided, for reasons which were not related to 
the results of the previously described experiments, not to develop this compound 
further it was impossible to receive any further drug supplies to continue the planned 
research programme. Unfortunately it was also impossible to continue to use 
levocabastine as a verum since the manufacturer had concluded that is was preferable 
to develop only the topical formulation further. Therefore a new test compound and a 
new verum had to be chosen for the next experiment.
This study assessed the sensitivity of a broader range of psychometrics in detecting 
sedative effects of ebastine, both after single and repeated administration. Triprolidine 
was chosen as the verum, as it had been successfully used as a positive control in AH 
studies before (Betts et al., 1988; Bradley and Nicholson, 1987; Nicholson, 1979; 
Nicholson and Stone, 1982; Nicholson et al., 1982; Nicholson and Stone, 1983; 
Nicholson and Stone, 1986; O'Hanlon et al., 1988), and it gave the author the 
opportunity to examine whether the test battery would be able to discriminate between 
this verum and the other treatments, in the same way as the restricted battery 
discriminated between levocabastine and R 72 075 in the two previous experiments 
(Rombaut and Vanden Bussche, 1989a; 1989b).
Ebastine is an HI-antagonist, chemically related to terfenadine, which, in animal 
models and early clinical studies, proved to be free of sedation (Vincent et al., 1988). 
Because of the kinetics of the compound, for which reported half-lives ranged 
between 10.3 and 12.5 hours (Simons and Simons, 1993) treatment was continued for
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5 days to ensure that the drug had reached pharmacokinetic steady state levels at the 
last assessment day.
The final design of this study was the result of discussions between two parties (the 
manufacturer and the author). Each party had its own specific objectives and 
hypotheses to be tested . The main objective are summarised below.
For the manufacturer:
Objective: To investigate whether ebastine up to 30 mg is free of sedation.
Hypothesis: No sedation can be demonstrated at 2,4 and 8 hours after one single or
five daily doses of either 10, 20 or 30 mg ebastine.
For the author:
Objectives: 1. To investigate the comparable sensitivity of CFF, CRT, SCTT,
SMST, LARS and LESQ in detecting possible time related sedative 
effects of 10, 20 or 30 mg ebastine.
2. To investigate the comparable sensitivity of CFF, CRT, SCTT, 
SMST, LARS and LESQ in detecting possible dose related sedative 
effects of 10, 20 or 30 mg ebastine..
3. To investigate the comparable sensitivity of CFF, CRT, SCTT, 
SMST, LARS and LESQ in detecting sedation as influenced by 
frequency of administration (single versus repeated).
Hypotheses: 1. Significant sedation, if demonstrable with CFF, CRT, SCTT, SMST,
LARS and LESQ, is related to time of administration.
2. Significant sedation, if demonstrable with CFF, CRT, SCTT, SMST, 
LARS and LESQ, is dose related.
3. Significant sedation, if demonstrable with CFF, CRT, SCTT, SMST, 
LARS and LESQ, is related to the frequency of administration.
5.3.2 Materials and methods
Ten female volunteers aged between 22 and 39 (mean age: 29.5) years were recruited 
to take part in the study. This double blind placebo and verum controlled study 
comprised five treatments, each given for a period of five days. The active 
experimental treatments were ebastine 10, 20 and 30 mg all given mane. Triprolidine 
10 mg mane was used as a verum.
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All treatments were administered using capsules which were identical in appearance. 
Treatments were given in the morning between 09.30 - 11.00 hours; individual 
subjects were staggered so testing could take place at fixed hours after administration. 
A one week washout period separated each treatment period (Table 23).
Table 23: Experimental design (example of possible sequence for one
subject)
Time Study Condition
interval period
Week -1 pre-trial screen
Week 1 day 1-5 
wash-out
treatment B
Week 3 day 1-5 
wash-out
treatment A
Week 5 day 1-5 
wash-out
treatment C
Week 7 day 1-5 
wash-out
treatment E
Week 9 day 1-5 treatment D
Week 10 post-trial screen
Subjects were randomly allocated to treatment according to a predetermined code, 
each receiving all treatments and acting as their own control.
Each test day 1 began with a pre-treatment baseline assessment on the test battery 
(D1H0) immediately after which the first treatment dose was administered. 
Performance, using a full battery of cognitive and psychomotor tests {CFF, CRT, 
SCTT, SMST, LARS), was assessed 2, 4 and 8 hours after the first administration 
(D1H2, D1H4 and D1H8). One hour after administration (D1H1) a short battery 
{CFF, CRT, LARS) was done. On day 5 the same measures where taken before the 
administration of the treatments (D5H0) and at the same time intervals there after 
(D5H1, D5H2, D5H4 and D5H8). A Sleep Evaluation Questionnaire (LSEQ) was 
completed the morning of day 1 (D1H0), 2 (D1H0) and 6 (D6H0). (Table 24).
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Table 24: Schedule of events
N day DAY 1 DAY 2
Time D1H0 D1H1 D1H2 D1H4 D1H8 D2H0
(day/hour)
Medication X X
Measures
CFF X X X X X
CRT X X X X X
SCTT X X X X
SMST X X X X
LARS X X X X X
LSEQ X
N day DAY 5 DAY 6
Time D5H0 D5H1 D5H2 D5H4 D5H8 D6H0
(day/hour)
Medication X
Measures
CFF X X X X X
CRT X X X X X
SCTT X X X X
SMST X X X X
LARS X X X X X
LSEQ X X
5.3.3 Results 
CFF
On both days 1 and 5 a decrement in CFF threshold was seen with all treatments, 
reflecting the general lowering of alertness during the course of the day, but no 
significant placebo v. treatment differences could be detected (see Appendix I, Table
4).
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CRT
The results of this test showed no significant placebo v. treatment differences and are 
therefore not discussed (see Appendix I, Tables, 5 to 7).
SCTT
Triprolidine 10 mg produced an overall increase of the peripheral reaction time 
component (RT), the difference with placebo reaching statistical significance on day 1, 
8 hours after intake (DlH8)(Fig. 14). None of the other treatments however were 
found to be significantly different from placebo at any time point (see Appendix I, 
Table 8).
Fig. 14: SCTT (RT): Mean changes from baseline (D1H0) for each
treatment condition, day 1
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI lOmg = triprolidine 10 mg, EB lOmg = ebastine 10 mg,
EB 20 mg = ebastine 20 mg, EB 30 mg = ebastine 30 mg; msec = 
millisecond)
msec
60-|
50 -
4 0 -
3 0 -
2 0 -
1 0 -
01 HO D1H2 D1H4 D1H8
Test Times
■®' placebo  
"•"TRI 10mg 
**" EB 10mg 
EB 20m g  
EB 30mg
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The mean tracking accuracy scores (RMS) showed, on day 1, 8 hours after 
administration (D1H8) a significant impairment for triprolidine 10 mg as compared to 
placebo (Fig. 15). However, none of the ebastine treatments were distinguishable 
from placebo. On day 5, no significant placebo differences could be detected (see 
Appendix I, Table 9).
Fig. 15: SCTT (RMS): Mean changes from baseline (D1H0) for each
treatment condition, day 1
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI lOmg = triprolidine 10 mg, EB lOmg = ebastine 10 mg,
EB 20 mg = ebastine 20 mg, EB 30 mg = ebastine 30 mg; units = root 
mean square of the deviation of the track program)
units
1 .51 *
-0.5 -
0 .5-
0
1 -
placebo  
-"-TRI 10mg 
•*" EB lOmg
EB 20mg
EB 30mg
-1 -
-1.5
01 HO D1H2 D1H4 D1H8
Test Times
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SMST
On day 1, triprolidine 10 mg produced a clear decrement (increase in reaction time) on 
this measure of short-term memory, which was significant w.r.t. placebo, 4 and 8 
hours after administration (D1H4 and D1H8) (Fig. 16). However, on day 5 the mean 
scores for all treatments were closely ranged together and no statistically significant 
differences could be seen (see Appendix I, Table 10).
Fig.16: SMST: Mean changes from baseline (D1H0) for each treatment
condition, day 1
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI 10 mg = triprolidine 10 mg, EB lOmg = ebastine 10 mg,
EB 20 mg = ebastine 20 mg, EB 30 mg = ebastine 30 mg; msec = 
milliseconds)
msec
30-1
20 -
10 -
- 1 0 -
- 20 -
-30
01 HO D1H2 D1H4 D1H8
-B- piacebo
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EB 20mg
EB 30mg
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LARS
At 2 and 4 hours (D1H2 and D 1H4) after the first administration of triprolidine 
10 mg, subjects felt clearly more sedated; this difference was statistically significant 
as w.r.t. placebo (Fig. 17). On day 5 ebastine 30 mg was rated as being significantly 
sedative, 4 hours after administration (Fig. 18; see also Appendix I, Table 11).
Fig.17: LARS: Mean changes from baseline (D1H0) for each treatment
condition, day 1
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI 10 mg = triprolidine 10 mg, EB lOmg = ebastine 10 mg, 
EB 20 mg = ebastine 20 mg, EB 30 mg = ebastine 30 mg; mm = 
millimeter)
mm
1 0 - 1
9 - * *
8 -
"B- placebo  
-"-TRI 10mg
EB 10mg
EB 20m g
EB 30m g
0
-1
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Fig.18: LARS: Mean changes from baseline (D1H0) for each treatment
condition, day 5
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI lOmg = triprolidine 10 mg, EB lOmg = ebastine 10 mg,
EB 20 mg = ebastine 20 mg, EB 30 mg = ebastine 30 mg; mm = 
millimeter)
mm
1 0 - 1
7 -
5 -
D5H0 D5H1 D5H2 D5H4 D5H8
Test Times
■®" placebo  
TRI 10mg 
EB lOmg 
-+-EB 20mg  
EB 30mg
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LSEQ
The results of the LSEQ showed significant placebo v. treatment differences for the 
night after the first administration only (D2H0), indicating that both triprolidine and 
ebastine 30 mg, had an effect on the ease of getting to sleep {GTS) (Fig. 19), while the 
effect on the quality of sleep {QOS) following both treatments fell short of being 
significantly different from that seen under placebo (Fig. 20 and Appendix I, Table 12 
and 13). None of the experimental treatments however was found to interfere with the 
ease of waking from sleep {WES) and the integrity of behaviour following waking 
{BFW). No placebo-treatment differences could be seen with regard to the night after 
the fifth administration (D6H0).
Fig. 19: LSEQ (GTS): Mean changes from baseline (D1H0) for each
treatment condition
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI lOmg = triprolidine 10 mg, EB lOmg = ebastine 10 mg,
EB 20 mg = ebastine 20 mg, EB 30 mg = ebastine 30 mg; mm = 
millimeter)
mm
14-i 
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Fig. 20: LSEQ (QOS): Mean changes from baseline (D1H0) for each
treatment condition
(TRI lOmg = triprolidine 10 mg, EB lOmg = ebastine 10 mg.
EB 20 mg = ebastine 20 mg, EB 30 mg = ebastine 30 mg; mm = 
millimeter)
mm
2 0 1
15-
10-
01 HO D2H0 D6H0
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5.3.4 Discussion and conclusions
This study failed to provide clear evidence that ebastine, at the doses tested produced 
sedation. No consistent effects could be seen. The sole significant drug-placebo 
difference which was detected, was found with subjective testing. The highest dose 
(ebastine 30 mg), produced daytime tiredness after the fifth administration, and a 
nighttime "sleep inducing" effect after the first administration. On the objective tests, 
however, none of the tested doses of ebastine produced any significant indication of 
sedation either after acute or repeated dosing (Rombaut et al., 1990a).
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Apart from the significant subjective sedative effects seen on the LSEQ after one 
administration of 30 mg, and on the LARS, 4 hours after 5 daily administrations of 30 
mg, a trend for sedation could be observed with the 20 mg dose on the same scales. 
The LARS results on day 1 demonstrated increased sedation 4 hours after intake after 
both 20 and 30 mg, and the LESQ showed better quality of sleep after one intake of 
both 20 and 30 mg as well. These findings might suggest a possible dose related effect 
of ebastine. However there are other trends which show the opposite. For instance the 
same LESQ component (QOS) which shows improved sleep after administration of 
both 20 and 30 mg on day 1, indicates an inverse dose relation ship after 5 days of 
administration, with highest values for 10 mg, followed by the verum, 30 mg and 
20mg and placebo. Also, no dose related effects are evident on the objective tests.
With SMST all ebastine groups improve (but not the verum levocabastine), while 
reaction times on the SCTT tend to be shorter with 30 mg than with 10 mg.
The few trends and significant changes observed after administration of ebastine, as 
described above, did not provide any evidence of a time course of sedative effects of 
this compound. Triprolidine, however, produced significant impairment between 4 
and 8 hours after the first administration, on objective measures (SCTT, SMST), and 
between 2 and 4 hours after the first administration on the subjective measure (LARS). 
This might indicate that antihistamine-induced sedation is subjectively experienced 
before it becomes evident in a performance test, and furthermore, that it is possible to 
tolerate and compensate for this sedation in performance tests so that no impairment 
can be detected.
It is concluded that, as AH induced sedation varies over the whole daytime period, it 
is important to plan assessments at frequent regular intervals, and to select time points 
which cover not only the pharmacokinetic profile of the test drug, but also the 
possible range and duration of action.
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5.4 Summary
This chapter examined the sensitivity of a range of tests in assessing the effects of 
dose ranging treatment regimens of two AH's in three placebo and verum controlled 
experiments, after both single and repeated administration. R 72 075 which was the 
compound under investigation in Experiments 1 and 2, was administered mane at 
doses of either 5, 10, 20, 30 and 40 mg. None of these doses produced any significant 
impairment at any of the test times, on any of the objective (CFF, CRT) or subjective 
{VAS, FRS, Y/N) tests, except that significant sedation was noted on the VAS , 2 hours 
after the first administration of the highest dose (40 mg). In Experiment 3 ebastine 
was given at doses of 10, 20, and 30 mg mane. None of the objective measures {CFF, 
CRT, SCTT, SMST) detected any significant sedation with any of the doses used at 
any of the test times, while the subjective measures {LARS, LSEQ) showed significant 
sedation with 30 mg of ebastine.
The fact that each of the two vera which were used in these experiments, produced 
significant detrimental effects on the majority of the tests (levocabastine significantly 
impaired CFF, CRT, VAS; triprolidine produced significant effects on SCTT, SMST, 
LARS and LSEQ) confirmed that these tests were sensitive to AH induced sedation 
and suggested that both R 72 075 and ebastine were free from sedation up to doses of 
respectively 30 and 20 mg a day. The significant effects observed on subjective 
measures {LARS with 40 mg of R 72 075, and LARS and LSEQ with 30 mg of 
ebastine) indicates that AH induced sedative effects are more readily subjectively 
experienced than that they are interfering with objective (performance) tests, during 
which subjects may be able to compensate for the perceived sedative effects. These 
results seem furthermore to suggest that both with R 72 075 and ebastine the highest 
dose which was tested also represented the threshold dose above which sedation could 
become more apparent.
The time course of the pharmacodynamic effects of both vera appeared to be quite 
different. Levocabastine showed significant sedative effects between 2 and 4 hours 
after the first administration while triprolidine displayed these effects mainly between 
4 to 8 hours after the first intake. Although levocabastine was not tested after more 
than 4 hours and the assessments with triprolidine did not take place after 8 hours (and 
therefore no conclusions can be drawn about their possible effects at these later time 
points) it appears that the sedation produced by levocabastine happens earlier than
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with triprolidine. Because of the differences in time of appearance of sedation after 
administration it is important to organise intermittent tests sessions at frequent time 
intervals so as not to miss any significant time related effects.
Almost all significant signs of sedation were observed after the first administration, 
although with both vera there was some evidence of sedation after repeated dosing on 
a subjective measure only: with levocabastine significant sedation was experienced 
(VAS) after 3 days of administration, with triprolidine sedative effects were still 
noticeable (LARS) after 5 days. As with the highest doses of R 72 075 and ebastine, 
the effects after repeated administration were only detectable on subjective measures, 
which suggests that subjective measures are more sensitive in detecting sedation than 
objective psychometrics.
129
CHAPTER 6 DIFFERENT ROUTES OF ADMINISTRATION: THEIR
INFLUENCE ON MEASURES OF SEDATION
6.1 Experiment 4: The central effects of two concentrations of 
Levocabastine eyedrops and nasal spray (single administration).
6.1.1 Introduction and rationale
Experiments 1 and 2 demonstrated some sedative effects of levocabastine. The 
following experiment investigated whether the measured sedation would be 
augmented or attenuated when the substance was given via a different route of 
administration. Different profiles of bioavailability were obtained using oral, ocular 
and nasal administration (Heykants and Janssens, 1994). It seemed interesting to see if 
the pharmacodynamic variables reflect these pharmacokinetic differences, and a pilot 
study was set-up to investigate the effects of repeated instillations of levocabastine in 
the eyes was measured (Arriaga and Rombaut, 1990).
Levocabastine is a HI antagonist which, in pharmacological studies, was found to be 
more potent in blocking HI receptors than any of the 13 other antihistamines tested 
(Awouters, 1986). Its HI receptor blocking activity is highly selective and its onset of 
action very fast. Because of this combination of properties the compound was selected 
for development as a topical therapeutic agent. Preclinical data suggested that the 
compound would have CNS effects (Janssen and Laduron, 1984); this was confirmed 
in an open pilot study in volunteers (Vanden Bussche, 1988) and in the two 
experiments described in the previous Chapter (Rombaut and Vanden Bussche,
1989a; 1989b) in which it successfully acted as a verum.
Clinical trials (Bende and Pipkom, 1987; Dechant and Goa, 1991; Pipkom et al.,
1985) confirmed levocabastine's therapeutic value for the treatment of allergic 
conjunctivitis and allergic rhinitis with a dose regimen of 0.5 mg/ ml administered as 
eyedrops (one to two drops/eye) or nasal spray (one to two puffs/ nostril) two to four 
times daily. In clinical practice, however, eye-drops and nasal spray are frequently 
used concomitantly in order to alleviate hay fever symptoms which affect both eyes
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and nose. It seemed interesting therefore to confirm the absence of sedation with the 
combined usage of both eyedrops and nasal spray, especially in view of the fact that 
the nasal application enables the drug to enter the systemic circulation more readily 
than when given via the ocular route. In fact, the bioavailability of the eye drops and 
nasal spray ranges between 30% and 60%, and 60% and 80%, respectively, with peak 
plasma concentrations one to two hours after administration (Heykants and Janssens, 
1994). This experiment investigates the combined use of ocular and nasal 
levocabastine, and examines whether a dose relationship can be established by using 
two different concentrations of the topical formulation. Additionally the time course 
of the pharmacodynamic effects of the drug is measured by applying a battery of 
psychometric tests at different times after administration of treatment.
The final design of this study was the result of discussions between two parties (the 
manufacturer and the author). Each party had its own specific objectives and 
hypotheses to be tested . The main objective are summarised below.
For the manufacturer:
Objective: To investigate whether levocabastine administered as eye-drops and
nasal spray is free of sedation.
Hypothesis: No sedation can be demonstrated at 75,150 and 300 minutes after one
single application of 0.5 mg/ml or 2 mg/ml solution of levocabastine.
For the author:
Objectives: 1. To investigate the comparable sensitivity of CFF, CRT, SCTT,
SMST and LARS in detecting sedation as influenced by route of 
administration.
2. To investigate the comparable sensitivity of CFF, CRT, SCTT, 
SMST and LARS in detecting possible dose related sedative effects of 
0.5 mg/ml or 2 mg/ml solution of levocabastine.
3. To investigate the comparable sensitivity of CFF, CRT, SCTT, 
SMST and LARS in detecting possible time related sedative effects of 
0.5 mg/ml or 2 mg/ml solution of levocabastine.
Hypotheses: 1. Significant sedation, if demonstrable with CFF, CRT, SCTT, SMST
and LARS, is related to the route of administration.
2. Significant sedation, if demonstrable with CFF, CRT, SCTT, SMST 
and LARS, is dose related.
3. Significant sedation, if demonstrable with CFF, CRT, SCTT, SMST 
and LARS, is related to time of administration.
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6.1.2 Material and methods
Twelve female volunteers aged between 18 and 45 (median: 31) years were recruited 
to take part in the study. The study was a double-blind double-dummy, placebo 
controlled cross-over study with the following four experimental treatments: 
Treatment A: the combined application of eye-drops (two drops per eye) and 
nasal spray (two sprays per nostril) of levocabastine (0.5 mg/ml) plus a placebo 
capsule orally.
Treatment B: the combined application of levocabastine eye-drops (two drops per eye) 
and levocabastine nasal spray (two sprays per nostril) of levocabastine (2 mg/ml) plus 
a placebo capsule orally.
Treatment C: the administration of an oral dose of triprolidine, 10 mg, in a capsule 
together with two drops per eye placebo and two sprays per nostril placebo.
Treatment D: the administration of an oral placebo capsule together with two drops 
per eye placebo and two sprays per nostril placebo.
Subjects acted as their own control and were allocated at random to the treatment 
schedules by means of a predetermined code derived from three balanced 4 x 4  Latin 
squares. All subjects received each treatment in a double-blind randomised order with 
a 2 week washout period between each administration. Placebo and active 
levocabastine eye-drops and nasal spray, as well as placebo and verum capsules were 
identical in appearance and packing (Table 25).
Table 25: Experimental design (example of possible sequence for one
subject)
Time Study Condition
interval period
Week -1 pre-trial screen
Week 1 day 1 
wash-out
treatment C
Week 3 day 1 
wash-out
treatment A
Week 5 day 1 
wash-out
treatment D
Week 7 day 1 treatment B
Week 8 post-trial screen
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Sedation was assessed using a battery of cognitive and psychomotor tests {CFF, CRT, 
SCTT, SMST, WRT, LARS) which was given at baseline and at approximately 75, 150, 
and 300 minutes following medication. At 40 minutes following dosing CFF, WRT 
and VAS were administered (Table 26). The times chosen for testing reflected the 
overall pharmacodynamic profile of levocabastine from pharmacodynamic data and 
previous studies (Rombaut and VandenBussche, 1989a; 1989b; Arriaga and Rombaut, 
1990).
Table 26: Schedule of events
Time D1M0 D1M40 D1M75 D1M150 D1M300
(day/minutes)
Medication X
Measures
CFF X X X X X
CRT X X X X
SCTT X X X X
SMST X X X X
WRT X X X X X
LARS X X X X X
6.1.3 Results 
CFF
There was a progressive decrement in CFF thresholds shown with all treatments, 
reflecting the general lowering of alertness and attention processes during the course 
of the day. Triprolidine was significantly lower than placebo at 150 minutes 
(DIM150). Neither levocabastine 0.5 mg/ml, nor levocabastine 2 mg/ml, were 
significantly different from placebo at any test point (Fig 21 and Appendix I, table 14).
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Fig. 21: CFF: Mean values for each treatment condition
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI lOmg = triprolidine 10 mg, LEV 0.5mg/ml = levocabastine 
0.5mg/ml, LEV 2mg/ml = levocabastine 2mg/ml; Hz = Hertz )
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CRT
There were no consistent or noticeable changes produced by any of the substances at 
any test point and these results are not discussed further (see Appendix I, Tables 15 to 
17).
SCTT
The mean tracking accuracy scores (RMS) showed that both levocabastine 0.5 mg/ml, 
and levocabastine 2 mg/ml, were indistinguishable from placebo. Triprolidine at 
D1M75 was worse than placebo, but particularly so at 300 minutes (D1M300), 
although this trend for impairment did not reach an acceptable level of statistical 
significance (Fig. 22). The mean scores for the Peripheral Reaction Time component 
{RT) of the simulated car tracking test showed no significant placebo-treatment 
differences (see Appendix I, Table 18 and 19).
Fig. 22: SCTT (RMS): Mean values for each treatment condition
(TRI lOmg = triprolidine 10 mg, LEV 0.5mg/ml = levocabastine 
0.5mg/ml, LEV 2mg/ml = levocabastine 2mg/ml; unit = root mean 
square of deviation from track programme)
units
1 2 -)
1 0 -
D1M0 D1M75 D1M150 D1M300
placebo  
■•"TRI 10mg 
LEV 0.5mg/ml 
LEV 2mg/ml
Test Times
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SMST
Triprolidine produced a decrement (increase in reaction time) on this measure of 
short-term memory function at all test points, and significantly so at 150 minutes 
(D1M150). This significant difference w.r.t. placebo occurred at the time at which an 
improvement was noted with placebo. Neither levocabastine 0.5 mg/ml, nor 
levocabastine 2 mg/ml, showed any noticeable difference from placebo scores at any 
assessment time (Fig. 23 and Appendix I, Table 22).
Fig. 23: SMST (RT): Mean values for each treatment condition
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI lOmg = triprolidine 10 mg, LEV 0.5mg/ml = levocabastine 
0.5mg/ml, LEV 2mg/ml = levocabastine 2mg/ml; msec = millisecond )
m s e c
4 9 0 1
4 8 0 -
4 7 0 -
4 6 0 -
4 5 0 -
■®" placebo  
TRI 10mg 
"*■ LEV 0.5mg/ml 
LEV 2mg/ml
D1M0 D1M75 D1M150 D1M300
Test Times
WRT
The results from this test of short-term memory for both matched and unmatched 
words showed no significant placebo-treatment differences and they are not discussed 
further (see Appendix I, Tables 20 and 21).
136
LARS
Triprolidine was rated as more sedative than placebo or levocabastine 0.5 mg/ml and 
levocabastine 2 mg/ml. A significant increase in sedation, with respect to placebo was 
found 75 minutes (D1M75) following administration of triprolidine. Neither 
levocabastine 0.5 mg/ml, nor levocabastine 2 mg/ml, were distinguishable from 
placebo (Fig 24 and Appendix I, Table 23).
Fig. 24: LARS: Mean values for each treatment condition
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI lOmg = triprolidine 10 mg, LEV 0.5mg/ml = levocabastine 
0.5mg/ml, LEV 2mg/ml = levocabastine 2mg/ml; mm = millimeter )
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6.1.4 Discussion and conclusions
In this experiment neither dose level of levocabastine showed any evidence of 
sedative activity at any time, while triprolidine produced significant impairment on 
the CFF, SMST, LARS, and showed a perceptible increase on the SCTT (RMS), which 
however failed to be significant. It therefore can be assumed that levocabastine,
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applied topically, has no demonstrable central nervous system activity. It is interesting 
to note that the lack of subjective feelings of sedation {LARS) was demonstrated in a 
situation where the verum control was rated as significantly sedative. However, 
despite the fact that the bioavailability of levocabastine, when administered as a nasal 
spray, is relatively high and, percentage wise, close to that of the oral formulation, no 
CNS effects could be observed with the combined ocular and nasal application 
(Rombaut et al., 1991). Oral administration, on the other hand, produced consistent 
CNS impairment. When considering the concentration of the weakest formulation 
(05.mg/ml) this might not be unexpected. With the higher concentration (2 mg/ml) 
however, the administration of 4 puffs at 0.8 mg/puff could produce plasma levels 
which are similar to the levels which are reached after oral intake of 2.3 mg 
(Heykants and Janssens, 1994). When adding to this the amount which is absorbed 
from the eye-drops at the highest concentration, it is clear that the amount of active 
drug available in the bloodstream cannot be too different from the levels which are 
reached with 3 mg oral levocabastine. Yet topical application at the doses studied here 
does not seemingly produce sedation while oral administration does.
As no significant effects were seen with either formulation of levocabastine no 
conclusions can be drawn as to the time course of their pharmacodynamic effects. 
Triprolidine however showed significant impairment between 150 (= 2.5hrs) and 300 
(=5 hrs) minutes after treatment on objective measures but earlier ie. after 75 minutes 
(1.25 hrs) on the LARS. This confirms some of the concluding remaks in the previous 
experiment (3) namely that it is possible to experience (and recognise) AH induced 
sedation before it is detecable in psychomotor performance tests, and that this 
sedation can be compensated for.
6.2 Summary
Experiments 4 examined the impact of different routes of administration on the 
capacity of the test battery to measure sedation. In this experiment the effects of 
topical levocabastine were tested using the normal, recommended concentration (0.5 
mg/ml) and a concentration which was 4 times higher (2mg/ml). At the higher 
concentration, simultaneous application of the nasal spray and the eyedrops resulted in 
the administration of a total dose of 3.84 mg of levocabastine. Although in 
Experiments 1 and 2 (Rombaut and Vanden Bussche, 1989a; 1989b) oral
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administration of 3 mg of levocabastine was found to produce significant detrimental 
effects on CFF, CRT, VAS, FRS, no sedative effects could be detected on the test 
battery (CFF, CRT, SCTT, SMST, LARS) used in this study. The verum triprolidine 
however produced sedative effects on CFF, SMST and LARS, demonstrating that not 
only the test battery but also the volunteers who participated in this study, were 
sensitive to AH induced sedation. The bioavailability of levocabastine, which is 
different after oral (100 %), nasal (60-80 %) and ocular administration (30-60%), 
undoubtedly plays a role in this observed difference of sedation potential (Heykants 
and Janssens, 1994). However, it is not unlikely that other, psychological factors such 
as anticipation (i.e. topical administration is usually not associated with central 
effects) may interfere with the experience and measurement of sedation. It seems 
therefore that, unless the total amount of levocabastine administered was just below 
the sedation threshold, the route of administration of a sedative AH may have an 
impact on the sensitivity of the test measures used in this experiment.
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CHAPTER 7 EFFECTS OF ANTIHISTAMINES ALONE OR IN
COMBINATION ON MEASURES OF SEDATION 
AND/OR AROUSAL DURING SLEEP/WAKE CYCLE
7.1 Experiment 5: The central effects of two doses of Hydroxyzine (single 
administration).
7.1.1 Introduction and rationale
Experiments 1 ,2 ,3  and 4 assessed various dose regimens and/or administration 
routes of AH's to measure the extent of sedation produced. However, under certain 
circumstances sedation may have a clinically beneficial function. This is particularly 
so when AH's are to be used as nocturnal sedatives. The extent to which sedation 
produced by a particular AH could be useful in inducing and/or maintaining sleep, 
depends not only on the acute sedative effects (sleep induction) of the drug under 
investigation, but also on the drug's ability to maintain sleep. As morning after effects 
also require evaluation, a new measure (C-EEG) was introduced. C-EEG allowed 24 
hour monitoring of CNS activity and this study therefore also served to explore the 
overall value of the C-EEG method in assessing the sedative activity of AH's.
First generation AH's enter the CNS more readily and may be associated with greater 
sedative effects than those of the second generation, which are supposed not to cross 
the blood brain bamer so easily, although their presence in the brain has been reported 
(Goodman et al., 1980; White and Rumbold, 1988). It was decided to use hydroxyzine 
(a first generation AH) as the investigational drug and to assess its potential use as an 
hypnotic.
Hydroxyzine has been used as an anxiolytic and anti-stress agent with known sedative 
effects (De Brabander and Deberdt, 1990). Effects on sleep have indicated a dose- 
related increase in subjective sleep duration (Brown, et al., 1974), although objective 
increases have not yet been established. Similarly, the sedative hangover potential on 
waking activity the following day, common to several benzodiazepine hypnotics 
(Alford and Hindmarch 1987), required investigation. Therefore a combination of a
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full test battery, including both objective and subjective measures, and 
electrophysiological monitoring (C-EEG) was used to examine any effects which 
would occur over a 24 hour period.
The final design of this study was the result of discussions between two parties (the 
manufacturer and the author). Each party had its own specific objectives and 
hypotheses to be tested . The main objective are summarised below.
For the manufacturer:
Objective: To investigate whether hydroxyzine had any sleep promoting effects.
Hypothesis: Sedation can be demonstrated at 1 hour after one single administration,
at bedtime, of either 25 or 50 mg of hydroxyzine.
For the author:
Objectives: 1. To investigate the comparable sensitivity of CFF, CRT, SCTT,
SMST, LARS, and C-EEG in detecting sleep promoting effects of 
hydroxyzine.
2. To investigate the comparable sensitivity of CFF, CRT, SCTT, 
SMST, LARS, and C-EEG in detecting possible dose related sedative 
effects of 25 and 50 mg of hydroxyzine.
3. To investigate the comparable sensitivity of CFF, CRT, SCTT, 
SMST, LARS, and C-EEG in detecting sedation as influenced by time 
of administration.
Hypotheses: 1. The sleep promoting effects of hydroxyzine, if any, will be
demonstrable with CFF, CRT, SCTT, SMST, LARS, LSEQ and C-EEG.
2. Significant sedation, if demonstrable with CFF, CRT, SCTT, SMST, 
LARS, LSEQ and C-EEG, is dose related.
3. Significant sedation, if demonstrable with CFF, CRT, SCTT, SMST, 
LARS, LSEQ and C-EEG, is related to the time of administration.
7.1.2 Material and methods
The volunteer sample comprised six females and six males (mean age 33.8 years; 
range 18-44 years), who were run in two single-sex groups. Hydroxyzine 25 mg and 
hydroxyzine 50 mg were compared to placebo. All treatments were administered 
orally 1.5 hours before bedtime. Subjects acted as their own controls in a double-blind 
crossover design; treatments were given according to a predetermined code based on
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Latin squares, and with the subjects randomly assigned to a treatment number. A 
washout period of 1 week was observed between the start of each treatment (Table 
27).
Table 27: Experimental design (example of possible sequence for one
subject)
Time Study Condition
interval period
Week -1 pre-trial screen
Week 1 day 1 
wash-out
treatment B
Week 3 day 1 
wash-out
treatment A
Week 5 day 1 treatment C
Week 6 post-trial screen
Each test period lasted 24 hours, beginning with a light meal after arrival at the study 
centre, in the evening. Electrodes were then attached to subjects and ambulatory 
monitoring commenced prior to a baseline psychometric test battery consisting of 
CFF, CRT, SCTT, SMST and LARS (D1H-.5). This was followed by medication 
(D1H0). An hour later (D lH l)a  shorter version of the test battery {CFF and LARS 
only) was administered, and volunteers went to bed half an hour later (1.5 hours after 
treatment). This schedule allowed the full pre-sleep absorption of the treatments 
(Gengo et al., 1987). The next day subjects were awakened after an 8 hour nocturnal 
sleep period (D2H9.5) and were asked to complete a sleep questionnaire {LSEQ).
Following breakfast and change of electrode placements to the daytime recording 
montage, a full test battery was undertaken at D2H10.5 (Table 28).
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Table 28: Schedule of events
N day DAY 1 NIGHT 1 DAY 2
N Administration I
Time D1H-0.5 D1H0 D1H1 D1H1.5 D2H9.5 D2H10.5 D2H21
(day/hour)
Medication X
Sleep period xxxxxxxxxxxxxxx
Measures
CFF X X  X X
CRT X X X
SCTT X X X
SMST X X X
LARS X X  x X
LSEQ X
C-EEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Subjects remained at the study centre where they had lunch, before completing a final 
test battery at 21 hours post-treatment D2H21. Electrodes were then removed before 
subjects returned home at the end of the study period. A complete 24 hours attendance 
preceded the first treatment block, being run as a ‘blind’ (placebo) treatment, to 
provide familiarisation with study procedure and a sleep adaptation period (Agnew et 
al., 1966). The use of Medilog ambulatory electrophysiological monitors enabled two 
groups of six to run, with bedrooms shared by subject pairs at the study centre.
7.1.3 Results 
CFF, CRT, SCTT, SMST
No significant effects were noticed for any of the objective tests at any of the test 
times and the results will therefore not be discussed further (Appendix I, Table 24 and 
25).
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LARS
An increase in subjective sedation was seen with both active treatments at one hour 
(D1H1) after administration and at waking (D2H10.5) but these changes failed to 
reach significance (Fig. 25 and Appendix 1. Table 26).
Fig. 25: LARS: Mean values for each treatment condition
(HYD 25mg = hydroxyzine 25 mg, HYD 50mg = hydroxyzine 50 mg; 
mm = millimeter)
mm
60-1
58-
56-
54-
52-
50-
48-
D1H0.5 D1H1 D2H10.5 D2H21
*®' placebo 
HYD 25mg 
**■ HYD 50mg
Test Times
LSEQ
Hydroxyzine did not produce any significant changes on either sleep induction (GTS) 
or sleep maintenance (QOS) scores of the LSEQ (see Appendix I, Table 27). However, 
significant increases in perceived sedation were seen in the LSEQ components 
measuring the ease of waking (AFS) and hangover (BFW) with 50 mg of Hydroxyzine 
but not with 25 mg (Fig. 26 and Appendix I, Table 27).
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Fig. 26: LSEQ (AFS and BFW): Mean values for each treatment condition
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(HYD 25mg = hydroxyzine 25 mg, HYD 50mg = hydroxyzine 50 mg; 
mm = millimeter)
mm
AFS BFA
LSEQ Factor
D  placebo 
SSHYD 25mg 
^HYD 50mg
C-EEG
Significant treatment effects were observed on the EEG for nocturnal sleep with both 
active doses showing a reduction in Sleep Onset Latencies to both stage 1 (SOLI) and 
stage 2 (SOL2), and in the Duration of Final Waking (DuFW). Frequency of Waking 
(FW) was reduced with both hydroxyzine doses but only significantly so after 50 mg 
(Table 29). None of the daytime C-EEG measures showed significant or consistent 
trends, and are, therefore not presented.
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Table 29: C-EEG: Nocturnal sleep parameters/latencies, overall durations
(95 % confidence intervals)
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(HYD 25mg = hydroxyzine 25 mg, HYD 50mg = hydroxyzine 50 mg; 
SOLI = Sleep Onset Latency to Stage 1, SOL2 = Sleep Onset Latency 
to Stage 2, FW = Frequency of waking, DuFW = Duration of Final 
Waking; mins = minutes, N = Number)
Placebo HYD HYD
25 mg 50 mg
SOLI (mins) 16.55 7.15* 7.30*
(2.83) (2.71) (2.71)
SOL2 (mins) 22.55 12.28* 11.72*
(3.61) (3.46) (3.46)
FW (N) 6.45 5.00 3.33*
(1.37) (1.37) (1.31)
DuFW (mins) 24.36 14.45* 14.62*
(4.46) (4.46) (4.27)
7.1A  Discussion and conclusions
The significant reductions in sleep onset latency (SOLI, SOL2) with hydroxyzine 
demonstrate the sleep enhancing potential of this compound when taken 1.5 hours 
before bedtime. That sleep onset latencies were halved without sleep inducing 
problems serves to emphasise the pro-hypnotic effects for both 25mg and 50mg doses 
of the drug. CFF scores failed to demonstrate a sleep inducing effect, however. This 
lack of measured sedation clearly distinguishes this AH from conventional 
benzodiazepine hypnotics (Hindmarch, 1982) and non benzodiazepine sleep inducers 
(Hindmarch and Musch, 1990) which all show profound sedation on nocturnal CFF 
measures. In line with the results observed in the previous experiments (1 to 4) with 
oral levocabastine, and triprolidine the subjective measure (LARS) seems to be 
somewhat more sensitive and suggests that subjects were experiencing a mild degree 
of sedation with both doses of hydroxyzine, but not with placebo. The AH's also differ 
from other hypnotics in that the LSEQ, previously shown to be a sensitive index of 
sleep inducers (Hindmarch, 1984) fails to show any subjective hypnotic effects.
The reductions in the frequency of waking during sleep (FPF),and in the duration of 
the final wake period (DuFW) reflect the consolidated nature of the resulting sleep 
over the 8 hour recording period. This reflects an increase in sleep efficiency (% of
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time asleep with respect to the time a subject is in bed) and argues well for the use of 
hydroxyzine as an hypnotic. The lack of significant treatment effects for all daytime 
intermittent (test battery) and continuous {C-EEG) measures, except for the subjective 
early morning sedation shown on the LSEQ, suggests that only the highest dose 
produces a morning hangover effect, which is mild and transient (Alford et al., 1992)
The fact that the objective measure {CFF) of the test battery which was taken 1 hours 
after administration failed to detect any significant sedation with either dose of 
hydroxyzine, appears to suggest that the sedative and/or sleep inducing effects of 
hydroxyzine are either mild or psychologically different from conventional hypnotics.
As far as the comparison between continuous-EEG and psychometric testing is 
concerned, the present study shows that the C-EEG is an objective measure of 
changes in sleep induction time and a useful index of sleep efficiency, and that the 
psychometric test battery is compromised and cannot be put forward as a reliable 
index of the hypno-sedative effects of hydroxyzine.
7.2 Experiment 6: CNS effects of two combinations of
pseudoephedrine and antihistamines (one day’s administration).
7.2.1 Introduction and rationale
The previous studies have assessed the extent to which psychometric tests were 
successful in detecting the sedative potential of antihistamines at different times 
following acute or repeated doses via varying routes of administration using different 
dose regimens. This experiment envisaged to assess the usefulness of the test battery 
in comparing the CNS effects of combinations of pseudoephedrine, a compound with 
known stimulating properties, with both a sedative (triprolidine) and a non-sedative 
(astemizole) AH. Both AH’s were administered at the recommended dose, and in the 
case of triprolidine at the dose (2.5 mg) which was used for the production of the 
combination product. In Experiments 3 and 4 triprolidine 10 mg had been found to 
produce sedative effects; the 2.5 mg dose has equally been reported to produce
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sedation (Peck et al., 1975; Cohen etal., 1985; Nicholson, 1979; Nicholson and Stone,
1986). As in the previous experiment, the effects on nighttime CNS functioning are 
investigated using C-EEG.
Two stereoisomers of ephedrine are in current therapeutic use. One is 
D(-)ephedrine, mainly used for its bronochodilator effects (Martindale, 1993). The 
other is L(+)pseudoephedrine, mainly used for its effects on nasal decongestion 
(Empey et al., 1980; Roth et al., 1977). Insomnia is a well recognised side-effect in 
patients receiving treatment with the dextroisomer, but it is generally assumed that the 
levoisomer, pseudoephedrine, is virtually free of central side-effects. The latter 
assumption stems mainly from animal studies which have demonstrated that 
ephedrine is considerably more potent in producing CNS stimulation than 
pseudoephedrine (Lanicault and Wolff, 1972). Attempts have been made to measure 
the effects of pseudoephedrine on daytime functioning (Bye et al., 1974) but the 
nighttime effects of this compound remains largely undocumented.
After having studied the effects of a typical decongestant and having compared its 
CNS effects in terms of different dosage schedules (Rombaut et al., 1989b), the 
present study evaluates the CNS effects of treatment with a combination of a 
decongestant and an AH treatment, and examines to what extent these possible effects 
are detectable on objective and subjective measures. The test hypothesis was that the 
combination of a controlled release formulation of the decongestant with a new non 
sedative AH would have fewer CNS effects than the existing combination of the 
immediate release preparation with a classical sedative agent.
The final design of this study was the result of discussions between two parties (the 
manufacturer and the author). Each party had its own specific objectives and 
hypotheses to be tested . The main objective are summarised below.
For the manufacturer:
Objective: To investigate whether the combination of astemizole and
pseudoephedrine has less CNS effects than the triprolidine 
pseudoephedrine combination.
Hypothesis: No daytime sedation or nighttime stimulation can be demonstrated
after one single administration of astemizole 10 mg plus 
pseudoephedrine.
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For the author:
Objectives: 1. To investigate the comparable sensitivity of CFF, CRT, SCTT,
SMST, LARS, LSEQ and C-EEG in assessing daytime and nighttime 
CNS effects.
2. To investigate the comparable sensitivity of CFF, CRT, SCTT, 
SMST, LARS, LSEQ and C-EEG in detecting CNS effects as influenced 
by time of administration.
3. To investigate the comparable sensitivity of CFF, CRT, SCTT, 
SMST, LARS, LSEQ and C-EEG in detecting the interaction potential 
of AH's and pseudoephedrine.
Hypotheses: 1. The sedative effects of the triprolidine combination, if not
counteracted by pseudoephedrine, and the stimulating effects of 
pseudoephedrine, if not counteracted by triprolidine will be 
demonstrable with either CFF, CRT, SCTT, SMST, LARS (daytime 
effects) or LSEQ and C-EEG (nighttime effects).
2. Significant CNS effects, if demonstrable with CFF, CRT, SCTT, 
SMST, LARS (daytime effects) or LSEQ and C-EEG (nighttime 
effects) are related to the time of administration.
3. The sedative effects of the AH's under investigation, if any, will be 
counteracted by pseudoephedrine, and demonstrable with either CFF, 
CRT, SCTT, SMST, LARS, LSEQ or C-EEG.
7.2.2 Materials and methods
Twelve female volunteers age range 22 to 46 years (mean age 36.9 years) participated 
in the study. A double-blind placebo-controlled design was employed comprising 
three single day experimental treatments. Each of the study periods ran over 24 hours. 
Each subject received all treatments, with subjects acting as their own controls. They 
were randomly allocated to the treatment code which comprised four 3x3 balanced 
order codes such that the order of treatments was balanced equally over weeks 3, 5 
and 7 of the study.
Although subjects were recorded at home, the first week provided an adaptation 
period to allow subjects to become familiar with the study protocol and to allow for 
possible 'first night effects' frequently seen with nocturnal sleep recording (Agnew et
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al., 1966). This first (adaptation) week was single-blind to subjects only, whilst the 
comparative treatments were administered double-blind to both investigators and 
subjects according to the predetermined study code. The results for week 1 have not 
been included in the analysis. The treatments were commenced at 2 weekly intervals 
providing 13 days washout between treatment administration (Table 30).
Table 30: Experimental design (example of possible sequence for one
subject)
Time Study Condition
interval period
Week -1 pre-trial screen
Week 1 day 1 single-blind Placebo
break
Week 3 day 1 double-blind treatment C
wash-out
Week 5 day 1 double-blind treatment B
wash-out
Week 7 day 1 double-blind treatment A
WeekS post-trial screen
The treatments comprised the combination astemizole 10 mg and pseudoephedrine 240 
mg (controlled release) mane as the test drug combination (AST/PS); triprolidine 
2.5mg and pseudoephedrine 60mg (immediate release) t.i.d. as the comparator 
(TRI/PS); and placebo (PLA). The triprolidine/pseudoephedrine combination may be 
considered as a verum as previous research (Cohen et al., 1985; Nicholson, 1979; 
Nicholson and Stone, 1986; Peck et al., 1975) had shown the profound sedative 
effects of 2.5 mg of triprolidine during the day, and sleep disruptive effects of 60 mg 
of pseudoephedrine when given in divided doses in its immediate release formulation. 
The astemizole/pseudoephedrine combination was investigated as this represented a 
novel commercial formulation. The dosages tested for both combinations were within 
the recommended range for the treatment of nasal allergies. All capsules were 
identical in appearance with extra placebo capsules added to provide a fixed t.i.d. 
treatment schedule.
The test battery comprised four objective and two subjective measures. These were: 
CFF, CRT, SCTT, SMST, LARS and LSEQ. All tests were assessed at each time
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interval, except for the LSEQ which was completed once only, following waking, on 
the morning of day 2.
Prior to first medication, at D1H-0.5, the C-EEG monitoring equipment was attached 
to the subjects and the first test battery was administered (baseline); the second test 
battery was administered 1.5 hours after the first intake (D1H1.5); the second dose 
was taken approximately 5 hours after the first, followed by the third test battery 1.5 
hours later (D1H6.5); the interval between the second and third dose was again 5 
hours; following the nocturnal sleep period at approximately 24 hours after the 
baseline assessments (D2H0) the first test battery of the second day was started and 
the C-EEG recording was completed and electrodes removed.
Daytime sedation as measured by C-EEG was analysed both for each period between 
doses and also for the combined 24 hour period. The daytime periods used for the C- 
EEG analysis were as follows:
Tl: from the start of recording (approx.DlH-0.5), to the start of the second
test battery (D1H1.5);
T2: from the end of the second test battery to the start of the third test battery
(D1H6.5); and
T3 : from the end of the third test battery to the start of the nocturnal sleep
period (end of first recording tape).
The final waking period (T4) from the start of day 2 to commencing the fourth test 
battery was not entered into the analysis as this was found to represent a forced 
activity period with insufficient time to allow subjects the opportunity to demonstrate 
C-EEG residual sedation. Nocturnal sleep disturbance was assessed for the time 
period from going to bed and settling down to sleep to the time of getting up in the 
morning. The assessment schedule was identical for each treatment (Table 31).
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Table 31: Schedule of events
N day DAY 1 NIGHT 1 DAY 2
Administration I II III
Time D1H-0.5 D1H1.5 D1H6.5 D2H0
(day/hour)
Medication X X X
Measures
CFF X X X X
CRT X X X X
SCTT X X X X
SMST X X X X
LARS X X X X
LSEQ X
C-EEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Subjects were transported to and from the study centre on treatment days. The third 
medication was therefore administered by the subjects at home with nocturnal sleep 
being recorded in the home environment. Subjects were urged not to sleep during the 
daytime at either the study centre or their own homes unless they felt physically tired 
or sedated and had a strong urge to do so.
7.2.3 Results 
CFF, CRT, SCTT, SMST
None of the psychometric tests revealed significant treatment effects except for the 
SCTT, on Tracking Accuracy (RMS) (Fig 27 and Appendix I, Tables 28 to 34).
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Fig. 27: SCTT (RMS): Mean values for each treatment condition
(AST lOmg/PS 240mg = astemizole/pseudoephedrine combination. 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination; unit 
= root mean square of the deviation from track programme)
units
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A significant contrast was seen with the astemizole combination between the initial 
baseline score (D1H-0.5) and the second test battery (D1H6.5) indicating an improved 
post drug score. Similarly, a significantly improved score was found with the 
astemizole combination in contrast to the triprolidine combination for the total scores 
(summed across all tests) with an overall trend toward sedation being seen with the 
triprolidine combination in contrast to placebo.
LARS, LSEQ
Neither the LARS nor the LSEQ revealed significant treatment effects with the overall 
analysis of variance nor were significant contrasts obtained with 95% confidence 
intervals (Appendix I, Tables 35 and 36). However, a review of mean treatment 
effects revealed different trends between the treatments. With the LARS (Fig. 28)
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Fig. 28: LARS: Mean values for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination; mm 
= millimeter)
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TRI 2.5mg/PS 60mg
assessment of differences from baseline indicated a possible trend toward increased 
subjective arousal at D1H1.5 with the astemizole combination, with a lesser effect 
being seen for the triprolidine combination in comparison to placebo. Results were 
similar for all treatments at D1H6.5. A possible enhancement of subjective arousal 
was also seen for the triprolidine combination at D2H0 . The results of the LSEQ (Fig. 
29) showed a marked increase in variance of subjective ratings with both the active 
treatments for 'Getting To Sleep’ (G7S); 'Quality Of Sleep' (gOS); and 'Awakening 
From Sleep' (AFS)', only the variances for 'Behaviour Following Awakening' (BFA) 
were similar across treatments. This indicates a marked heterogeneity of response 
with both AH pseudoephedrine combinations. Despite this variation the mean 
subjective response suggests that it was subjectively harder to fall asleep with the
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Fig. 29: LSEQ: Mean values for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination; mm 
= millimeter)
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astemizole combination than with the triprolidine combination. A trend towards 
reduced QOS was also seen with astemizole plus pseudoephedrine, but was more 
marked with triprolidine plus pseudoephedrine. AFS appeared hardest following the 
astemizole combination, whilst BFA was subjectively similar for all three 
experimental treatments.
C-EEG
From reviewing the summary results across the arousal continuum using a number of 
different scoring categories, it is evident that significant drug effects were limited to 
changes in Wake (WA: continuous alpha), Drowsiness (DR: continuous alpha and 
theta) and Stage 1 sleep ( STl: continuous Theta) alone. However, while the 
astemizole combination
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Fig. 30: C-EEG (ST 1): Mean values (SEM)for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination. 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination: sec 
= seconds)
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could not be distinguished from placebo at any time point, the triprolidine 
combination was significantly different to placebo for all three of the above categories 
{WA, DR ond STl) at the second and third time periods (T2, T3) (see Appendix I, 
Tables 37 and 39). Fig.30 illustrates the summated differences over the three periods 
for Stage 1 sleep.
No significant drug effects were evident for either the more active waking categories 
(e*S* Quiet Waking Plus: ; Quiet Waking: ; Wake Intermittent Alpha: ) or for sleep 
(e.g Total Sleep from Stage 2: TST2) or total C-EEG sedation.
Analysis of variance for overall treatment effects for nocturnal C-EEG traces failed to 
reveal significant treatment differences for the different measures of sleep, although
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increases in both Waking Frequency (FW) and Duration o f Waking (DuW) during 
sleep were seen for both the active treatments (Appendix I, Table 40). The Duration 
o f Final Waking (DuFW), reflecting early morning awakening, revealed a non 
significant trend for the triprolidine combination to double the amount of early 
morning awakening in contrast to both placebo and the astemizole combination (Fig. 
31).
Fig. 31: C-EEG (DuFW): Mean values (SEM) for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination; sec 
= second)
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7.2.4 Discussion and conclusions
The results for both active combinations failed to show consistently significant 
sedative effects for any of the subjective or objective performance and C-EEG 
measures taken. Tracking Accuracy {SCTT, RMS) demonstrated significantly better
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performance with the astemizole combination in contrast to baseline values, and with 
the triprolidine results when summed across test times. Subjective sedation (LARS) 
revealed trends towards increased subjective alertness with the astemizole 
combination at 1.5 hours and towards increased subjective alertness with the 
triprolidine combination at the residual test battery on the morning of the second day. 
However, with C-EEG significant daytime drowsiness was seen with the triprolidine 
combination, for the periods between the end of the second test battery and the start of 
sleep period (Stanley et al, in press). These findings are in line with results obtained in 
a clinical study in patients suffering from allergic rhinitis (Purello d'Ambrosio et al., 
1994).
The LSEQ results suggested some perceived difficulty in falling asleep with the 
astemizole combination, and trends towards reduced Quality O f Sleep with the 
astemizole combination and more markedly with the triprolidine combination. 
Awakening From Sleep was easiest with the triprolidine combination. The latter 
subjective finding was further supported by the C-EEG findings of trends towards 
increased Duration o f Final Waking.
The individual treatment effects on nocturnal sleep failed to achieve significance, 
showing that the combined effects of AH's and pseudoephedrine were not as 
disruptive as pseudoephedrine alone (Rombaut et al., 1989b). However, as in the 
experimental study comparing astemizole 10 mg plus pseudoephedrine 240 mg with 
terfenadine 60 mg plus pseudoephedrine 120 mg reported by Idzikowski and Emanuel 
(in press), trends were seen towards slight sleep disruption with both active treatment 
combinations. This was most marked for triprolidine where increased early morning 
awakening was evident (C-EEG: DuFW). The apparent increase in subjective 
alertness with the triprolidine combination at the residual test (LARS: AFS) may 
reflect the fact that subjects tended to awake early with this treatment combination 
and could therefore have achieved a greater subjective alertness by the time of the test.
The results of the present study seem to indicate that concomitant use of 
decongestants appears to nullify or greatly reduce the potential primary daytime 
sedation produced by AH's such as triprolidine. None of the intermittent tests were 
able to detect any sedative effects with the triprolidine combination, although 
continuous assessment (C-EEG) demonstrated significant drowsiness. This particular 
finding seems to suggest that there are mild states of sedation which not only fail to
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impair performance on the psychometric tests used in this study, but moreover fail to 
be subjectively recognised as such by the individual. That these states can be detected 
by C-EEG is not surprising as this method makes it possible to collect continuous data 
over long periods of time. The summation of a large number of subtle sedative effects 
may be of importance if the individual "bouts" of tiredness are sufficient, in 
themselves, to impair psychomotor or cognitive function. Although the clinical 
significance of the observation may be doubtful as regards accident risks it may reflect 
a positive attribute in that the patient is tranquilised but not to the point of being 
impaired. It seems therefore interesting to further investigate whether this type of 
mild, sedation (or drowsiness) can be detected in other similar experiments using the 
same (C-EEG) measures, and whether the lack of sedation on objective performance 
tests and subjective assessments can be confirmed.
7.4 Summary
The two experiments discussed in this Chapter were both concerned with measuring 
CNS effects on the sleep/wake cycle, either after administration of a sedative AH 
(hydroxyzine), or the combination of a decongestant with either a sedative 
(triprolidine) or a non sedative (astemizole) AH.
The assessments used in both studies consisted of psychometric testing and 
continuous EEG (C-EEG). It is evident that only the latter test (through continuous 
nighttime recording) is able to provide objective information about nighttime sleep 
and that psychometrics tests (LARS, LSEQ) are inevitably limited to collecting 
subjective information a posteriori. Nevertheless, the results of the subjective 
measures seem to compare well with the results obtained with C-EEG. In Experiment 
6 (Stanley et al., in press) both the astemizole and the triprolidine combination 
disrupted the QOS , although not significantly so, while C-EEG measures of Waking 
Frequency, Duration and Final waking Duration reflected this disturbance without, 
however, reaching statistical significance.
C-EEG also seems to be a valuable tool for measuring improved and/or enhanced 
nighttime sleep, while subjective measures appear to be less sensitive. Significant 
effects were noted with hydroxyzine 50 mg (SOLI, SOL2, FW, DuFW) and, to a
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slightly lesser extent with hydroxyzine 25 mg {SOLI, SOL2, DuFW). LSEQ scores, 
however, only showed clear differences with regard to waking behaviour (AFW,
BFW), pointing towards a possible hangover after both active doses, but only the 
difficulties in waking experienced with 50 mg of hydroxyzine reached statistical 
significance.
Daytime effects were assessed in both experiments using a standard test battery of 
objective and subjective tests, supported by C-EEG measures. The assessment of 
daytime effects in Experiment 5, apart from a short battery (CFF and LARS) which 
was performed 1 hour after administration, just before retiring, started 10 hours after 
administration of hydroxyzine, after a proper night's sleep. Apart from the so-called 
hangover effects observed in the subjective measures (LARS: trend only; LSEQ: 
significant, as discussed before) no significant effects could be detected neither with 
C-EEG, nor with the psychometric battery testing. In Experiment 6, the daytime C- 
EEG measures (WA, DR, STl) showed significant sedative effects with the triprolidine 
combination (at T2 and T3). However, no signficant effects could be seen with 
psychometric tests, although a trend towards impairment could be noted with the 
triprolidine combination on the SCTT.
Based upon these findings it seems that C-EEG should be considered as a useful 
addition to the regular psychometric testing procedures. It is especially valuable for 
evaluating nighttime effects of AH's or AH combinations, and may also be of 
importance in detecting mild sedative daytime effects which could be missed by 
intermittent testing, even with a variety of psychometric test batteries.
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CHAPTER 8 FIRST AND SECOND GENERATION AH's:
POTENTIAL INTERACTION W ITH ALCOHOL
8.1 Experiment 7: The possible sedative effects of two doses of 
cetirizine, alone and combined with alcohol (single and repeated 
administration).
8.1.1 Introduction and rationale
From the previous studies it became clear that some of the issues which were 
addressed in separate experiments (e.g. dose response relationships, time course of 
pharmacodynamics, interaction with other CNS substances etc.) were strongly 
interrelated. It was therefore decided to perform an experiment which would take the 
relative importance of several of these factors into account. Also it seemed interesting 
to compare a number of currently used HI-antagonists rather than, as in the previous 
studies, to use a single AH and an established sedative compound (positive control). 
For such comparisons, however, an additional measure was needed to assess the 
extent to which the doses of antihistamines tested were truly comparable. Since it was 
expected that the sedative potential of different antihistamines would be directly 
related to their histamine inhibitory potential (and consequently, to their therapeutic 
efficacy) the histamine wheal and flare test seemed to be the logical choice. The 
sedative effects of psychoactive drugs are often potentiated by alcohol. This 
experiment also investigated to which extent this was true for the AH's under 
investigation.
Cetirizine is an HI-antagonist which has been reported to be non-sedative in several 
experimental studies (Gengo and Galvos, 1987; Gengo et al., 1987; Seidel et al.,
1987). It was decided to compare the sedative potential of this compound with that of 
other AH's, which either have been repeatedly proven to be sedative (Betts et al.,
1984; Cohen et al., 1985; Nicholson and Stone, 1986), or are recognised to produce 
drowsiness in the clinical situation (Tester-Daldrup, 1984) or on the other hand, are 
claimed to be devoid of central, sedative effects (Clarke and Nicholson, 1982; 
Nicholson et al., 1982). The following compounds were thus selected for comparison:
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triprolidine (considered as a verum, produces considerable sedation in the laboratory), 
chlorpheniramine (produces drowsiness in patient populations) and terfenadine (free 
from sedation). Triprolidine 10 mg had been successfully used as a verum in 
Experiments 3 and 4; for the present study however, it was decided to use the 5 mg 
t.i.d. dose as it matched the administration schedule of one of the AH's under 
investigation (chlorpheniramine).The 5 mg dose of triprolidine has also been found to 
produce impairment in psychomotor functioning (Swire et ah, 1988; Volkerts et ah, 
1992).
It was the objective of this study to evaluate the effects of daily therapeutic doses on 
CNS/sedative activity, using tests of cognitive and psychomotor function, and to 
investigate the possible interaction of the various treatments with a social dose of 
alcohol.
The final design of this study was the result of discussions between two parties (the 
manufacturer and the author). Each party had its own specific objectives and 
hypotheses to be tested . The main objective are summarised below.
For the manufacturer:
Objective: To compare the lack of sedation of cetirizine, given with or
without alcohol, with other AH's which are available on the market. 
Hypothesis: No daytime sedation can be demonstrated after one single.
administration of either 10 or 20 mg of cetirizine, whether it is given in 
combination with alcohol or not.
For the author:
Objectives: 1. To investigate the comparable sensitivity of CFF, CRT, SCTT,
SMST, LARS, LSEQ and C-EEG in detecting the interaction potential 
of AH's, and alcohol.
2. To investigate the comparable sensitivity of CFF, CRT, SCTT, 
SMST, LARS, LSEQ and C-EEG in detecting possible dose related 
sedative effects of 10 and 20 mg of cetirizine.
3. To investigate the comparable sensitivity of CFF, CRT, SCTT, 
SMST, LARS, LSEQ and C-EEG in detecting sedation as influenced by 
time of administration.
Hypotheses: 1. The sedative effects of the AH's under investigation, if any, will be
potentiated by alcohol, and demonstrable with CFF, CRT, SCTT,
SMST, LARS, LSEQ and C-EEG.
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2. Significant sedation, if demonstrable with CFF, CRT, SCTT, SMST, 
LARS, LSEQ and C-EEG is dose related.
3. Significant sedation, if demonstrable with CFF, CRT,
SCTT, SMST, LARS, LSEQ and C-EEG is related to the time of 
administration.
8.1.2 Materials and methods
Twelve female volunteers aged between 18 and 39 (mean age: 28) were recruited to 
take part in the study. This double-blind placebo and verww-controlled cross-over 
study comprised 6 treatments given both with and without alcohol, making a total of 
12 experimental sessions. Each experimental session involved 2 test days. 
Experimental sessions were separated by a 1 week washout period (Table 32.)
The experimental treatments were cetirizine lOmg mane; cetirizine 20mg mane', 
terfenadine 60mg b.i.d', chlorpheniramine 4mg t.i.d.. and triprolidine 5mg t.i.d.
To ensure double-blind conditions all treatments were administered using capsules 
which were identical in appearance, and extra placebo capsules were added to obtain a 
fixed t.i.d. treatment schedule for all treatments on day 1. For all treatements, only the 
first daily dose was given in the morning of day 2. Treatments were administered 
between 10.00 - 11.30 hours for the first daily dose, 13.00 - 14.30 hours for the 
second, whilst the third dose was taken at home approximately half an hour before 
retiring to bed. The time of administration of the medication was staggered at 15 
minute intervals and two laboratories were available with identical testing equipment. 
This modus operandi meant that all 12 subjects could be tested at 1.5 hours after 
dosing. All assessments took place at the Study Centre. Testing took place at 1.5 
hours after each of the first two administrations (day 1) and before the first 
administration of the next day (day 2). The wheal and flare test was performed 1.5 
hours after dosing on day 2.
Dose regimens selected all corresponded to the manufacturers recommended daily 
doses with the exception of the cetirizine which was administered both at the advised 
dose of lOmg and at twice this daily dose (20mg).
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Table 32: Experimental design (example of possible sequence for one
subject)
Time
interval
Week -1
Study
period
Condition 
pre-trial screen
Week 1 day 1-2 
wash-out
treatment E condition II
Week 3 day 1-2 
wash-out
treatment A condition I
Week 5 day 1-2 
wash-out
treatment C condition I
Week 7 day 1-2 
wash-out
treatment B condition II
Week 9 day 1-2 
wash-out
treatment F condition II
Week 11 day 1-2 
wash-out
treatment D condition I
Week 13 day 1-2 
wash-out
treatment F condition I
Week 15 day 1-2 
wash-out
treatment B condition I
Week 17 day 1-2 
wash-out
treatment C condition II
Week 19 day 1-2 
wash-out
treatment A condition II
Week 21 day 1-2 
wash-out
treatment E condition I
Week 23 
Week 24
day 1-2 treatment D 
post-trial screen
condition II
All experimental treatments were evaluated under two conditions: Condition I 
(without alcohol) and Condition II (with alcohol). Alcohol (given as white gin and 
made up to 200ml orange juice) corresponding to 0.5 g absolute alcohol/kg body 
weight or alcohol-placebo: 200ml orange juice with the rim of the glass moistened 
with gin and a few drops 1ml gin floating on the surface of the drink; was 
administered 45 minutes after the second dose of medication on day 1 of treatment.
The test battery comprised the following measures: CFF, CRT, SCTT, SMST, WRT, 
LARS, LSEQ. Continuous electrophysiological measures {C-EEG) of daytime 
drowsiness and stage 1 sleep were obtained from six of the twelve subjects using 4 
channel Oxford medilog portable recorders, throughout day 1.
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Each test day 1 began with a pre-treatment baseline assessment ( D1H0) on the 
psychometric battery immediately after which the first treatment was administered. 
Performance, was assessed 1.5 hours after the first (D1H1.5) and 1.5 hours after the 
second (D1H4.5)* administration of the test substances. On day 2, the LSEQ was 
completed after waking and performance measures where taken before the 
administration of the treatments (D2H0) (Table 33).
Table 33: Schedule of events
N day DAY 1 DAY 2
N administration I II III IV
Time D1H0 D1H1.5 D1H4.5 D2H0 D2H1.5
(day/hour)
Medication X X X X
Measures
CFF X X X X
CRT X X X X
SCTT X X X X
SMST X X X X
WRT X X X X
LARS X X X X
LSEQ X
C-EEG X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
Skin Tests X
Peripheral antihistaminic activity was evaluated by calculating the areas of wheal and 
flare skin reactions produced 10 mins after intradermal injections of 5 ng of histamine. 
This was done on test day 2,1.5 hours after administration of treatment (D2H1.5).
8.1.3 Results
Two of the 12 subjects had violated the protocol procedures and were therefore 
excluded from the analysis. This meant that the results from only 4 of the 6 subjects
T 4.5 on day 1 corresponds to 4.5 hours after the first administration o f active medication for 
cetirizine lOmg, cetirizine 20mg and terfenadine 60mg, and to 1.5 hours after the second 
administration of triprolidine 5mg and chlorpheniramine 4mg.
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recorded were included in the C-EEG analysis, which was performed on data obtained 
in Condition I only (i.e. without the concurrent administration of alcohol).
Condition I  (without alcohol)
CFF
At D1H1.5, and less so at D1H4.5, a decrement in CFF threshold was seen with all 
treatments, except cetirizine 20 mg, reflecting the general lowering of alertness during 
the course of the day. This was pronounced after the verum (triprolidine 5mg) which, 
at D1H1.5 was significantly different from cetirizine 20mg, but but failed to be 
statistically significant from placebo. All other treatments were similar to placebo.
The next morning (D2H0) all thresholds were back to baseline values (see Appendix 
I, Table 41).
CRT
Triprolidine 5 mg produced an increase in reaction time at both D1H1.5 and D1H4.5, 
which was mainly due to its effect on the Recognition Reaction Time aspects {RRT) of 
this test: at D1H1.5, triprolidine 5 mg was significantly worse than placebo. None of 
the other treatments was distinguishable from placebo at any time point (Fig. 32).
The mean scores for the Movement Reaction Time component (MRT) were generally 
higher at D1H1.5 and D1H4.5 (except for cetirizine lOmg) but showed no significant 
placebo treatment differences. The Total Reaction Time (77?7) reflected the effect 
observed for both components {RRT and MRT), and showed that reaction times of all 
treatments were within a close and comparable range, except for triprolidine 5 mg, 
following which reaction times were increased (Appendix I, Table 42).
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Fig. 32: CRT (RRT): Mean values for each treatment condition, without
alcohol
P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI 5mg = Triprolidine 5 mg, CET lOmg = Cetrizine 10 mg,
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg; msec = millisecond)
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SCTT
The mean score of the peripheral Reaction Time component (RT) was significantly 
higher (than placebo) with triprolidine 5 mg at D1H1.5. None of the other treatments 
however were found to be significantly different from placebo at any time point 
(Fig. 33).
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Fig. 33: SCTT (RT): Mean values for each treatment condition, without
alcohol
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI 5mg = Triprolidine 5 mg, CET lOmg = Cetrizine 10 mg,
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg; msec = millisecond)
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8 0 1
70-
60-
50-
40-
30-
2 0 -
1 0 -
D1H0 D1H1.5 D1H4.5 D2H0
Test Times
"®* Placebo  
TRI 5mg 
CET lOmg 
CET 20mg 
"♦"TER 60mg 
"S" CHLOR 4mg
The mean tracking accuracy scores (RMS) showed, at D1H1.5, an impairment (higher 
RMS values) for both triprolidine 5 mg and cetirizine 10 mg as compared to placebo. 
However, neither cetirizine 20 mg nor any of the other treatments were 
distinguishable from placebo (Fig. 34).
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Fig. 34: SCTT (RMS): Mean values for each treatment condition, without
alcohol
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI 5mg = Triprolidine 5 mg, CET lOmg = Cetrizine 10 mg,
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg; unit = root mean square of 
the deviation from track programme)
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2 -
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At D1H1.5 triprolidine 5 mg produced a significant decrement (increase in RT) on 
this measure of short-term memory. At D1H4.5 the mean scores for all active 
treatments were within close range; placebo, however, showed a marked decrease in 
RT, and was found to be statistically significant from cetirizine 20 mg (Fig. 35).
Fig. 35: SMST(RT): Mean values for each treatment condition, without
alcohol
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI 5mg = Triprolidine 5 mg, CET lOmg = Cetrizine 10 mg,
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg; msec = millisecond)
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WRT
The results from this test of short term memory for both matched and unmatched 
words showed no significant placebo v. drug treatment differences and they are not 
discussed further.
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LARS
At one and a half hours (D1H1.5) after the first administration of triprolidine 5 mg, 
subjects felt clearly more sedated; this difference was statistically significant when 
compared with placebo. None of the other treatments were rated as being 
significantly sedative at any time point, although both terfenadine 60 mg and 
chlorpheniramine 4 mg were noticeably more sedative than placebo treatments a 
D1H1.5 (Fig. 36).
Fig. 36: LARS: Mean values for each treatment condition, without alcohol
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI 5mg = Triprolidine 5 mg, CET lOmg = Cetrizine 10 mg,
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg; mm = millimeter)
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LSEQ
The results of the LSEQ revealed no significant placebo v. drug treatment differences 
indicating that none of the experimental treatments produced any effects on Getting
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To Sleep, Quality O f Sleep, the ease of Awakening From Sleep and the integrity of 
Behaviour Following Awakening.
C-EEG
The EEG results for the summated periods of drowsiness and sleep stages 1 and 2 
were analysed. Technical problems with recordings in 2 subjects and in one case 
bizarre recordings (the subject had had 2 previous nights of disturbed sleep), resulted 
in the data from 3 subjects (12.5%) being lost.
There were over 5,000 seconds (approx. 1 hour and 23 minutes) of "sedation" i.e. the 
sum of drowsiness with stage 1 and stage 2 sleep, produced by triprolidine during the 
day of C-EEG recording (Table 37). During the same time period 2,100 seconds
Fig. 37: C-EEG (sedation) : Mean values for each treatment condition,
without alcohol
(TRI 5mg = Triprolidine 5 mg, CET lOmg = Cetrizine 10 mg,
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg)
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(approx. 35 minutes) were found with chlorpheniramine, 960 seconds (approx. 16 
minutes) with terfenadine, 500 seconds (approx. 8 minutes) with cetirizine 20 mg and 
350 seconds (approx. 6 minutes) with placebo. The zero score for cetirizine 10 mg is 
due to effects of lost data described above and should be discounted.
The limited number of subjects which could be analysed on C-EEG data precluded 
statistical evaluation of this variable, but a visual comparison may be made. In order 
to indicate the relative percentage of EEG "sedation” the scores given for triprolidine 
(as a verum) were given a value of 100% and the scores obtained for the other 
treatments proportioned accordingly. The percentages represented in Fig. 38 thus 
show the relative sedation produced by various AH's w.r.t. the verum control.
Fig. 38: LARS (right columns) and C-EEG sedation (left columns): Mean
values as a percentage of triprolidine, for each treatment 
condition, without alcohol
(TRI 5mg = Triprolidine 5 mg, CET lOmg = Cetrizine 10 mg,
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg)
PLA TRI CET 10 CET 20 TER CHL
Treatment Condition
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Similarly if, with the LARS, a value of 100 % is given to the scores obtained with the 
verum (triprolidine)and the other treatments also assigned percentage values 
proportional to the scores obtained, then the LARS percentage sedation is close to that 
obtained from C-EEG measures of sedation.
Histamine Skin Tests
The histamine induced flare reaction was markedly inhibited by all active treatments 
but only cetirizine 10 mg and 20 mg were found to be significantly different from 
placebo. The same effect was seen on the wheal reaction: significant inhibition was 
observed with cetirizine 10 mg and 20 mg only, while the inhibition produced by 
terfenadine, triprolidine and chlorpheniramine failed to reach statistical significance.
Condition II (with alcohol)
At D1H4.5, i.e. 45 minutes after administration of alcohol, an overall diminution of 
CNS-activity was observed with all experimental treatments. In two tests, (SCTT and 
LSEQ) significant differences were found between the effects produced by the co­
administration of test treatments and alcohol. The other tests did not show any 
significant differences, although an interesting trend was noticeable in both CFF and 
LARS.
CFF
At D1H4.5 all test treatments produced a decrease in threshold as compared to both 
baseline and D1H1.5 (before administration of alcohol), except triprolidine which 
showed virtually identical detrimental effects at both time intervals (Appendix I,
Table 43).
SCTT
The addition of alcohol increased reaction time (RT), the peripheral component of the 
test, with all treatments (Fig. 39). This prolongation was at D1H4.5 significantly
more pronounced with triprolidine and chlorpheniramine than with placebo. The 
increase in RT  seen with terfenadine was noticeable but did not reach statistical 
significance w.r.t. placebo. The impairment seen with cetirizine 20 mg was less 
pronounced than with 10 mg. No significant changes were noted in the tracking 
accuracy component (RMS).
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Fig. 39: SCTT (RT): Mean values for each treatment condition, with
alcohol
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI 5mg = Triprolidine 5 mg, CET lOmg = Cetrizine 10 mg, 
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg; msec = millisecond)
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LSEQ
With the combination of triprolidine and alcohol, Getting To Sleep {GTS) was felt to 
be significantly easier than with the combination of placebo and alcohol. The other 
treatments showed no statistically significant effects. No significant effects were 
detected in any of the other three components {QOS, AFS, BFA) of the questionnaire.
LARS
Tripolidine was found to produce significant sedation on the LARS at D1H1.5, i.e. 
prior to the administration of alcohol. After alcohol intake, at D1H4.5, the sedative 
effect, although still more pronounced than with the other treatments failed to reach 
significance (Fig. 40).
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Fig. 40: LARS: Mean values for each treatment condition, with alcohol
*P<0.05 w.r.t. placebo (based upon confidence intervals)
(TRI 5mg = Triproiidine 5 mg, CET 10mg = Cetrizine 10 mg,
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg. 
CHLOR 4 mg = Chlorpheniramine 4 mg; mm = millimeter)
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C-EEG
The C-EEG data were not analysed in the alcohol potentiation studies for a variety of 
technical reasons beyond experimental control.
Histamine Skin Tests
Significant inhibition of the histamine induced flare reaction was observed with 
cetirizine 10 mg and 20 mg, terfenadine and triproiidine, while the inhibitory effects 
observed with chlorpheniramine failed to reach statistical significance. The histamine 
induced wheal reaction was significantly inhibited by all active treatments.
176
8.1.4 Discussion and conclusions
Under the treatment conditions without alcohol triproiidine 5 mg consistently showed 
impaired performance indicative of pronounced sedation, which, in most tests (Œ 7 1, 
SCTT, SMST and LARS) was found to be significantly different from placebo 
treatment scores. Cetirizine showed no consistent effects although an isolated 
significant difference from placebo on the accuracy component of the tracker (SCTT, 
RMS) was observed at D1H.5 with 10 mg, but not with twice that dose. Further 
investigation of the raw data revealed that the above significant difference was due to 
the results obtained in one volunteer, who, at that time point, generated scores which 
were completely out of the range of all other subjects. Also, on the overall memory 
test, cetirizine 20 mg, although failing to produce any relevant changes from baseline, 
was found to be significantly different from placebo, which showed lower values 
indicating improved performance.
Chlorpheniramine, an a so-called sedative AH from the first generation, did not 
produce any significant impairments on the test battery. It seems therefore that 
intermittent testing with psychometrics is a valuable way to detect the CNS effects of 
a known sedative AH (triproiidine) but that it is not necessarily sensitive enough to 
discriminate between the effects of AH's with a relatively milder sedative profile (e.g. 
chlorpheniramine) or those AH's which are considered free of sedation (terfenadine, 
cetirizine). C-EEG measures therefore may represent an important addition to the 
psychometric test battery. Although limited by subject numbers, the sedation scores 
obtained from the C-EEG analysis demonstrated that this technique is sensitive and 
valid in relation to other pharmacodynamic measures of sedation. In comparison with 
triproiidine (100%), the placebo score of 7% demonstrated the range of sensitivity 
with this measure. Whilst the score for cetirizine 10 mg may be considered invalid 
due to loss of data, the higher dose (20 mg) gave a relative sedation score of 10%, 
being little more than placebo. Roughly twice this level of sedation was seen with 
terfenadine (19%), and an increase of about twice again for chlorpheniramine (42%) 
(Rombaut et ah, 1989c; Alford et al., 1989). It is also interesting to note the apparent 
relationship between the C-EEG scores and those obtained from the LARS.
When given together with alcohol, no significant effects could be seen with 
terfenadine, nor with either dose of cetirizine. With triproiidine and chlorpheniramine 
however, a significant impairment was observed in the RT  component of the tracker
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test suggesting additive effects of alcohol. A similar effect, although not statistically 
significant, was observed with both terfenadine and both doses of cetirizine however. 
Triproiidine alone also produced significant subjective sedation after the first 
administration, but this sedative effect failed to reach significance after the second 
administration and alcohol challenge, which could be due to tolerance to the acute 
effects of the drug. The sleep questionnaire (LSEO) showed that the combination of 
triproiidine and alcohol significantly facilitated Getting To Sleep.
These findings demonstrate that the SCTT is sensitive to the possibly additive effects 
of the consumption of a social dose of alcohol. The fact that no significant additive 
effects were observed on the remainder of the tests could be due to the fact that the 
subjects were not unduly sedated, as the dose of alcohol was relatively low. Hence, 
the subjects were able to compensate by adopting different behavioural strategies to 
cope with the combined effects of AH's and alcohol.
Histamine-induced wheal and flare inhibition was assessed in order to evaluate the 
comparative potency of the test treatments included in this experiment. Ideally 
comparisons between the sedative effects of various AH's should be made using 
equipotent doses. In the present study the recommended doses which were 
administered proved to be below optimal activity levels for triproiidine, 
chlorpheniramine and, to a lesser extent, terfenadine. It is therefore not unlikely that 
higher (optimal) doses of chlorpheniramine, and possibly terfenadine, might have 
resulted in demonstrable statistically significant sedation on the test battery.
Consistent and significant inhibition of both the histamine induced wheal and flare 
reactions was seen with cetirizine 10 mg and cetirizine 20 mg only. The effects of 
terfenadine were less pronounced, whilst with triproiidine and chlorpheniramine there 
was minimal inhibition at this time point. These results for cetirizine and terfenadine 
are in keeping with previous research (Rihoux and Dupont, 1987). Although the 
inhibition of the wheal and flare reactions with terfenadine, triproiidine and 
chlorpheniramine was much less pronounced in condition I than in condition II, it was 
evident that the ranking order of the 5 test treatments was consistent over both 
conditions. Both ceterizine 10 and 20 mg produced a dependable significant inhibition 
of both wheal and flare reactions, which was more pronounced than with any of the 
other treatments. Terfenadine was found to be less potent, followed by triproiidine and 
chlorpheniramine which were respectively less and much less effective in inhibiting
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the histamine induced skin reactions. The results of the test battery however show a 
completely different ranking in terms of sedation: both doses of cetirizine and 
terfenadine seemed to be devoid of sedation, chlorpheniramine and especially 
triproiidine were showing distinct sedation. It is suggested therefore that the 
compound under investigation (cetirizine) tested, at effective antihistaminic doses is 
superior, in terms of absence of sedation, to triproiidine and chlorpheniramine, which 
both seem to induce sedation long before reaching their optimal antihistamine 
activity.
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CHAPTER 9 METHODS AND MEASURES TO ASSESS
ANTIHISTAMINE INDUCED SEDATION: RESULTS 
AND CONCLUSIONS
This thesis was effectively a three part investigation into the ways of measuring 
sedation following the use of AH's in volunteer and patient populations.
The first part assessed the utility of subjective measures of sedation. In Chapter 2 the 
clinical literature on AH's was reviewed and analysed in order to investigate the value 
and accuracy of patient reports with regard to AH induced sedation. The analysis of 
this selected sample of studies confirmed the general consensus published in 
numerous articles and reviews (Simons and Simons, 1993) namely that AH's from the 
second generation (e.g. terfenadine, astemizole, loratadine) were relatively free from 
sedation whereas AH's from the first generation (e.g. chlorpheniramine, clemastine) 
were not. It was therefore concluded that the compilation of subjective reports 
obtained in efficacy studies, even though not standardised, was not to be discarded as 
a means for gathering information on the sedative potential of AH's. Patients seem to 
be able to discriminate successfully between AH's with and without sedative effects, 
despite the lack of validated assessment tools with which to make their assessment.
As the majority of the studies which were analysed in this review were conducted 
using a parallel group design, it could not be guaranteed that the subjects comprising 
the placebo and the AH treatment groups were comparable in terms of their sensitivity 
to AH induced sedation. Nevertheless, the analysis of the incidence of sedation 
reported in PG comparisons showed statistically significant differences between 
placebo and the first generation AH's. It is assumed that the relatively large number 
of patients per treatment group (mean number in the placebo group: 53) in these 
studies was able to compensate for the variability due to intraindividual differences in 
sensitivity to AH's. Although this analysis demonstrated that subjective reports in 
clinical studies can successfully distinguish between sedative and non sedative AH's, 
it was thought that there was scope for more objective and more refined ways of 
assessing AH induced sedation. Firstly, in clinical studies the perceived clinical effect, 
or lack of it, may have partly unblinded the patients and influenced them, in some 
cases, to feel "sedated" due to the some "activity" of the AH. Similarly, a perceived
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lack of clinical effect could well cause subjects to report zero side effects. It is clear 
that the vagaries of psychological reporting of subjective experiences would make any 
outcome possible.
It is true that the first generation AH's are less specific in their effects as antiallergics 
(Martindale, 1993). They may therefore be less efficacious in reducing the symptoms 
of allergy, although their ability to produce side-effects does not seem to be 
diminished. Secondly, and more importantly, the unsophisticated, unstandardised, 
unvalidated, manner of evaluating subjective sedation in clinical trials leaves the door 
wide open for any potential intervening variables to confound the results in various 
ways.
The second part of this thesis investigated a range of tests and/or test batteries with 
proven validity and reliability in a series of well-controlled experimental studies for 
the detection and measurement of AH induced sedation. Chapter 3 reviewed the 
experimental literature on psychopharmacological effects of AH's. The overall 
findings were disappointing in so far as there did not seem to be any individual test or 
even category of tests which seemed to be particularly useful for discriminating 
between AH's in terms of sedation. It was difficult to produce a combined analysis of 
the results obtained from each of the individual experiments due to a number of 
different variables which precluded the formation of homogeneous samples and 
groups. Of these variables the large number of different tests and the wide range of 
test measures used were certainly not the least important. Many individual tests were 
used infrequently and data from these tests does not represent a range of AH's. The 
grouping of tests into categories, (which were introduced for reasons of parsimony), 
was not a functional classification and any particular category contained tests with 
differing sensitivities, degrees of validation and reliability. Even with an overtly clear 
categorisation (e.g. CFF) it was not possible to guarantee that the apparatus used to 
measure the threshold was identical, and, as Bobon reports (1982), there is more 
disagreement between CFF results and certain psychometric tests due to the 
equipment used to measure CFF than to any other source of variance. Furthermore, 
other intervening variables such as dose response relationship, the time course of 
pharmacodynamic action, time of test administration etc. could not be taken into 
account for the overall analysis, as it would have fragmented the data available for a 
particular test even further. In order to reduce these sources of variability it was 
decided to focus on the results obtained with triproiidine, which seemed the most 
reliable of the frequently used vera in the studies reviewed. According to the results
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obtained with this verum, some tests appeared to be more successful than others in 
detecting AH induced sedation; these included: actual car driving, aspects of 
sensorimotor coordination, attention and vigilance and CFF . Other categories were 
successful but to a somewhat lesser extent, these were: subjective questionnaires, 
sensory discrimination, EEG measures and visual search. When results obtained with 
all AH's which had been used as a verwn in at least one study are combined, then only 
the categories actual car driving, attention and vigilance, and EEG measures were able 
to successfully detect sedation. However, actual car driving did not appear in these 
studies (as it was only used with triproiidine) but was used only 6 times in total. As 
the majority of the other test categories were employed much more frequently (>10 to 
66 times) the comparative success of actual car driving to detect sedation seemed less 
convincing, particularly in the light of the catch-all categorisation which included 
many different tasks from gymkhana style off-road tests (Betts et al., 1984) to 
measures of the standard deviation of lateral position while driving a car on the 
highway (O'Hanlon et al., 1988)
The third part of this thesis (Chapters 4-8) concentrated on original experiments with 
patients and volunteers. The literature reviews showed that, on one hand, subjective 
evaluations were a valuable tool in the detection of AH induced sedation and that, on 
the other hand, a number of intervening variables needed to be taken into account for 
the interpretation of the results obtained on a variety of tests. A series of experiments 
was designed which investigated the extent to which each of these variables had an 
effect on the results obtained in studies of the sedative effects of AH's. In order to be 
able to separate the impact of each of the variables, it was felt important that the 
psychometrics should be kept as constant as possible, and a core battery of 
standardised, validated and reliable tests was chosen for use in all experiments. Part of 
this core battery was a subjective measure (VAS or LARS) based upon the visual 
analogue principle as a means of standardising individual subject's reporting of 
sedation. The core objective tests of the battery (CFF and CRT) were selected because 
of their proven sensitivity to drug induced sedation. They also happened to belong, 
together with the SCTT, a test which was added to the core group, to the more 
successful test categories described in the analysis of the experimental literature.
Seven separate experiments were earned out, investigating the impact of: inter-subject 
variability, dose response relationship, route of administration, single versus repeated 
dosing, pharmacodynamic time course of drug action, interactions with other
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substances and atopic versus non-atopic subjects on the results from various 
psychometrics after administration of AH's.
Chapter 5 described three experiments in which inter-subject variability was shown to 
partly reduce the sensitivity of the core tests. The CFF failed to detect, at an 
acceptable level of statistical significance any verum induced sedation either in 
Experiment 1 (levocabastine 3 mg) and in Experiment 3 (triproiidine 
10 mg) while the CRT was unable to show any significant effects after triproiidine 
10 mg in Experiment 3; on the other hand significant sedation was reported on the 
VAS and LARS after both vera.
The significant sedation after administration of the highest dose of the compounds 
under investigation (i.e. 40 mg of R 72 075 in Experiment 2; 30 mg of ebastine in 
Experiment 3) seen on the LARS and the LSEQ respectively, suggests that the latter 
measures also seem to be the most sensitive with regard to discovering any potential 
dose related sedative effects. Although it cannot be denied that this may be a chance 
finding, as the other tests showed no effect and there are other instances where the 
LARS and LSEQ were not sensitive to AH induced sedation.
Both Experiments 2 and 3 investigated the effects of single versus repeated 
administration. After an acute administration of either levocabastine or triproiidine 
sedative effects were found on several tests i.e. CFF, Œ T and  VAS after 
levocabastine 3 mg; SCTT, SMST, LARS and LSEQ after triproiidine 10 mg. On the 
other hand sedation after repeated dosing with either levocabastine or triproiidine was 
only noticed in three instances (i.e. CFF and VAS after the third administration of 
levocabastine 3 mg; LARS after the fifth administration of triproiidine 10 mg). This 
points again towards a possible superiority of subjective over objective measures in 
detecting AH induced sedation.
A first evaluation of the impact of the pharmacodynamic time course of AH's activity 
was also made in Chapter 5 (Experiment 2: up to 4 hours after administration; 
Experiment 3: up to 8 hours after administration). In Experiment 2 both CFF and 
VAS showed significant effects 2 and 4 hours after administration of levocabastine 
3 mg, while CFF in addition, detected significant impairment 24 hours after the 
second administration of this verum ( i.e. immediately before the third 
administration). CRT was less consistent and only demonstrated significant sedative 
effects 2 hours after the first and immediately before the third administration. These
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results were in contrast with Experiment 1, in which Œ 7 b u t not CFF was found to 
be significantly impaired 2 hours after administration of levocabastine 3 mg. In 
Experiment 3, on the other hand, significant effects were noted on different test 
measures at different times: SCTT at 8 hours, SMST at 4 and 8 hours, and LARS at 2 
and 4 hours after administration of triproiidine 10 mg, while no significant effects 
were seen on CFF and CRT at any time. As the issue of pharmacodynamic time 
course was further assessed in Chapters 6, 7 and 8, it is premature to draw any 
conclusions at this point. The results of all experiments which addressed this question 
will be fully reviewed at the end of this Chapter, as they form an important part of the 
final discussion on the value of the measures used in the full set of 10 experiments.
Chapter 6 assessed the potential impact of route of drug administration on the 
sensitivity of test measures for detecting AH induced sedation. The experiment 
(Experiments 4) described in this Chapter investigated the effects of topical 
administration of levocabastine, an AH which had been used successfully as a verum 
in Experiments 1 and 2. As the manufacturer of the compound wanted to develop the 
topical formulation only, it was not possible to obtain oral levocabastine for direct 
comparison with the topical formulation of the drug. Therefore only general, indirect 
(between experiment) comparisons could be made between the results obtained after 
oral and topical administration on the core test battery, which was identical for both 
sets of experiments. Furthermore, although it was impossible to administer equal 
doses of the oral and topical formulation, the pharmacokinetic studies suggested that 
the total amount of drug available after topical administration of the highest 
concentration (2mg/ml) was comparable to that after oral administration of 3 mg. 
Experiment 5 investigated whether the test battery would be able to discriminate 
between the concentration used in the clinic (0.5 mg/ml) and the one which was 
assumed to be equivalent to 3 mg oral levocabastine. The results showed that the core 
tests (CFF, CRT and LARS or VAS) failed to show any significant sedation after any 
concentration of topical levocabastine, while previously, the same tests had 
successfully detected sedation after oral levocabastine 5 out of 6 (CFF), 3 out of 6 
(CRT) and 5 out of 6 (VAS) times in Experiment 1 and 2 combined. This failure to 
demonstrate sedation after topical levocabastine was further in disagreement with the 
significant sedative effects observed on CFF, SMST and LARS after administration of 
the verum, triproiidine, in the same experiment (Experiment 5). It seems therefore 
that the route of administration of AH's does affect the sensitivity of both objective
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and subjective test measures, in that possible sedation after topical administration is 
more difficult to discover than it is after oral administration of AH's.
Although the assessment of the effect of different routes of administration was the 
main objective of both studies described in this Chapter 6, additional information 
about the effects of the pharmacodynamic time course of AH's was gathered in 
Experiment 4 with regard to the verum triproiidine 10 mg. As in Experiment 3 
significant effects were noted on SMST and LARS, but at 2.5 hours (instead of 4 and 8 
hours) and 1.25 hours (instead of 2 and 4 hours) after administration respectively. In 
contrast to the results obtained in Experiment 3, however, no significant sedation 
could be found with the SCTT, while CFF deteriorated significantly 2.5 hours after 
administration of triproiidine 10 mg.
In Chapter 7, two experiments were described which had as a common objective the 
assessment of effects of AH's, alone or in combination with another psychoactive 
substance, on the sleep/wake pattern and on the sensitivity of test measures for 
evaluating sedation/arousal. For this purpose a new measure was introduced 
"Continuous EEG" (C-EEG) which enabled continuous evaluation of sedation/arousal 
over 24 hours after drug administration. In Experiment 5 the sleep inducing 
properties of 2 doses of a sedative AH (hydroxyzine 25 and 50 mg) were investigated. 
Experiment 6 assessed both potential (daytime) sedative and (nighttime) sleep 
disturbing effects of the combination of a so-called non-sedative AH (astemizole) and 
a pseudoephedrine formulation which in an earlier experiment (Rombaut et al. 1989b) 
was found to be relatively free of sleepdisrupting effects, in comparison with placebo 
and with the combination of a sedative AH (triproiidine) and a pseudoephedrine 
formulation which was found to produce sleep disruption. It was interesting to note 
that, apart from the LSEQ, none of the measures of the test battery succeeded in 
showing any significant effects at any time after administration of any of the active 
treatments, except for a "hangover" on CFF the morning after the third administration 
of pseudoephedrine 60 mg, and an isolated shortening of reaction time after 60 mg 
pseudoephedrine which reached significance w.r.t. placebo. This result is somewhat 
spurious as there was a random increased reaction time observed with placebo which 
caused the placebo/drug comparison to reach statistical significance. On the other 
hand, both the LSEQ and C-EEG were able to distinguish between different doses of 
the active treatments and placebo. In Experiment 5 hydroxyzine 50 mg was found to 
have a significant detrimental effect on Awakening From Sleep (AFW) and Behaviour
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Following Waking (BFW); no hangover effects were detected, however, on the other 
tests of the battery which was performed one hour after waking. Also, although no 
sedative effects suggestive of sleep inducing properties could be found on the core 
battery which was performed before retiring, 1 hour after administration of the test 
medication, C-EEG measures assessing the ease of falling asleep (SOLI and SOL2) 
demonstrated significant superiority of both active doses over placebo. Duration o f  
Final Waking (D uW) was significantly shorter with both doses, as was Final Waking 
(FW) but this difference reached statistical significance for the highest dose (50 mg) 
only. Similarly, in Experiment 6, Quality O f Sleep {QOS) was seen to be impaired 
with both pseudoephedrine 60 mg t.i.d and 120 mg b.i.d. This result was in 
concordance with C-EEG measures, showing significantly more Restlessness during 
the night with both of these doses. Nighttime Wakefulness however was significantly 
greater after pseudoephedrine 60 mg only, and could be held responsible for the 
detrimental effects observed on the CFF the next morning. It is concluded that LSEQ 
and C-EEG are more sensitive than other intermittent test measures for detecting sleep 
enhancing, hang over or sleep disruptive effects after administration of AH's or 
psychoactive agents in combination with AH's. However, none of the measures used 
in these experiments proved to be able to detect any effects produced by the 
combination treatments, either because they all lacked sensitivity to this mixture of 
sedative and stimulating effects, or because the administration of such combinations 
nullified the effects produced by each of the components.
Chapter 8 compared the sensitivity of psychometrics in detecting a potential 
interaction between alcohol and AH's belonging to the first and the second generation. 
Experiment 8 also investigated dose relationship, pharmacodynamic time course of 
AH induced sedation. No indication of dose related effects were found. Significant 
sedation was shown on the majority of the tests {CRT, SCTT, SMST, LARS) 1.5 hour 
after the first administration of the verum, triproiidine, while after cetirizine 10 mg 
only one isolated significant impairment was noted on the SCTT, but not with 
cetirizine 20 mg, while the latter treatment was found to be significantly worse than 
placebo on the SMST (because of an isolated improvement of placebo). Furthermore, 
significant effects with triproiidine 5 mg were only detected 1.5 hours after the first 
administration but not after the second or third, suggesting that sedative effects, if  any, 
could not be discovered later. Finally only one measure {SCTT) was able to 
demonstrate a significant interaction with alcohol after both triproiidine 5 mg and
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chlorpheniramine 4 mg. The same test showed increased values for both terfenadine 
and both doses of cetirizine, but these failed to reach significance.
In conclusion, there seems not to be one single measure which is capable of rising 
above the impact of all of the intervening variables studied in the series of 
experiments described in this thesis:
- Dose response effects on the test battery were not very obvious as most of the AH's 
(R 72 075; ebastine; cetirizine) which were tested at different dose regimens were 
relatively free of sedation. Nevertheless, the highest dose (30 mg) of ebastine was 
found to produce significant sedation on subjective measures {LARS and LSEQ) of 
sedation. Likewise the highest dose of R 72 075 produced significant sedation on the 
VAS. With cetirizine, on the contrary, a significant effect was observed with 10 mg 
(but not with 20 mg) on the SCTT, while the significant impairment seen on the 
SMST with 20 mg was probably an artefact (due to improved scores of the placebo 
group).
- The time course of action could not be consistently tracked by any particular test, not 
even with the verum triproiidine: e.g. the effects of the 10 mg dose observed on the 
SMST (Experiment 3) occurred at 4 and 8 hours but not at 2 hours following dosing 
whereas in Experiment 4, on the same test, significant sedation was found at 2.5 
hours but not at 5 hours after treatment.
- The effect of repeated administration on the sensitivity of measures was mixed: 
Experiment 2 demonstrated that the core test battery {CFF, CRT, VAS) was still able 
to detect the sedative effects of levocabastine after 3 days of administration, while in 
Experiment 3 only the LARS was able to demonstrate sedation after 5 days of 
treatment with triproiidine 10 mg, and in Experiment 8 no significant sedative effects 
could be detected during the course of a months treatment with triproiidine 5 mg, 
except on the CRT, on day 8. It may be important, in this context, to consider that the 
tachyphylaxis observed with certain AH's may not be restricted to their primary, 
therapeutic effects, but may also involve secondary i.e." side" effects.
- The oral as opposed to topical route of administration of an AH appears to result in 
less detectable sedation: similar amounts of drug were presumed to become available 
after oral administration of levocabastine 3 mg (Experiment 1 and 2) and topical 
application of eyedrops and nasal spray of 2mg/ml (Experiment 3), but the oral 
administration showed significant sedation {CFF, CRT, VAS) whilst the topical 
application failed to demonstrate significant sedative effects.
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- The possible interaction between AH's and other centrally acting substances affected 
the sensitivity of the test battery in a negative way in so far as the combination of a 
known sedative AH (triproiidine 2.5 mg) with a stimulating sympathomimetic 
(pseudoephedrine 60 mg) was concerned: no significant sedative nor stimulating 
effects could be detected with this combination (Experiment 6). When the 
combination of AH's with a central depressant, such as alcohol, was studied 
(Experiment 7) only the SCTT was found to be capable of demonstrating potentiating 
effects for the triproiidine and chlorpheniramine combinations.
- Inter-subject variability clearly seems to be an important sensitivity impairing factor 
for obtaining consistent results with any test battery: Experiment 1 showed how the 
substantial differences in sensitivity to the sedative effects of levocabastine 3 mg 
failed to produce significant impairment on the CFF for this treatment group. This 
interindividual variability in sensitivity to the sedative effects of AH's was seen 
throughout all the experiments, to various degrees, and it is not unthinkable that the 
importance of all the above mentioned intervening variables is greatly overrated and 
only secondary to this interindividual variability.
This thesis provided an interesting opportunity to investigate some of the 
methodological, psychometric and experimental issues relating to the measurement of 
sedation with HI receptor antagonists. To a great extent the approach adopted was 
successful in that a number of important intervening variables were identified. What 
proved disappointing was that there did not emerge a single test or indeed test battery 
that reliably and consistently detected sedation. Undoubtedly the main reason for this 
failure to identify a particular sensitive measure was the broad inter-subject variability 
in sensitivity to the sedative efffects of AH's. Such inter-subject variability in response 
is compounded by intrinsic inter-drug/ dose regimen differences in the capacity of 
AH's to produce sedation. In spite of these problems it has been possible to identify 
some AH's (e.g. triproiidine) which have a relatively greater "risk" of sedation when 
compared with others (e.g. terfenadine, astemizole), although it is evident that the use 
of objective psychometrics does little to improve the assessment of sedation over and 
above the subjective evaluation of tiredness, sleepiness etc.
From the experiments described in this thesis, it has to be concluded that the AH's, at 
the doses tested, produce sedative effects which are probably less consistent* and 
much more subtle than the sedation observed with other psychoactive drugs (e.g.
* see Experiments 3 and 4: inconsistency of effect o f 10 mg triproiidine on CFF
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benzodiazepines, antidepressants etc.). The relative inconsistency of these subtle 
effects makes it difficult to obtain clearcut (i.e. statistically significant) differences 
w.r.t. placebo over a series of experiments. This is illustrated by Table 34: when 
comparing the number of times that a test was able to detect significant sedation with 
the verum with the times that it was used in to test the verum, it is clear that subjective 
measures {LARS and LSEQ) and an isolated objective test {SMST) can be successful, 
but other well-established measures much less so (CFF succeeds two out of five 
times, CRT three out of five times, SCTT two out of three times). When considering
Table 34: Experimental measures used in each of the 7 experiments
(S: significant difference found w.r.t. placebo; ns: no significant
differences found; (ns): no statistical analysis performed)
Experiment No.
Measures 1 2 3 4 5 6 7
CFF
verum ns S ns S ns
test compound(s) ns ns ns ns ns ns ns
CRT
verum S S ns ns S
test compound(s) ns ns ns ns ns ns ns
SCTT
verum S ns S
test compound(s) ns ns ns ns ns
SMST
verum S S S
test compound(s) ns ns ns ns S
LARS/VAS
verum S S S S s
test compound(s) ns S S ns ns ns ns
LSEQ
verum S
test compound(s) S S ns
C-EEG
verum
test compound(s) S S (ns)
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the ability of detecting sedation with test compounds it is much more difficult to draw 
conclusions as it can be assumed that most of these at the doses tested are probably 
genuinely lacking sedative efffects (apart from the highest doses of R 72 075 and 
ebastine, which showed some evidence of subjective sedation). Nevertheless, even 
though results are not always straightforward, it is possible to use these tests to 
distinguish between (doses of) AH's. Table 35 shows the result o fam eta analysis 
(Cohenn's D) performed on the available CFF results of the AH studies which were 
performed at the Human Psychopharmacology Research Unit, by Hindmarch and 
associates. It is clear from the ranking that the strenght of effect of e.g. 12 mg of 
chlorpheniramine is much greater than that of e.g. triproiidine 10 mg, and that high 
doses of terfendine produce mild sedative effects. This analysis suggests also that 
even for the so-called sedative AH's (e.g. chlorpheniramine) relatively high doses 
have to be given to produce detectable sedation.
Table 35: Ranked magnitudes of drug effects on CFF.
The top and the bottom groups have been found to be significantly 
better or worse repectively as compared to placebo at PO.05 or better. 
The doses indicated for these drugs are the minimum needed to 
produce an effect.
Cohen's D
Drug (dose mg) d CFF
astemizole (10) 1.052
placebo 0.000
terfenadine (240) 0.157
mequitazine (5) 0.178
hydroxyzine (50) 0.357
triproiidine (10) 0.367
chlorpheniramine (12) 1.473
There is one notable exception observed in the use of the physiological C-EEG, which 
seems to be able to successfully discriminate the subtle differences which do exist 
between different AH's, although in the one instance in which it was used to assess 
daytime effects the number of subjects on whom valuable data were available was too 
small to perform a statistical analysis of the data. C-EEG provides a continuous
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assessment of sedation over an extended time base making it thus more independent 
of pharmacokinetic and pharmacodynamic changes, which may not be appropriately 
monitored by testing on an intermittent basis at fixed time points. C-EEG however is a 
rather cumbersome technique as subjects have to be wired up for long periods and 
prohibited from taking showers, swim or engage in sport activities. This, however, is 
not the case with the actigraph. As recently shown in a AH study performed at the 
Human Psychopharmacology Research Unit, the actigraph, a device which is battery 
driven and, strapped around the pulse, records body movements, seems to hold 
notable promises for future research into the sedative potential of AH's. It has the 
advantage of being able to provide a continuous measure of sedation, and, as it 
records the diurnal variation under placebo, provides useful information as to when 
the test battery would be most likely to detect sedation (e.g. in the period between 250 
and 290 minutes as illustrated by Fig. 41). It furthermore seems to be sensitive to the 
subtle effects of AH's.
From the literature review and the results described in this thesis, it seems that future 
research projects with AH's should not only include objective and subjective tests 
which are performed intermittently, but also an easy to administer continuous measure 
e.g. actigraph, to record the diurnal variation and variability of the subtle sedative 
effects of AH's.
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APPENDIX I 
Selected tables
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Experiment 1
Table 1: CFF: Individual scores (Hz), mean values and SEM for each
treatment condition.
(P = placebo, L 3mg = levocabastine 3mg, R 5mg = R 72 075 5 mg, 
R lOmg = R 72 075 lOmg, R 20mg = R 72 075 20mg)
Initials P L 3mg
RK 32.14 32.86
JT 31.20 29.70
MP 22.37 23.00
GS 32.86 32.62
GVDB 30.74 29.19
BM 31.64 30.34
JP 27.49 20.41
LC 29.41 29.51
LB 31.69 29.05
TR 29.41 29.99
Mean 29.89 28.67
SEM .97 1.25
R5m g R lOmg R20m g
30.61 31.92 33.06
28.88 30.71 30.01
26.05 25.85 26.48
34.17 32.41 33.05
28.88 28.28 29.41
29.94 29.67 30.18
25.53 27.13 29.13
31.69 31.69 30.19
29.94 30.55 31.97
28.84 30.13 29.72
29.43 29.83 30.32
.81 .68 .62
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Experiment 1
Table 2: CRT: Mean values (secs) and SEM for each treatment condition,
for each component (*: P<0.05 w.r.t. placebo)
(P = placebo, L 3mg = levocabastine 3mg, R 5mg = R 72 075 5 mg, 
R lOmg = R 72 075 lOmg, R 20mg = R 72 075 20mg)
Initials P L 3mg R 5mg R lOmg R20m g
RRT
Mean .2011 .2329* .2157 .2000 .2073
SEM .0280 .0326 .0294 .0243 .0264
MRT
Mean .3637 .3786* .3649 .3618 .3611
SEM .0069 .0090 .0106 .0122 .0080
TRT
Mean .5648 .6115* .5806 .5618 .5684
SEM .0283 .0343 .0317 .0270 .0284
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Experiment 1
Table 3: VAS: Individual scores (mm), mean values and SEM, per
treatment condition (*: P<0.05 w.r.t. placebo).
(P = placebo, L 3mg = levocabastine 3mg, R 5mg = R 72 075 5 mg, 
R lOmg = R 72 075 lOmg, R 20mg = R 72 075 20mg)
Initials P L 3mg R5m g R lOmg R20m g
RK 15 17 18 17 30
JT 4 40 3 5 3
MP 6 54 11 5 5
GS 1 31 9 5 2
GVDB 8 90 6 9 5
BM 9 18 20 20 12
JP 19 67 9 16 10
LC 5 2 1 2 1
LB 22 55 20 21 25
TR 5 88 13 3 6
Mean 9.4 46.2* 11.0 10.3 9.9
SEM 2.2 9.4 2.1 2.3 3.4
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Experiment 3
Table 4: CFF: Mean changes (SD) from baseline (D1H0) for each
treatment condition
(TRI = triprolidine 10 mg, EB 10 = ebastine 10 mg, EB 20 = ebastine 
20 mg, EB 30 = ebastine 30 mg)
Hz Placebo TRI 10 EB 10 EB 20 EB 30
D l HO 28.110 27.710 27.615 2.110 27.893
(3.796) (3.605) (3.683) (3.796) (3.615)
D l H I -1.055 .053 .196 -.173 .159
(1.349) (1.066) (1.221) (1.297) (1.458)
D1H2 -1.652 -1.830 -.515 -.862 -.724
(1.413) (1.161) (.921) (1.317) (.792)
D l H4 -1.187 -1.062 -1.026 -1.137 -.856
(1.160) (1.692) (.829) (1.557) (1.137)
D l H8 -1.978 -1.519 -1.770 -1.465 -1.676
(.901) (1.297) (.766) (1.778) (1.189)
D5 HO -.773 .392 -.357 -.307 .430
(.971) (.903) (.867) (1.163) (1.023)
D5 H I -1.168 -.163 -.374 .092 .357
(1.568) (1.126) (1.874) (.986) (1.447)
D5H2 -1.373 -1.038 -.835 -1.318 -.405
(1.103) (.914) (1.526) (1.177) (1.566)
D5 H4 -1.142 -.655 -.322 -1.043 -.615
(1.075) (.914) (1.066) (1.132) (1.566)
D5 H8 -2.688 -1.390 -1.654 -1.562 -1.348
(.713) (1.255) (.610) (1.753) (1.334)
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Experiment 3
Table 5: CRT (RRT): Mean changes (SD) from baseline (D1H0) for each
treatment condition
(TRI = triprolidine 10 mg, EB 10 = ebastine 10 mg, EB 20 = ebastine 
20 mg, EB 30 = ebastine 30 mg)
msec Placebo TRI 10
D l HO 365.0
(46.089)
355.3
(39.092)
D l H I 16.20
(24.794)
9.70
(29.963)
D1H2 .0
(20.572)
11.30
(22.957)
D l H4 9.30
(19.875)
19.20
24.955)
D l H8 11.70
(21.195)
35.20
(23.596)
D5 HO -5.50
(31.059)
1.0
(19.058)
D5 H I 2.0
(18.665)
8.30
(35.791)
D5 H2 -6.10
(33.330)
20.0
(19.380)
D5H4 .300
(28.489)
12.90
(25.050)
D5 H8 -10.100
(28.853)
7.50
(26.151)
EB 10 EB 20 EB 30
348.333
(26.629)
355.4
(41.341)
359.6
(27.936)
24.778
(36.248)
11.70
(26.959)
1.556
(27.056)
13.778
(22.562)
11.60
(12.878)
9.222
(21.395)
13.889
(20.485)
14.50
(21.671)
15.222
(18.504)
25.444
(21.833)
14.10
(17.902)
12.0
(20.843)
-1.667
(24.363)
-5.70
(20.411)
1.0
(28.095)
14.667
(42.455)
11.20
(39.122)
10.778
(23.427)
17.667
(26.998)
-4.0
(17.367)
13.556
(35.409)
21.333
(23.281)
10.0
(22.472)
6.889
(28.645)
11.111
(24.511)
10.40
(15.939)
7.111
(28.777)
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Experiment 3
Table 6: CRT (MRT): Mean changes (SD) from baseline (D1H0) for each
treatment condition
(TRI = triprolidine 10 mg, EB 10 = ebastine 10 mg, EB 20 = ebastine 
20 mg, EB 30 = ebastine 30 mg)
msec Placebo TRI 10
D l HO 141.30
(30.584)
149.0
(39.857)
D l H I 6.30
(19.945)
17.10
(45.065)
D1H2 3.40
(15.914)
9.20
(17.016)
D 1H4 7.30
(27.416)
9.80
(29.580)
D l H8 10.8
(31.758)
3.50
(27.768)
D5 HO -7.0
(19.980)
-2.50
(22.787)
D5 H I 6.40
(15.435)
4.10
(24.415)
D5 H2 2.0
(12.767)
-14.30
(31.394)
D5 H4 .300
(13.229)
1.90
(32.932)
D5 H8 1.70
(27.753)
3.80
(20.464)
EB 10 EB 20 EB 30
156.222
(37.166)
149.0
(34.647)
154.0
(39.764)
2.556
(21.603)
8.80
(23.502)
1.222
(16.652)
-13.0
(15.442)
3.50
(15.429)
-7.667
(19.125)
-7.778
(18.226)
15.90
(37.416)
-6.556
(21.813)
-9.333
(13.106)
11.20
(23.638)
2.889
(22.869)
-15.444
(26.605)
-15.20
(18.411)
-15.778
(24.339)
-2.556
(24.762)
-3.30
(19.048)
1.0
(30.649)
-15.0
(26.683)
3.90
(25.816)
-4.444
(25.087)
-11.444
(22.416)
-.900
(18.886)
-5.667
(16.925)
-5.556
(26.904)
2.60
(15.749)
2.667
(13.548)
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Table 7: CRT (TRT): Mean changes (SD) from baseline (D1H0) for each
treatment condition
(TRI = triprolidine 10 mg, EB 10 = ebastine 10 mg, EB 20 = ebastine 
20 mg, EB 30 = ebastine 30 mg)
msec Placebo TRI 10
D l HO 506.30
(60.063)
504.50
(66.655)
D l H I 22.50
(23.876)
26.80
(44.158)
D1H2 3.40
(16.311)
20.50
(23.355)
D l H4 16.60
(35.245)
29.0
(38.215)
D l H8 22.50
(32.141)
38.70
(38.125)
D5 HO -12.50
(30.985)
-1.50
(21.542)
D5H2 -4.10
(32.531)
5.70
(43.391)
D5 H4 .600
(28.211)
14.80
(37.934)
D5 H8 -8.40
(30.816)
11.30
(23.728)
EB 10 EB 20 EB 30
504.556
(54.827)
504.40
(59.259)
513.60
(54.169)
27.333
(33.533)
20.50
(22.236)
2.778
(38.746)
.778
(28.909)
15.10
(19.445)
1.556
(30.848)
6.111
(24.260)
30.40
(49.328)
8.667
(29.040)
16.111
(26.447)
25.30
(19.079)
14.889
(34.565)
-17.111
(35.560)
-20.90
(26.782)
-14.778
(28.782)
2.667
(38.549)
-.100
(21.163)
9.111
(36.934)
.9.889
(25.137)
9.10
(29.941)
1.222
(30.637)
5.556
(37.880)
13.0
(20.050)
9.778
(32.605)
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Table 8: SCTT (RMS): Mean changes (SD) from baseline (D1H0) for each
treatment condition (* : P < 0.05 w.r.t. placebo)
(TRI = triprolidine 10 mg, EB 10 = ebastine 10 mg, EB 20 = ebastine 
20 mg, EB 30 = ebastine 30 mg)
units Placebo TRI 10
D l HO 5.770 6.028
(1.618) (1.947)
D1H2 -.255 .803
(.413) (.741)
D l H4 -.118 .800
(.530) (1.744)
D l H8 -.095 1.318*
(.447) (4.000)
D5 HO -.526 -.683
(.396) (.987)
D5H2 -.572 -.662
(.724) (1.081)
D5 H4 -.361 -.513
(.840) (1.258)
D5 H8 -.374 -.411
(.600) (1.093)
EB 10 EB 20 EB 30
6.515 5.609 6.272
(2.573) (1.621) (1.947)
-.429 .803 -.034
(.648) (.741) (.356)
-.010 .800 .215
(1.159) (1.744) (.458)
.304 1.318 .184
(2.163) (4.000) (.851)
-.800 -.683 -.649
(1.206) (.987) (.701)
-1.273 -.662 -.560
(1.214) (1.081) (1.114)
-1.307 -.513 -.349
(1.301) (1.258) (1.519)
-1.012 -.411 -.533
(1.263) (1.093) (1.066)
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Table 9: SCTT (RT): Mean changes (SD) from baseline (D1H0) for each
treatment condition (* : P < 0.05 w.r.t. placebo)
(TRI = triprolidine 10 mg, EB 10 = ebastine 10 mg, EB 20 = ebastine 
20 mg, EB 30 = ebastine 30 mg)
msec Placebo TRI 10
D 1H 0 374.976
(45.311)
375.689
(40.460)
D1 H2 10.286
(13.289)
34.614
(17.114)
D1 H4 18.724
(16.514)
39.719
(25.774)
D1 H8 18.504
(17.854)
57.398*
(46.783)
D5 HO 10.868
(21.992)
10.950
(27.898)
D5H2 19.414
(20.853)
34.174
(30.980)
D5 H4 26.180
(26.558)
45.644
(34.004)
D5 H8 26.022
(15.737)
27.045
(30.927)
EB10 EB 20 EB 30
379.658
(49.757)
381.515
(50.676)
381.281
(45.622)
24.238
(18.627)
12.586
(23.673)
22.166
(24.398)
21.731
(41.767)
20.470
(30.574)
32.766
(17.533)
37.589
(39.603)
30.203
(37.248)
17.354
(26.515)
14.513
(23.293)
13.125
(26.739)
11.064
(46.550)
20.786
(22.893)
17.890
(39.513)
24.540
(52.433)
17.267
(32.256)
2.756
(53.997)
14.568
(27.806)
9.411
(24.534)1
21.527
(51.607)
19.339
(33.812)
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Table 10: SMST: Mean changes (SD) from baseline (D1H0) for each
treatment condition (* : P < 0.05 w.r.t. placebo)
(TRI = triprolidine 10 mg, EB 10 = ebastine 10 mg, EB 20 = ebastine 
20 mg, EB 30 = ebastine 30 mg)
msec Placebo TRI 10 EB 10 EB 20 EB 30
D1 HO 384.670
(60.320)
364.590
(43.252)
366.978
(45.933)
376.720
(56.265)
374.740
(63.506)
D1H2 -7.80
(34.097)
21.80
(32.746)
-12.967
(21.168)
-2.480
(17.524)
-19.022
(34.896)
D1 H4 -21.690
(20.392)
24.310*
(32.480)
5.456
(12.700)
-9.600
(18.740)
-10.40
(37.436)
D1 H8 -26.40
(30.480)
23.410*
(48.656)
-5.189
(35.796)
-16.80
(14.117)
-8.389
(33.131)
D5 HO -21.830
(32.787)
-10.070
(16.829)
-9.533
(31.763)
-14.10
(17.835)
-27.044
(28.970)
D5H2 -25.270
(33.632)
-2.670
(24.913)
1.178
(25.961)
-25.250
(41.454)
-14.789
(45.869)
D5 H4 -23.440
(48.738)
-4.290
(41.940)
-9.456
(41.384)
-13.720
(30.254)
-11.789
(69.857)
D5 H8 -14.250
(47.077)
-.080
(23.147)
-16.189
(30.789)
-17.730
(33.986)
-21.778
(45.695)
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Table 11: LARS: Mean changes (SD) from baseline (D1H0) for each
treatment condition (* : P < 0.05 w.r.t. placebo)
(TRI = triprolidine 10 mg, EB 10 = ebastine 10 mg, EB 20 = ebastine 
20 mg, EB 30 = ebastine 30 mg)
mm Placebo TRI 10 EB 10 EB 20 EB 30
D1 HO 51.433 50.733 50.704 50.50 50.467
(3.422) (1.181) (.853) 0563) (40)
D1 HI -.533 .033 -.445 .167 .519
(1.956) (433) (1.054) (.833) (918)
D1H2 2.20 7.933* 1.630 1.70 1.185
(3.560) (6.335) ((4.476) (2.904) (2.085)
D1 H4 2.0 8.0* 2.926 5.634 5.333
(3.827) (7.309) (3.295) (6.165) (4.879)
D1 H8 1.533 5.333 1.889 2.967 2.815
(2.227) (5.871) (3.236) (3.035) (3.225)
D5 HO -.367 -.30 -.297 -.10 -.407
(4.446) (433) (576) (857) (1.538)
D5H1 -.167 -.533 -.370 .033 1.371
(2.237) (1.045) (429) (.849) (4.084)
D5H2 2.233 2.30 .518 .233 3.778
(4.669) (4.664) (1.744) (1.086) (5.482)
D5 H4 1.30 4.767 1.074 2.433 7.444*
(3.542) (4.782) (2.083) (4.101) (9.383)
D5 H8 2.967 2.133 2.741 1.50 2.926
(4.212) (4.385) (6.415) (2.372) (4.011)
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Table 12: LSEQ (GTS): Mean changes (SD) from baseline (D1H0) for each
treatment condition (* : P < 0.05 w.r.t. placebo)
(TRI = triprolidine 10 mg, EB 10 = ebastine 10 mg, EB 20 = 
ebastine 20 mg, EB 30 = ebastine 30 mg)
Placebo TRI 10 EB 10 EB 20 EB 30
D1 HO 50.967
(1638)
51.833
(4.113)
51.333
(2.250)
49.833
(4.729)
52.10
(3.323)
D2 HO 1.233
(6.136)
11.10*
(10.790)
4.333
(5.756)
7.60
(10.875)
12.592*
(11.919)
D6 HO 4.867
(7.137)
4.967
(10.017)
8.222
(10.183)
2.0
(6.189)
10.741
(12.637)
Table 13: LSEQ (QOS): Mean changes (SD) from baseline (D1H0) for each 
treatment condition
(TRI = triprolidine 10 mg, EB 10 = ebastine 10 mg, EB 20 = ebastine 
20 mg, EB 30 = ebastine 30 mg)
mm Placebo TRI 10 EB 10 EB 20 EB 30
D1 HO 49.550
(3.643)
51.2
(3.551)
49.944
(1.877)
49.60
(5.389)
51.050
(3.798)
D2 HO 1.80
(13.437)
14.250
(12.758)
3.50
(11.993)
7.850
(11.354)
15.167
(13.762)
D6 HO 2.850
(4.172)
7.50
(12.307)
9.50
(11.232)
2.70
(7.467)
5.111
(15.663)
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Table 14: CFF: Mean values (SD) for each treatment condition
(*: P <0.05 versus placebo) in 12 subjects
(P = placebo, T = triprolidine 10 mg, L0.5 = levocabastine 0.5mg/ml, 
L2 = levocabastine 2mg/ml )
Hz D1M0 D1M40
P 27.6 (2.9) 27.5 (3.3)
T 28.2 (3.2) 27.1 (2.8)
L0.5 21.4 (2.3) 26.5 (2.0)
L2 21,5 (3.1) 21.6(2.9)
D1M75 D1M150 D1M300
26.6 (3.0) 27.0 (2.6) 26.5 (2.6)
26.0(3.1) 25.6 (2.9)* 25.9 (2.8)
26.5 (2.5) 26.4 (2.3) 25.8 (2.4)
27.1 (3.2) 26.6 (2.8) 25.8 (2.6)
Table 15: CRT (RRT): Mean values (SD) for each treatment condition in 12
subjects
(P = placebo, T = triprolidine 10 mg, L0.5 = levocabastine 0.5mg/ml, 
L2 = levocabastine 2mg/ml )
msec D1M0 D1M40 D1M75 D1M150 D1M300
P 375 (40) 385 (29) 397(36) 389 (47)
T 385 (41) 410 (49) 399 (45) 402 (39)
L0.5 376 (45) 383 (39) 391 (45) 367 (58)
L 2 382 (46) 406 (66) 401 (48) 400 (54)
255
Experiment 4
Table 16: CRT (MRT): Mean values (SD) for each treatment condition in 12
subjects
(P = placebo, T = triprolidine 10 mg, L0.5 = levocabastine 0.5mg/ml, 
L2 = levocabastine 2mg/ml )
msec D1M0 D1M40 D1M75 D1M150 D1M300
P 187 (35) 194 (36) 195 (35) 91 (36)
T 179 (32) 199 (27) 190 (23) 92(32)
L0.5 180(40) 191 (36) 180 (32) 86(31)
L 2 187(41) 197 (36) 205 (34) 95(35)
Table 17: CRT (TRT): Mean values (SD) for each treatment condition in 12
subjects
(P = placebo, T = triprolidine 10 mg, L0.5 = levocabastine 0.5mg/ml, 
L2 = levocabastine 2mg/ml )
msec D1M0 D1M40 D1M75 D1M150 D1M300
P 562(58) 579(55) 592 (54) 560 (73)
T 563 (57) 609 (61 ) 589 (51 ) 593 (58)
L0.5 556 (64) 573 (57) 571(55) 573 (75)
L 2 569 (73) 603 (65) 607 (56) 595(75)
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Table 18: SCTT (RMS): Mean values (SD) for each treatment condition
(*: P <0.05 versus placebo) in 12 subjects
(P = placebo, T = triprolidine 10 mg, L0.5 = levocabastine 0.5mg/ml, 
L2 = levocabastine 2mg/ml )
units D1M0 D1M40 D1M75 D1M150 D1M300
Placebo 7.1(2.1) 7.2 (2.5) 6.7 (1.9) 7.8(3.2)
T 7.7 (2.2) 9.3 (2.9) 8.6 (2.6) 11 .5(9.5)
L0.5 7.7(2.4) 7.3 (2.4) 7.7 (2.4) 7.1 (2.4)
L 2 7.2(1.9) 7.4 (2.2) 7.9(2.4) 7.2 (1.9)
Table 19: SCTT (RT): Mean values (SD) for each treatment condition 
(*: P <0.05 versus placebo) in 12 subjects
(P = placebo, T = triprolidine 10 mg, L0.5 = levocabastine 0.5mg/ml, 
L2 = levocabastine 2mg/ml )
msec D1M0 D1M40 D1M75 D1M150 D1M300
P 466 (65) 466 (81 ) 448(52) 471 (81)
T 457(68) 472 (66) 484 (64) 479 (59)
L0.5 456 (54) 449 (57) 444 (51) 452 (52)
L 2 465 (56) 452(52) 466 (70) 459 (58)
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Table 20: WRT (matched): Mean values (SD) for each treatment condition
in 12 subjects
(P = placebo, T = triprolidine 10 mg, L0.5 = levocabastine 0.5mg/ml, 
L2 = levocabastine 2mg/ml )
secs D1M0 D1M40
P 2.8 (0.1) 2.9 (0.1)
T 2.8 (0.1 ) 2.8 (01 )
L0.5 2.8 (0.1 ) 2.8 (0.1)
L 2 2.8 (0.1) 2.8 (0.1 )
D1M75 D1M150 D1M300
2.8 (0.1) 2.8 (0.1) 2.8 (0.1)
2.9 (0.2) 2.6 (0.1) 2.8 (0.1 )
2.8 (0.1) 2.8 (0.1) 2.8 (0.1 )
2.8 (0.1) 2.8 (0.1) 2.8 (0.1 )
Table 21: WRT (unmatched): Mean values (SD) for each treatment
condition in 12 subjects
(P = placebo, T = triprolidine 10 mg, L0.5 = levocabastine 0.5mg/ml, 
L2 = levocabastine 2mg/ml )
sec D1M0 D1M40
P 2.8 (0.0) 2.8 (0.1)
T 2.8 (0.1) 2.6 (0.1)
L05 2.8 (0.1) 2.9 (0.1 )
L 2 2.8 (0.1) 2.8 (0.0)
D1M75 D1M150 D1M300
2.8 (0.1) 2.9 (0.3) 2.8 (0. 1 )
2.9 (0.1) 2.9 (0.2) 28 (0.1)
2.8 (0.1 ) 2.8 (0.1) 2.8 (0.1)
2.8 (0.1 ) 2.8 (0.1 ) 2.8 (0.1)
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Table 22: SMST: Mean values (SD) for each treatment condition
(*: P <0.05 versus placebo) in 12 subjects
(P = placebo, T = triprolidine 10 mg, L0.5 = levocabastine 0.5mg/ml, 
L2 = levocabastine 2mg/ml )
msec D1M0 D1M40 D1M75 D1M150 D1M300
P 466 (65) 466 (81 ) 448 (52) 471 (81)
T 457(68) 472 (66) 484 (64)* 479 (59)
L0.5 456 (54) 449 (57) 444 (51) 452 (52)
L 2 465 (56) 452(52) 466 (70) 459 (58)
Table 23: LARS: Mean values (SD) for each treatment condition
(*: P <0.05 versus placebo) in 12 subjects
(P = placebo, T = triprolidine 10 mg, L0.5 = levocabastine 0.5mg/ml, 
L2 = levocabastine 2mg/ml )
mm D1M0 D1M40 D1M75 D1M150 D1M3(
P 51(2) 52(3) 54(4) 53(3) 55(4)
T 52(4) 51(4) 63 (10)* 58(7) 61(10)
L0.5 51(2) 51(2) 52(7) 53(4) 61(6)
L 2 52(4) 53(5) 53(4) 56(5) 61(7)
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Table 24: CFF: Mean values (95% confidence intervals) for each treatment
condition
(HYD 25mg = hydroxyzine 25 mg, HYD 50mg =
Hz Placebo HYD 25mg HYD 50mg
D1H-0.5 29.1 29.2 29.0
(0.6) (0.6) (0.6)
D1H1 29.5 29.2 29.1
(0.6) (0.6) (0.6)
D2H10.5 29.6 29.5 29.6
(0.6) (0.6) (0.6)
D2H21 29.3 28.6 29.2
(0.6) (0.6) (0.6)
Table 25: CRT: Mean values (95% confidence intervals) :
condition
(HYD 25mg = hydroxyzine 25 mg, HYD 50mg =
msec Placebo HYD 25mg HYD 50mg
D1H-0.5 493 507 512
(20) (20) (20)
D1H1 495 529 520
(20) (20) (20)
D2H10.5 496 522 529
(20) (20) (20)
D2H21 486 506 496
(20) (20) (20)
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Table 26: LARS: Mean values (95% confidence intervals) for each treatment
(HYD 25mg = hydroxyzine 25 mg, HYD 50mg = hydroxyzine 50 mg)
mm Placebo HYD 25mg HYD 50mg
D1H-0.5 49.7 50.2 51.7
(4.0) (4.0) (4.0)
D1H1 50.2 53.4 56.1
(4.0) (4.0) (4.0)
D2H10.5 51.2 57.8 58.3
(4.0) (4.0) (4.0)
D2H21 53.8 53.1 54.7
(4.0) (4.0) (4.0)
Table 27: LSEQ : Mean values (95% confidence intervals) for each
treatment condition (* : P < 0.05 w.r.t. placebo)
(HYD 25mg = hydroxyzine 25 mg, HYD 50mg = hydroxyzine 50 mg)
mm Placebo HYD 25mg HYD
GTS 50.4 60.1 58.6
(6 1) (6.1) (6.1)
QOS 49.0 58.0 52.0
(7.1) (7.1) (7.1)
AFW 48.7 55.2 57.8*
(4.1) (4.1) (4.1)
BFW 49.1 56.0 58.6*
(4.6) (4.6) (4.6)
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Table 28: CFF : Mean values (SD) for each treatment condition
(AST lOmg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
msec Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
D1H-0.5 28.2 27.7 28.0
(2.7) (3.0) (3.1)
D1H1.5 27.0 27.2 26.5
(2.7) (3.2) (3.2)
DIH6.5 26.2 26.9 26.3
(2.5) (3.3) (2.9)
D2H0 27.9 28.4 28.3
(2.6) (3.0) (2.8)
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Table 29: CRT (RRT) : Mean values (SD) for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
msec Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
D1H-0.5 331 342 340
(25.2) (38.0) (29.0)
D1H1.5 353 346 353
(32.7) (41.7) (37.1)
DIH6.5 354 350 352
(37.7) (33.3) (33.5)
D2H0 342 338 337
(22.0) (36.8) (27.7)
263
Experiment 6
Table 30: CRT (MRT) : Mean values (SD) for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
No Subjects 12 12 12
D1H-0.5 168 165 168
(31.7) (44.7) (41.8)
D1H1.5 171 170 177
(4L4) (46.5) (40.9)
DIH6.5 182 173 173
(32.7) (45.6) (38.3)
D2H0 172 177 171
(39.1) (55.7) (34.1)
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Table 31: CRT (TRT) : Mean values (SD) for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
msec Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
D1H-0.5 489 508 509
(38.8) (47.0) (42.7)
D1H1.5 525 516 530
(42.6) (39.7) (34.8)
DIH6.5 536 524 525
(55.7) (37.5) (37.2)
D2H0 513 514 508
(40.9) (44.7) (37.6)
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Table 32: SCTT (RT) : Mean values (SD) for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
msec Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
D1H-0.5 379 387 391
(42.9) (42.1) (53.6)
D1H1.5 401 397 400
(46.9) (49.2) (52.7)
DIH6.5 411 396 401
(52.4) (60.5) (48.9)
D2H0 399 394 380
(54.7) (49.1) (48.3)
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Table 33: SCTT (RMS) : Mean values (SD) for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
units Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
D1H-0.5 6.6 6.4 6.8
(1.3) (1.4) (1.3)
D1H1.5 6.1 5.9 6.5
(1.3) (1.1) (1.2)
DIH6.5 6.4 5.8 6.3
(1.3) (1.1) (1.4)
D2H0 6.0 5.9 6.4
(1.3) (1.4) (1.5)
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Table 34: SMST: Mean values (SD) for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
msec Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
D1H-0.5 425 427 427
(60.5) (76.2) (51.1)
D1H1.5 404 417 418
(37.0) (60.0) (55.2)
DIH6.5 410 420 424
(56.2) (70.0) (50.0)
D2H0 423 419 410
(53.1) (66.2) (55.3)
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Table 35: LARS: Mean values (SD) for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
mm Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
D1H-0.5 50.4 50.3 51.3
(0.6) (0.5) (3.3)
D1H1.5 54.2 50.6 53.0
(9.2) (0.8) (4.2)
D1H6.5 54.7 54.6 56.3
(7.0) (5.1) (6.4)
D2H0 52.0 52.1 50.8
(3.1) (2.6) (0.8)
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Table 36: LSEQ: Mean values (SD) for each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
mm Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
GTS 52.3 43.8 53.8
(11.5) (21.0) (20.6)
QOS 48.3 41.8 38.3
(15.3) (23.2) (20.0)
AES 48.3 52.1 45.1
(3.1) (14.5) (15.2)
BFA 51.0 51.5 52.9
(8.2) (9.5) (10.1)
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Experiment 6
Table 37: C-EEG (WA): Mean values (SEM) for each treatment condition
(* : P < 0.05 w.r.t. placebo)
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
sec Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
T1 9.6 0 12.7
(9.6) (0) (12.7)
T2 86.4 40.8 289.0*
(69.8) (38.2) (191.8)
T3 88.8 73.5 385.5*
(52.3) (44.5) (170.4)
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Experiment 6
Table 38: C-EEG (DR): Mean values (SEM) for each treatment condition
(* : P < 0.05 w.r.t. placebo)
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
sec Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
T1 9.6 0 12.7
(9.6) (0) (12.7)
T2 124.8 79.2 561.0*
(107.4) (76.6) (288.1)
T3 174.0 192.9 723.5*
(105.6) (104.0) (268.5)
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Experiment 6
Table 39: C-EEG (ST1): Mean values (SEM) for each treatment condition
(* : P < 0.05 w.r.t. placebo)
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
sec Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
T1 0 0 0
(0) (0) (0)
T2 38.4 38.4 272.0*
(38.4) (38.4) (150.6)
T3 85.2 119.4 338.0*
(56.9) (69.5) (150.7)
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Experiment 6
Table 40: C-EEG (nighttime) : Mean values (95% confidence intervals) for
each treatment condition
(AST 10mg/PS 240mg = astemizole/pseudoephedrine combination, 
TRI 2.5mg/PS 60mg = triprolidine/pseudoephedrine combination)
sec Placebo AST 10mg/ TRI 2.5mg/
PS 240mg PS 60mg
WF 330 558 585
(211.2) (211.2) (236.4)
DuW 1011 1362.6 1194.6
(649.8) (649.8) (726.6)
FDuW 646.8 720 1321.8
(649.8) (649.8) (726.6)
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Experiment 7
Table 41: CFF: Mean baseline values (SD) and changes from baseline (SD)
for each treatment condition, without alcohol
(TRI 5mg = Triprolidine 5 mg, CET 10mg = Cetrizine 10 mg,
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg)
Hz PLA CET CET TER TRI CHLOR
10mg 20mg 60mg 5mg 4mg
D1H0 27.48 27.40 27.29 27.30 26.91 27.38
(3.86) (3.75) (3.47) (3.88) (3.86) (3.66)
D1H1.5 -.610 -.772 .417 -.828 -1.498 -.593
(.889) (.917) (1.421) (.674) (1.269) (1.170)
D1H4.5 -.323 -959 .141 -.752 -1.250 -.550
(1.281) (1.106) (1.086) (.900) (1.666) (1.170)
D2H0 .232 .161 .083 -.239 -.237 .502
(1.287) (1.066) (1.559) (1.167) (1.637) (.906)
Table 42: CRT (TRT): Mean baseline values (SD) and changes from baseline
(SD) for each treatment condition, without alcohol
(TRI 5mg = Triprolidine 5 mg, CET 10mg = Cetrizine 10 mg,
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg)
msec PLA CET CET TER TRI CHLOR
10mg 20mg 60mg 5mg 4 mg
D1H0 533.90 551.56 537.56 545.00 539.56 537.00
(52.24) (58.95) (56.96) (59.69) (46.61) (44.07)
D1H1.5 14.100 -1.889 6.889 11.000 58.000 19.000
(27.747) (28.754 (44.995) (33.417) (55.470) (35.561)
D1H4.5 28.000 8.667 12.222 26.222 50.889 5.300
(28.702) (26.907) (37.558) (33.687) (65.113) (31.010)
D2H0 2.900 -10.111 -4.000 -4.444 9.667 20.600
(28.219) (34.148) (36.544) (36.942) (34.957) (52.416)
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Experiment 7
Table 43: CFF: Mean baseline values (SD) and changes from baseline
(SD) for each treatment condition, with alcohol
(TRI 5mg = Triprolidine 5 mg, CET 10mg = Cetrizine 10 mg, 
CET 20mg = Cetrizine 20 mg, TER 60mg = Terfenadine 60 mg, 
CHLOR 4 mg = Chlorpheniramine 4 mg)
Hz PLA GET GET TER TRI CHLOR
lOmg 20mg 60mg 5mg 4mg
D1H0 27.19 27.05 27.50 26.77 27.23 27.54
(3.96) (3.59) (4.37) (3.60) (3.47) (3.92)
D1H1.5 -.583 .070 -.575 .002 -1.262 -.458
(1.125) (1.163) (.992) (1.551) (1.552) (.794)
D1H4.5 -1.162 -.368 -1.434 -.510 -1.244 -.947
(1.231) (1.721) (1.656) (1.498) (1.605) (1.140)
D2H0 -.065 .348 -.274 .193 -.135 -.040
(1.189) (.926) (1.418) (1.253) (1.026) (1.414)
